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A B S T R A C T
Background
Selenium is a trace element essential to humans. Higher selenium exposure and selenium supplements have been suggested to protect
against several types of cancers.
Objectives
Two research questions were addressed in this review: What is the evidence for
1. an aetiological relationship between selenium exposure and cancer risk in women and men?
2. the efficacy of selenium supplementation for cancer prevention in women and men?
Search strategy
We searched electronic databases and bibliographies of reviews and included publications.
Selection criteria
We included prospective observational studies to answer research question (a) and randomised controlled trials (RCTs) to answer
research question (b).
Data collection and analysis
We conducted random effects meta-analyses of epidemiological data when five or more studies were retrieved for a specific outcome.
We made a narrative summary of data from RCTs.
Main results
We included 49 prospective observational studies and six RCTs. In epidemiologic data, we found a reduced cancer incidence (summary
odds ratio (OR) 0.69 (95% confidence interval (CI) 0.53 to 0.91) and mortality (OR 0.55, 95% CI 0.36 to 0.83) with higher selenium
exposure. Cancer risk was more pronouncedly reduced in men (incidence: OR 0.66, 95% CI 0.42 to 1.05) than in women (incidence:
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OR 0.90, 95% CI 0.45 to 1.77). These findings have potential limitations due to study design, quality and heterogeneity of the data,
which complicated the interpretation of the summary statistics.
The RCTs found no protective efficacy of selenium yeast supplementation against non-melanoma skin cancer or L-selenomethionine
supplementation against prostate cancer. Study results for the prevention of liver cancer with selenium supplements were inconsistent
and studies had an unclear risk of bias. The results of the Nutritional Prevention of Cancer Trial (NPCT) and SELECT raised concerns
about possible harmful effects of selenium supplements.
Authors’ conclusions
No reliable conclusions can be drawn regarding a causal relationship between low selenium exposure and an increased risk of cancer.
Despite evidence for an inverse association between selenium exposure and the risk of some types of cancer, these results should be
interpreted with care due to the potential limiting factors of heterogeneity and influences of unknown biases, confounding and effect
modification.
The effect of selenium supplementation from RCTs yielded inconsistent results. To date, there is no convincing evidence that selenium
supplements can prevent cancer in men, women or children.
P L A I N L A N G U A G E S U M M A R Y
Selenium for preventing cancer
Selenium is a trace element that is important for human health, but might also be harmful for humans when the taken in excess.
Fifty-five studies with more than one million participants were included in this systematic review. Forty-nine studies observed and
analysed whether healthy people with high selenium levels in blood or toenail samples or with a high selenium intake developed cancer
more or less often than other people. We found that people with higher selenium levels or intake had a lower frequency of certain
cancers (such as bladder or prostate cancer) but no difference for other cancers such as breast cancer. However, it was not possible to
determine from these studies that selenium levels or selenium intake were really the reason for the lower risk of cancer in some people.
Factors apart from higher selenium levels could also influence the cancer risk: They might have had a healthier nutritional intake or
lifestyle, have had a more favourable job or overall living conditions.
Six randomised controlled trials (RCTs) assessed whether the use of selenium supplements might prevent cancer. In general, there are
two types of selenium supplements: one type uses the salt of selenium as main ingredient, the other type uses organic selenium. These
two types may act differently in the human body when ingested. We assessed the quality of each trial according to four established
methodological criteria. The trials with the most reliable results found that organic selenium did not prevent prostate cancer in men and
increased the risk of non-melanoma skin cancer in women and men. Other trials found that participants using selenium salt or organic
supplements had a decrease in liver cancer cases. However, due to methodological shortcomings this evidence was less convincing.
We advise further investigation of selenium for liver cancer prevention before translating results into public health recommendations.
We also recommend that there should be further evaluation of the effects of selenium supplements in populations according to their
nutritional status as they may differ between undernourished and adequately nourished groups of people.
To maintain or improve health, access to healthy food and a healthy diet is important. Currently, there is no convincing evidence that
individuals, particularly those who are adequately nourished, will benefit from selenium supplementation with regard to their cancer
risk.
B A C K G R O U N D
Selenium
Selenium is a trace element essential to humans. Humans usually
ingest selenium with crop and animal products and sometimes as
functional foods or supplements. Speciation and concentration of
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selenium in food sources vary considerably, depending on plant
and animalmetabolism and growth conditions or animal nutrition
(Duffield 1999).
Selenium species can be classified into selenium-containing or-
ganic compounds (e.g. selenomethionine, selenocysteine) and in-
organic forms (selenate, selenite) (Rayman 2008a). Selenium yeast
refers to a selenium-enriched yeastmediumwhich usually contains
80% to 90% organically bound selenium with a high proportion
of selenomethionine (Rayman 2004). Whether selenium is linked
to specific beneficial health effects in humans is suspected but
unproven and the debate on those effects is controversial (Drake
2006; Rayman 2008a).
The recommended daily allowance differs between regulatory
agencies. For example, the highest amount of daily intake (55 µg
selenium for adults) has been recommended by the US Institute of
Medicine (Institute ofMedicine 2009), whereas theWHO (World
HealthOrganization) recommendations range between 30 and 40
µg/day for men and women (WHO 2004).
To prevent the risk of developing selenosis, the US Institute of
Medicine has set the tolerable upper intake level to 400 µg per
day for adults (Office of Dietary Supplements 2009). Besides the
acute and chronic toxicity of high selenium exposure, possible
harmful effects of long-term intake of lower dosages have also been
discussed. However, effects of long-term intake of lower dosages
are not sowell investigated or understood (Vinceti 2001) and there
may be differences between organic and inorganic forms (Rayman
2008a). A recent publication has questioned the current upper
limit of ’safe intake’ and proposed a far lower ’safe level’ for long-
term usage (20 µg/day for organic selenium) and a differentiation
between organic and inorganic selenium sources (Vinceti 2009).
An accurate estimation of selenium exposure in epidemiologi-
cal research presents a challenge. Individual exposure is often as-
sessed as the concentration in blood specimens or toenail clippings
(Longnecker 1996) or as estimated dietary or supplemental in-
take, but the validity of dietary logs and recall questionnaires has
been questioned (Patterson 1998). For the measurement in blood
specimens, either whole blood or blood fractions (plasma = blood
without the cells; serum = plasma without the clotting factors) are
used.
Selenium levels found in human specimens (Rayman 2008b) as
well as the estimated intake of selenium (Alfthan 1996) show a
high global variability. Different selenium levels within popula-
tions have been found to be related to ethnicity (Kant 2007), gen-
der, age or smoking behaviour. Smoking tends to lower selenium
biomarker concentrations despite being a source of selenium ex-
posure (Kafai 2003). Globally, however, there are also inconsis-
tencies as to how these factors are associated with selenium levels.
For example, selenium levels increased with age in women, but
not in men, in the French SU.VI.M.AX cohort study (Arnaud
2007), decreased with age in a female population in Ohio (Smith
2000) and two studies from Switzerland and Austria could not
find an association between age and selenium status in either gen-
der (Burri 2008; Gundacker 2006). Gender-specific nutritional
and health behaviours, as well as gender-specific differences in se-
lenium metabolism, may contribute to the observed discrepancies
in selenium levels between genders (Rodriguez 1995).
These global and within-population differences formed the early
basis of investigations into the association of selenium exposure
and cancer risk (Schrauzer 1977; Shamberger 1969).
The hypotheses about the potentially anticarcinogenic mecha-
nisms of selenium include its effects on DNA stability, cell prolif-
eration, necrotic and apoptotic cell death in healthy andmalignant
cells and its effects on the immune system (Whanger 2004). Sele-
nium is involved in these processes as a source of selenometabo-
lites and is part of selenium-containing enzymes (Hatfield 2001).
The optimum level for the prevention and retardation of carcino-
genesis in human cells has been discussed to be higher than the
level commonly achieved under a diet not deficient in selenium
(Whanger 2004). Gender differences regarding the effects of sele-
nium on health, including cancer diseases, have been increasingly
debated in recent years. Apart from gender differences in selenium
levels, gender differences in selenium distribution in tissue or tu-
mour biology might be involved in the differential health effects
in women and men (Waters 2004).
However, selenium has also been shown to promote malignant
cell transformation (Kandas 2009; Novoselov 2005; Su 2005) and
protect cancer cells against stress-induced apoptosis (Sarada 2008)
in animal and in-vitro studies and might therefore work as car-
cinogen.
Cancer
Cancer is a leading cause of death worldwide. According toWHO
estimates, 11.3 million people developed and 7.9 million died of
cancer in 2007, with more than half of all new cases occurring in
middle-income or low-income countries (WHO 2008).
The role of diet and nutrition for carcinogenesis and, as a poten-
tially modifiable factor, in cancer prevention is still under debate.
The identification of a nutrient supplement with cancer preven-
tive properties would be a major breakthrough for public health.
However, cancer is not a uniform disease and the existence of such
a nutrient, or combination of nutrients, has been debated.
Case-control studies as well as systematic and non-systematic re-
views have found conflicting results on risks of specific cancers
and selenium exposure. Zhuo 2004 found a summary risk esti-
mate suggestive for a protective effect of higher selenium expo-
sure against lung cancer in a systematic review and meta-analysis
of epidemiological studies; Brinkman 2006 found similar results
for prostate cancer. However, two other epidemiological reviews
concluded that studies did not support an association between se-
lenium status and breast cancer risk in women (Navarro Silvera
2007; Waters 2004).
Vinceti and colleagues observed an increased melanoma incidence
(Vinceti 1998) and mortality from melanoma (Vinceti 2000a)
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in both genders in a cohort of people from Northern Italy who
where accidentally exposed to long-term consumption of drinking
water with a high content of inorganic selenium. The standardised
mortality ratio for melanoma in comparison to the non-exposed
individuals in the municipality was 4.15 (95% CI 0.21 to 20.47)
in women and 10.98 (95% CI 1.84 to 36.27) in men.
The first indication from an RCT that selenium supplements may
reduce risk of gastrointestinal (GIT) cancers came from the Gen-
eral Population Trial in Linxian, China (Blot 1993; Dawsey 1994;
Wang 1994). Study participants were living in regions with a very
high rate of GIT cancers and subclinical deficiencies of several nu-
trients. The RCT investigated the efficacy of vitamin and mineral
supplements to reduce cancer incidence and mortality, especially
of oesophageal and gastric cancer, in middle-aged adults with four
treatment factors for a period of 5.25 years. Participants receiv-
ing one study supplement (containing 50 µg selenised yeast, beta-
carotene, alpha-tocopherol) had a reducedmortality from, but not
incidence of, gastric cancer. Oesophageal cancer risk was not al-
tered.
In the more recent French SU.VI.M.AX trial (Hercberg 2004),
a supplementation with beta-carotene, vitamin C, vitamin E and
100 µg selenium-enriched yeast did not alter the incidence of can-
cer of the digestive tract after a median period of 7.5 years in
women. In men, the incidence rate was lower in the intervention
group than in the placebo group, but risk ratios (RRs) with confi-
dence intervals (CIs) were not calculated because of low numbers.
Bjelakovic 2006 conducted a Cochrane Review on antioxidant
supplements for the prevention of gastrointestinal (GIT) cancers.
Nine RCTs that investigatedmono-seleniumor selenium-contain-
ing supplements were included in this review. The authors con-
cluded that seleniummay potentially possess beneficial effects, but
the results required further research before any recommendation
could be made.
Why it is important to do this review
Selenium is suggested to be involved in central anti-carcinogenic
processes. Selenium supplements are widely marketed with many
health claims, the prevention of cancer being one of them. There
is a worldwide debate about the association between selenium ex-
posure and cancer risk or whether selenium supplements are effec-
tive in decreasing the incidence or mortality of cancer. Epidemio-
logic and other data suggest differential effects in men and women
and there are hints that selenium supplements might even have
harmful effects, this especially being the case in certain popula-
tions. This review is timely and important as several meta-analyses
and systematic reviews have been published, but a comprehensive
summary providing evidence from both prospective studies and
intervention trials which a) include all types of cancer and b) look
for gender-related differences does not exist.
O B J E C T I V E S
Two research questions were addressed in this review: What is the
evidence for
1. an aetiological relationship between selenium exposure and
cancer risk in women and men?
2. the efficacy of selenium supplementation for cancer
prevention in women and men?
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) and prospective observa-
tional studies (cohort studies and nested case-control studies) were
included, irrespective of publication year, publication status or
language.
Types of participants
All adult participants (aged 18 years and over) at risk of malignant
neoplastic diseases.
Types of interventions
We considered prospective observational studies (cohort studies
including sub-cohort controlled studies and nested case-control
studies) for inclusion if they assessed baseline exposure to sele-
nium in apparently cancer-free individuals either as biochemical
selenium status or estimated selenium intake at study inception.
We considered RCTs for inclusion if they used selenium supple-
mentation at any dose or route of administration for a minimum
of four weeks versus placebo or no intervention. We excluded tri-
als using selenium supplementation as part of a multi-component
preparation, without a study arm using selenium monotherapy
supplementation.
Types of outcome measures
The primary outcome measures were
1. the number of participants developing cancers (incidence of
any cancer);
2. the number of participants dying from cancers (cancer-
related mortality).
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Search methods for identification of studies
We conducted electronic searches in the Cochrane Central Reg-
ister of Controlled Trials (CENTRAL, The Cochrane Library Is-
sue 1, 2011), MEDLINE (via PubMed, 1966 to February 2011),
EMBASE (1980 to 2010 week 50), CancerLit (February 2004)
and CCMed (February 2011). We conducted the initial search in
2004 and updates in July 2007, January 2009, October 2009, and
February 2011. AsMEDLINE now includes the journals indexed
in CancerLit, no further searches were conducted in this database
after 2004.
We also searched the following online clinical trials databases:
Clinical Trials of the American Cancer Society (http://
www.cancer.gov, February 2011), the metaRegister of Controlled
Trials (mRCT, http://www.controlled-trials.com, February 2011)
and the German Cancer Study Register (http://www.studien.de,
February 2011). The search strategies are given in Appendix 1.
We scanned conference abstracts to identify unpublished material
and searched the database for grey literature SIGLE (February
2004). This electronic database was discontinued in 2005.
Data collection and analysis
Selection of studies
Two review authors independently checked all electronic search
results for eligibility. When search results could not be rejected
with certainty on the basis of title and/or abstract, we obtained
full text material.
We scanned bibliographies of papers retrieved with the described
search strategy, and included publications to identify additional
studies. If additional information was necessary we tried to contact
all the correspondent authors of the included studies and asked
investigators for information about unpublished trials.
Two review authors (GD, MH) independently applied the inclu-
sion and exclusion criteria, if necessary with the assistance of an
interpreter. We resolved disagreements by discussion and with the
involvement of a third review author.
Data extraction and management
We used pre-tested extraction forms for epidemiological studies
and RCTs to document data from the original material and assess
the quality of studies. GD and another review author indepen-
dently extracted data unblinded. GD checked extracted data for
discrepancies and any discrepancies were discussed between both
extracting review authors. In a small number of cases, we sought
the opinion of a third review author to reach a consensus. If several
reports from the same studywere available, we considered themost
recent to be the primary publication, but study details available
from other publications were also extracted if not reported in the
primary study reference.
We entered data from the extraction forms into aMicrosoft Access
database by hand. GD double-checked completely for errors and
MH and GD triple-checked using descriptive database methods
and plausibility checks.
For comparisons of selenium exposure as measured in serum and
plasma specimens, we converted all data into the unit µg/l. Results
provided as ppm (parts per million) or µg/g were converted using
the factor 1.026 g/ml (weight density of serum) and data provided
as µmol/l using the factor 78.96 (molecular weight of selenium).
In order to be included, prospective observational studies had to
report estimates of relative risk (RR (e.g. odds ratio (OR)) for each
selenium exposure level.
Assessment of risk of bias in included studies
Observational studies
The risk of bias in observational studies was assessed using an as-
sessment form adapted from the Newcastle-Ottawa Quality As-
sessment Scale (NOS) for cohort and case-control studies (Wells
2004). The NOS was developed using a ’star system’ in which co-
hort or case-control studies are judged on the selection and com-
parability of the study groups and the ascertainment of either the
exposure or outcome of interest.
The NOS form for cohort studies was used for all included obser-
vational studies. In addition, we assessed the risk of bias of nested
case-control studies with the NOS case-control form. Both forms
must be adapted a priori for use in a systematic review according
to the research question and the review topic. For each question
within this standardised assessment procedure either a ’star’ or ’no
star’ is assigned to a study. A ’star’ indicates that study design was
considered adequate and less likely to introduce bias.
We used the questions as reported in the appendices for study
assessment; (*) means that for the corresponding item a ’star’ ac-
cording to the NOS was assigned to the study. Key domains are
the selection and comparability of the exposed and non-exposed
cohort, the ascertainment of exposure and outcome and the length
of follow-up. A study could receive a maximum of 9 stars in the
cohort assessment (Appendix 2) and 9 stars in the assessment of
the case-control part (Appendix 3).
The risk of bias assessment was based on the data provided in
the included publications. We did not check other, not included
publications for details. If an included study encompassed more
than one publication with divergent rating in the NOS, we used
the highest score.
Randomised controlled trials
We categorised generation of allocation sequence, allocation con-
cealment, blinding and completeness of outcome data as adequate
(low risk of bias), inadequate (high risk of bias) or unclear follow-
ing the criteria specified in the Cochrane Handbook of Review
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of Interventions (Higgins 2009a). We considered these four items
to be the key domains for bias risk assessment. Studies that were
categorised as “adequate” in all four domains were considered to
have a low risk of bias; studies with inadequate procedures in one
or more key domains were considered to have a high risk of bias.
Studies with unclear procedures in one or more key domains were
considered to have an unclear risk of bias.
We assessed the fulfillment of ethical standards as follows:
• Was informed consent obtained from patients? (yes/no/
unclear)
• Was approval obtained from an ethical board? (yes/no/
unclear)
Dealing with missing data
When data were missing or discrepancies in study publications
were found, we tried to make contact with the study investigators
for further information. Contacting study authors helped to clarify
discrepancies in several publications, e.g. differing data in text and
tables within the same report, however, we retrieved no missing
data or study details.
Data synthesis
Data synthesis and analysis
We performed data synthesis and analysis separately for RCTs and
observational studies.
We restricted meta-analyses to cancers for which at least 5 studies
were available. There were two reasons for this restriction. The
first was practical and was to limit the number of analyses to be
performed. The second was that we expected that results are het-
erogeneous, but heterogeneity cannot be described and quantified
well if only very few studies are available (Higgins 2009b). Al-
though the cut-off at 5 studies is somewhat arbitrary, this decision
was made very early in the review process and was declared in the
protocol.
Observational studies
This review includes only binary outcomes. If five or more studies
were available for a specific type of cancer, we conducted a meta-
analysis.
Study authors defined cancer cases either as diagnosis (i.e. cancer
incidence) or death from cancer (i.e. cancer mortality) or as a
combination of both. The term ’cancer risk’ is used in this paper
as a generic term and refers likewise to cancer incidence, cancer
mortality and combined incidence/mortality data.
A meta-analysis of highest versus lowest selenium exposure cate-
gory was performed using a random effectsmodel and by analysing
the natural logarithm of theOR or RR, using the squared standard
error of the natural logarithm of theOR or RR as weights. The lat-
ter was calculated from the reported upper and lower boundaries
of the 95% CI of the OR or RR. If a 95% CI was not reported, we
used the total number of cases and the total number of controls as
well as the number of categories of selenium exposure to estimate
the number of cases and controls per exposure category. We then
used the standard normal approximation formula to calculate the
standard error of the OR (comparing the highest versus the lowest
exposure category (lnOR = ( 1/a + 1/b +1/c +1/d ) where a, b, c, d
are the four counts needed to calculate the OR via (a*d)/(b*c)).
We took theOR from the analysis that included themost extensive
adjustment in the publication. For the calculation of the summary
risk estimate, gender-aggregated data ofmixed-gender studies were
used when available.
We performed a Chi2 test for heterogeneity of study results. Ad-
ditionally, we used I2 statistics (Higgins 2003) to quantify incon-
sistency. Meta-analyses were conducted using STATA 10.0 and
STATA 11.0 software. We repeated meta-analyses that were in-
cluded in this review publication using the Review Manager 5 sta-
tistical tool; for this, logarithmic data for the OR and the standard
error were copied from STATA into ReviewManager 5 and results
were double-checked for errors.
We conducted sensitivity analyses to assess the effect of the meth-
ods used to assess selenium status/intake. We used gender-disag-
gregated data from mixed-gender studies together with data from
single-gender cohorts for subgroup analyses by gender. We con-
ducted the latter subgroup analyses to account for potential gen-
der differences in selenium health effects (see Background).
Randomised controlled trials
We did not perform a meta-analysis of summary statistics with
RCT data in this review as the minimum number of five studies,
required for meta-analysis according to our review protocol, was
not reached for any type of cancer.
Risk ratios (RR) of intervention trials that were not reported in the
original publication were calculated on the basis of the number of
participants and cases using the statistical tool for meta-analysis
included in Review Manager 5. We also calculated the RR of
adverse outcomes and its 95% CI, if sufficient data were available.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
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Citation style: Please note that we reference the sources of relevant
information in a certain way to increase traceability of our results
for interested readers. When the source of information is not the
primary publication of an included study, the specific publication
of interest is also referenced. For example “Hakama 1990 in: Knekt
1990” indicates that the cited paper is “Hakama 1990” as part of
the mentioned study.
Three full text theses published in the US, could not be accessed
(Coates 1987, in: Coates 1988; Menkes 1986a, in: Menkes 1986;
Schober 1986, in: Menkes 1986). However, later journal publi-
cations were available and included in this review as main study
publications (Coates 1988, in: Coates 1988; Menkes 1986b, in:
Menkes 1986; Schober 1987, in:Menkes 1986). Thus the retrieval
of the full text theses was considered to be unnecessary.
Results of the search
After excludingduplicates, the electronic search retrieved 4082hits
(flow chart of literature search: Figure 1). Of these, we excluded
3802 references as being clearly irrelevant due to title and abstract.
The reasons for exclusion were:
Figure 1. Flow chart literature search
• the paper did not report a study on selenium and cancer
with humans (n = 3184),
• the paper dealt with selenium in the treatment of cancer (n
= 278),
• the study did not meet other inclusion criteria, e.g.
retrospective case-control studies or RCTs using a multi
component vitamin/trace element supplement (n = 340).
Twelve publications of potential relevance were identified in the
latest update search in February 2011. Due to time restrictions,
these publications could not be included in the current review
version and are listed in the section “Classification pending refer-
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ences”.
The remaining 268 publications were considered of possible rele-
vance and re-evaluated.
Included studies
One hundred and thirty-seven papers were identified for inclusion
in this review: 80 papers referred to one ongoing and 49 completed
observational studies. Fifty-seven papers referred to five ongoing
and six completed randomised controlled trials.
A detailed description of the studies included is given in the table
Characteristics of included studies.
1. Observational studies
Forty-nine completed observational studies were included in this
review. Thirty-six studies were nested case-control studies, the oth-
ers were sub-cohort controlled or cohort studies and one study
used a cohort together with a nested case-control design. Sub-co-
hort controlled studies used (random) samples of the cohort as
controls. The original papers were published between 1983 and
2009. Five studies were conducted in Asia (China, Japan and Tai-
wan), one in Australia, 19 in Europe (including data from Bel-
gium, Denmark, Germany, Greece, Italy, Netherlands, Norway,
Spain, Sweden, Channel Islands, Finland, France and theUK) and
24 in the US Overall, the studies included more than 1,078,000
participants. European study populations made up 45%, the US
45%, Asia 9.7%, and Australia 0.2% of all study participants.
The median size of the study populations was 10,494. Twenty-six
studies included men and women, one did not report gender, 17
included only men and five only women. For a substantial pro-
portion of the study populations (38%), gender was not reported.
Forty-one percent of participants were men, 21% were women.
Six studies with gender-mixed populations reported results strati-
fied by gender. The study populations were derived from42 differ-
ent cohorts. Twenty-three cohorts were non-randomly recruited,
e.g. included volunteers, and 19 cohorts consisted of a random
(or total) sample of the population of interest, which was either a
specifically exposed population such as male tin-miners in China
or the general population.
Thirty-seven studies specified the age range of their included par-
ticipants, the majority of which included adults over 40 years.
Five studies investigatednutritional and/or supplemental selenium
intake, using food-frequency questionnaires or interviews. Forty-
three studies assessed biochemical selenium status:
• eight used toenail specimens,
• 11 plasma specimens,
• 23 serum specimens,
• and one used both serum and plasma specimens.
One study measured both serum selenium levels and intake.
Themean follow-up periodwas up to three years in five studies and
longer than three years in the remaining studies. Generally, study
authors grouped the cases following the ICDclassification that was
up-to-date at the inception of the cohort observation. The level
of disaggregation of data varied remarkably between the studies.
While some studies reported cancer risk according to organ systems
(e.g. urinary tract, respiratory tract), others stratified their data by
one or two organs (e.g. female breast, urinary bladder). Only in
the case of skin cancer did studies also differentiate according to
histological type (e.g. melanoma, basal cell carcinoma).
For the following outcomes, five or more studies were included in
the review and observational data were meta-analysed:
• any cancer (15 studies)
• female breast cancer (7)
• urinary bladder cancer (5)
• lung cancer (13)
• prostate cancer (14)
• stomach cancer (5)
• colon/colorectal cancer (5)
Table 1 provides an overview on the studies for each outcome.
Five studies gave data for the group of “other” cancers, which en-
compassed any type of cancer not reported separately in the study
publications. The definition of the group of “other” cancers var-
ied between studies including predominantly rare cancers but also
cancers of unknown origin. The results of the studies within the
category “other cancers” are mentioned for the sake of complete-
ness, however, due to the diversity of outcomes the results were
not included in further analysis or discussion of this review.
Table 1. Included observational studies by outcome
Organ Sys-
tem
Outcome Num-
ber of stud-
ies/case def-
inition
Meta-
analysis
Countries Num-
ber of par-
ticipants
Number of
cases
Selenium
assessment
Reporting
study
Any cancer Any cancer Total: 15
incidence: 8
mortality: 6
incidence &
√
yes US
Finland
Nether-
lands
total: ~
151,000
total: 3220
male: 1700
female: 736
serum: 11
plasma: 2
serum +
plasma: 1
Knekt 1990
Coates
1988
Kok 1987
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Table 1. Included observational studies by outcome (Continued)
mortality
combined: 1
Sweden
Norway
Belgium
France
plasma sele-
nium P: 1
Salonen
1984
Nomura
1987
Virtamo
1987
Willett
1983
Fex 1987
Ringstad
1988
Persson
2000
Salonen
1985
Peleg 1985
Kornitzer
2004
Akbaraly
2005
Bleys 2008
Gynecolog-
ical cancer
Fe-
male breast
cancer
Total: 7
incidence: 7
mortality: 0
incidence &
mortality
combined: 0
√
yes US
Finland
Nether-
lands
Channel Is-
lands
to-
tal / female:
> 155,000
(one study
did not re-
port cohort
size)
total / fe-
male: 992
serum: 2
plasma: 1
serum +
plasma: 1
toenail: 3
Dorgan
1998
vd Brandt
1993
Coates
1988
Overvad
1991
Knekt 1990
Garland
1995
van Noord
1987
Cervical
cancer
Total: 2
incidence: 2
mortality: 0
incidence &
mortality
combined: 0
×no US to-
tal / female:
> 15,161
(one study
did not re-
port cohort
size)
total / fe-
male: 62
serum: 2 Menkes
1986
Coates 1988
Uterine can-
cer
Total: 1
incidence: 1
mortality: 0
incidence &
mortality
combined: 0
×no US to-
tal / female:
62,641
total / fe-
male: 91
toenail: 1 Garland
1995
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Table 1. Included observational studies by outcome (Continued)
Ovarian
cancer
Total: 4
incidence: 4
mortality: 0
incidence &
mortality
combined: 0
×no US
Finland
to-
tal / female:
~ 214,000
total / fe-
male: 568
serum: 2
toenail: 1
supplemen-
tal intake: 1
Knekt 1990
Garland
1995
Menkes
1986
Thomson
2008
Gyneco-
logical can-
cer (without
breast can-
cer)
Total: 1
incidence: 1
mortality: 0
incidence &
mortality
combined: 0
×no Finland to-
tal / female:
~ 18,000
total / fe-
male: 86
serum: 1 Knekt 1990
Urological
cancers
Uri-
nary bladder
cancer
Total: 5
incidence: 5
mortality: 0
incidence &
mortality
combined: 0
√
yes US/Hawaii
Finland
Netherlands
total:
279,100
female:
130,786
male:
128,009
total 965
female: 175
male 755
serum: 2
toenail: 3
Menkes
1986
Nomura
1987
Michaud
2002
vd Brandt
1993
Michaud
2005
Urinary
tract cancer
Total: 2
incidence: 2
mortality: 0
incidence &
mortality
combined: 0
×no Nether-
lands
Finland
total:
48,000
total: 104
male: 91
female: 13
serum: 1
plasma: 1
Knekt 1990
Persson
2000
Respi-
ratory tract
cancers
Lung cancer Total: 13
incidence:
12
mortality: 1
incidence &
mortality
combined: 0
√
yes China
Japan
US
Finland
Netherlands
total: ~
333,000
male:
125,341
female:
181,895
total: 1835
male: 1256
female: 333
serum: 8
serum +
plasma: 2
toenail: 2
dietary
intake: 1
(one study
re-
ported both
serum levels
and food in-
take)
Knekt 1990
Knekt 1998
Garland
1995
Coates
1988
Nomura
1987
vd Brandt
1993
Kabuto
1994
Menkes
1986
Goodman
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Table 1. Included observational studies by outcome (Continued)
2001
Comstock
1997
Kromhout
1987
Ratnasinghe
2000
Epplein
2009
Oral / pha-
ryngeal can-
cer
Total: 1
incidence: 1
mortality: 0
incidence &
mortality
combined: 0
×no US total:
25,804
total: 28 serum: 1 Menkes
1986
Any cancer
of the respi-
ratory tract
Total: 1
incidence: 1
mortality: 0
incidence &
mortality
combined: 0
×no Sweden total / male:
~ 9500
total / male:
69
Plasma sele-
nium P: 1
Persson
2000
Andrologi-
cal cancers
Prostate
cancer
Total: 14
incidence:
14
mortality: 0
incidence &
mortality
combined: 0
√
yes US
Europe
total / male:
> 416,500
(one study
did not re-
port cohort
size)
total / male:
5249
serum: 6
plasma: 3
toenail: 3
dietary
intake: 2
Hartman
1998
Helzlsouer
2000
Coates
1988
Brooks
2001
vd Brandt
1993
Nomura
2000
Goodman
2001
Yoshizawa
1998
Li 2004a
Peters 2007
Peters 2008
Allen 2008
Epplein
2009
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Table 1. Included observational studies by outcome (Continued)
Gastroin-
testinal
cancers
Oe-
sophageal
cancer
Total: 2
incidence: 2
mortality: 1
incidence &
mortality
combined: 0
×no China
US
total:
29,923
total: > 959 serum: 1
supplemen-
tal intake: 1
Wei 2004
Dong 2008
Oe-
sophageal /
stomach
cancer
Total: 1
incidence: 1
mortality: 0
incidence &
mortality
combined: 0
×no Netherlands total:
36,265
total: 86
male: 51
female: 35
serum: 1 Knekt 1998
Stomach
cancer
Total: 5
incidence: 5
mortality: 1
incidence &
mortality
combined: 0
√
yes China
Japan
US/Hawaii
Finland
Netherlands
total: ~
197,000
male:
86,311
female:
80,669
total: 955
male: 626
female: 329
serum: 4
toenail: 1
Knekt 1990
vd Brandt
1993
Nomura
1987
Kabuto
1994
Wei 2004
Primary
liver cancer
Total: 2
incidence: 1
mortality: 1
incidence &
mortality
combined: 0
×no Taiwan total:
46,404
total: 235
male: 223
female: 12
plasma: 1
toenail: 1
Yu 1999
Sakoda
2005
Pancreatic
cancer
Total: 2
incidence: 2
mortality: 0
incidence &
mortality
combined: 0
×no US
Finland
total:
65,072
total: 67
male: 31
female: 36
serum: 2 Menkes
1986
Knekt
1990).
Colon/col-
orectal can-
cer
Total:
colon 2, col-
orectum 3
incidence: 5
mortality: 0
incidence &
mortality
combined: 0
√
yes US
Nether-
lands
Finland
total:
255,425
male:
86,311
female:
143,310
total: 617
male: 285
female: 332
serum: 3
toenail: 2
vd Brandt
1993
Nomura
1987
Menkes
1986
Garland
1995
Knekt 1990
Rectal can-
cer
Total: 2
incidence: 2
×no US/Hawaii
Netherlands
total:
127,712
total: 145
male: 109
serum: 1
toenail: 1
vd Brandt
1993
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Table 1. Included observational studies by outcome (Continued)
mortality: 0
incidence &
mortality
combined: 0
female: 36 Nomura
1987
All gastroin-
testinal can-
cers
Total: 2
incidence: 2
mortality: 0
incidence &
mortality
combined: 0
×no US
Sweden
total: > 9500
(one study
did not re-
port cohort
size)
total: 143 plasma +
serum: 1
plasma sele-
nium P: 1
Coates 1988
Persson
2000
Skin cancer Melanoma Total: 3
incidence: 3
mortality: 0
incidence &
mortality
combined: 0
×no US total: ~
158,000
total: 547 serum: 1
toenail: 1
supplemen-
tal intake: 1
Garland
1995
Menkes
1986 Peters
2008
Basal cell
carcinoma
Total: 3
incidence: 3
mortality: 0
incidence &
mortality
combined: 0
×no Australia
US
Finland
total: >
66,000
total: 292 serum: 3
dietary
intake: 1
Knekt 1990
Menkes
1986
Mc-
Naughton
2005
Squamous
cell
carcinoma
Total: 4
incidence: 4
mortality: 0
incidence &
mortality
combined: 0
×no Australia
US
total: ~
30,000
total: 488 serum: 2
plasma: 1
dietary
intake: 1
Combs
1993
Karagas
1997
Menkes
1986
Mc-
Naughton
2005
Total non-
melanoma
skin cancer
Total: 1
incidence: 1
mortality: 0
incidence &
mortality
combined: 0
×no US total: 117 total: 19 plasma: 1 Clark 1985
Rare and
other can-
cers
Haemato-
logical can-
cers
Total: 1
incidence: 1
mortality: 0
incidence &
mortality
×no US total: ~
6,200
total: 12 serum +
plasma: 12
Coates 1988
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Table 1. Included observational studies by outcome (Continued)
combined: 0
Thyroid
cancer
Total: 1
incidence: 1
mortality: 0
incidence &
mortality
combined: 0
×no Norway total:
100,000
total: 43
male: 12
female: 31
serum: 1 Glattre
1989
Other can-
cers
Total: 5
incidence: 4
mortality: 1
incidence &
mortality
combined: 0
×no China
US
Finland
Sweden
total: 573
male: 230
female: 285
Garland
1995
Coates
1988
Knekt 1990
Wei 2004
Persson
2000
Some studies did not report the gender of participants or cancer cases; consequently, figures for women and men not always sum up
to the total number of participants or cancer cases.
2. Randomised controlled trials
Six randomised controlled trials with a total of 43,408 participants
(94% men) were included in this review. All used parallel group
designs with either two arms ( Li 2000; NPCT 1996; Reid 2008;
Yu 1991; Yu 1997) or four arms (SELECT 2009). Three were
conducted in China ( Li 2000; Yu 1991; Yu 1997), two in the US
(NPCT 1996; Reid 2008) and one in the USA/Canada/Puerto
Rico (SELECT 2009).
Selenium supplements and placebos were administered daily. As
an active intervention, trials used 200 µg (NPCT 1996; Yu 1991;
Yu 1997) or 400 µg (Reid 2008) selenium in the form of selenised
yeast tablets. Li 2000 used 500 µg sodium selenite and SELECT
2009 used 200 µg L-selenomethionine.
2.1. Primary liver cancer
Three Chinese trials investigated the preventive efficacy of sele-
nium supplementation against primary liver cancer in different
high-risk populations. Participants were either carriers of theHep-
atitis B surface antigen (HBs-Ag) with normal liver function or
first-degree relatives of liver cancer patients. Two trials used se-
lenised yeast (Yu 1991; Yu 1997) and one sodium selenite (Li
2000).
2.2. Non-melanoma skin cancer
The US Nutritional Prevention of Cancer Trial (NPCT) investi-
gated the influence of selenium on the development of squamous
and basal cell skin cancer in a high-risk group (NPCT 1996). Par-
ticipants were men and women between 18 and 80 years. All had
a history of two or more basal cell carcinomas or of one squamous
cell carcinoma. All results were reported for two periods of follow-
up: the intended study period (from 15 September 1983 to 31De-
cember 1993: Clark 1996 see NPCT 1996) and the entire blinded
intervention period (from15 September 1983 to 31 January 1996:
Duffield-Lillico 2002; Duffield-Lillico 2003 see NPCT 1996).
A sub-study of the NPCT (Reid 2008) investigated the efficacy
of a higher selenium dose, supplied as selenised yeast orally, in the
prevention of non-melanoma skin cancer in one of the NPCT
study sites. Study design was similar to the NPCT study, except
that 423 participants at this study site were randomised to placebo
or intervention with higher selenium content.
2.3. Prostate cancer
The Selenium and Vitamin E Cancer Prevention Trial (SELECT)
investigated the preventive potential of selenium, as selenomethio-
nine, and vitamin E supplementation in men of diverse ethnic
backgrounds against prostate cancer (SELECT 2009).
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2.4. Other cancers
In 1990 additional secondary endpoints were identified post-hoc
in NPCT 1996 (total cancer mortality, total cancer incidence,
incidence of lung, prostate, colorectal cancers). Furthermore, the
incidences of female breast cancer, bladder cancer, oesophageal
cancer, melanoma, haematological cancers and cancers of the head
and neck were also reported in trial publications (NPCT 1996).
Reid 2008 reported the incidence of internal cancers.
SELECT 2009 investigated several pre-specified secondary out-
comes, including the incidence of and deaths from any type of
cancer, lung cancer, colorectal cancer and other cancers (excluding
prostate, basal cell and squamous cell skin cancer).
Excluded studies
Of these, 131 papers did not fulfil the inclusion criteria. Eighty-
eight of these publications were rejected on the basis of abstract
and title in the second evaluation, 43 papers were retrieved as
full-text and their reasons for exclusion are described in the table
Characteristics of excluded studies.
The main reasons for exclusion were:
• The publication was a review or comment.
• Cancer was not a study endpoint.
• Selenium was not the exposure/intervention of interest.
• The study was a retrospective case-control study.
• The RCT had not been started.
• A multi component supplement was used.
• A control group was not included in the trial.
• Observational studies did not report their results according
to the inclusion criteria, e.g. only differences in the mean
selenium exposure between cases and controls were provided.
Risk of bias in included studies
Observational studies
The median value of ’assigned stars’ was seven in the cohort study
assessment and eight in the (nested) case-control study assessment
out of a maximum of nine stars each (Figure 2 and Figure 3). A
summary of the rating according to the Newcastle-Ottawa-Scale
(NOS) is presented in Table 2.
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Figure 2. Newcastle-Ottawa-Scale: number of studies by number of “stars” assigned in the case-control
part of studies
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Figure 3. Newcastle Ottawa-Scale: number of studies by number of “stars” assigned in the cohort part of
studies
Table 2. Risk of bias: observational studies
Study Publica-
tion
Newcastle Ottawa Scale (Cohort) Newcastle Ottawa Scale (Case-Control)
Selection Compara-
bility
Outcome Total Selection Compara-
bility
Exposure Total
Kabuto
1994
Kabuto
1994
0-1-1-1 2 1-1-0 7 0-1-1-1 2 1-1-1 8
Ratnas-
inghe
2000
Ratnas-
inghe
2000
1-1-1-1 2 1-0-0 7 0-0-1-1 2 1-1-1 7
Sakoda
2005
Sakoda
2005
0-1-1-0 1 1-1-0 5 1-1-1-1 1 1-1-1 8
Wei 2004 Wei 2004 1-1-1-1 1 1-1-1 8 .-.-.-. .-.-.
Mark 2000 1-1-1-1 1 1-1-1 8 .-.-.-. .-.-.
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Table 2. Risk of bias: observational studies (Continued)
Yu 1999 Yu 1999 0-1-1-1 2 1-1-0 7 1-1-1-1 2 1-1-1 9
Mc-
Naughton
2005
Mc-
Naughton
2005
1-1-1-1 1 1-1-0 7 1-1-1-1 1 1-1-1 8
Heinen
2007
1-1-1-1 2 1-1-1 9 .-.-.-. .-.-.
van der
Pols 2009
1-1-1-1 2 1-1-0 8 .-.-.-. .-.-.
Akbaraly
2005
Akbaraly
2005
0-1-1-1 2 0-1-0 6 .-.-.-. .-.-.
Allen 2008 Allen 2008 1-1-1-1 2 1-1-0 8 1-1-1-1 2 1-1-1 9
Fex 1987 Fex 1987 1-1-1-0 2 1-1-1 8 1-0-1-1 2 1-1-1 8
Glattre
1989
Glattre
1989
0-1-1-0 1 1-1-1 6 1-1-1-1 1 1-1-1 8
Hartman
1998
Hartman
1998
1-1-0-1 2 1-1-0 7 .-.-.-. .-.-.
Knekt
1990
Knekt
1990
1-1-1-1 2 1-1-1 9 0-1-1-1 2 1-1-1 8
Hakama
1990
1-1-1-1 2 1-1-1 9 0-1-1-1 2 1-1-1 8
Knekt
1988
1-1-1-1 2 1-1-1 9 0-0-1-1 2 1-1-1 7
Knekt
1996
1-1-1-1 1 1-1-1 8 0-1-1-1 1 1-1-1 7
Knekt
1991
1-1-1-1 2 1-1-1 9 0-1-1-1 2 1-1-1 8
Knekt
1998
Knekt
1998
1-1-1-1 2 1-1-1 9 0-1-1-1 2 1-1-1 8
Kok 1987 Kok1987b 1-1-1-1 2 1-1-1 9 1-0-1-1 2 1-1-1 8
Kok 1987a .-.-.-. .-.-. .-.-.-. .-.-.
Kornitzer
2004
Kornitzer
2004
1-1-1-0 1 1-1-1 7 1-1-1-1 1 1-1-1 8
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Table 2. Risk of bias: observational studies (Continued)
Kromhout
1987
Kromhout
1987
1-1-1-0 2 1-1-1 8 .-.-.-. .-.-.
Michaud
2002
Michaud
2002
1-1-1-1 2 1-1-0 8 0-1-1-1 2 1-1-1 8
Overvad
1991
Overvad
1991
1-1-1-0 1 1-1-0 6 .-.-.-. .-.-.
Persson
2000
Persson-
Moschos
2000
1-1-1-0 2 1-1-1 8 1-0-1-1 2 1-1-1 8
Ringstad
1988
Ringstad
1988
1-1-1-1 2 1-1-0 8 1-1-1-1 2 1-1-1 9
Salonen
1984
Salonen
1984
1-1-1-1 2 1-1-1 9 0-1-1-1 2 1-1-1 8
Salonen
1985
Salonen
1985
1-1-1-1 2 1-1-1 9 1-1-1-1 2 1-1-1 9
van Noord
1987
van Noord
1987
1-1-1-0 1 1-0-1 6 1-1-1-0 1 1-1-1 7
vd Brandt
1993
van
den Brandt
1993
1-1-1-1 2 1-1-1 9 .-.-.-. .-.-.
van
den Brandt
1994
1-1-1-1 2 1-1-1 9 .-.-.-. .-.-.
van
den Brandt
1993
1-1-1-1 2 1-1-1 9 .-.-.-. .-.-.
van
den Brandt
2003
1-1-1-1 2 1-1-1 9 .-.-.-. .-.-.
Zeegers
2002
1-1-1-1 2 1-1-1 9 .-.-.-. .-.-.
Virtamo
1987
Virtamo
1987
0-1-1-1 2 1-1-1 8 .-.-.-. .-.-.
Bleys 2008 Bleys 2008 1-1-1-1 2 1-1-1 9 .-.-.-. .-.-.
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Table 2. Risk of bias: observational studies (Continued)
Brooks
2001
Brooks
2001
0-1-1-0 2 1-0-0 5 1-0-1-1 2 1-1-0 7
Clark
1985
Clark
1985
0-1-1-0 0 0-0-0 2 .-.-.-. .-.-.
Coates
1988
Coates
1988
0-1-1-0 1 1-1-0 5 1-0-1-0 1 1-1-1 6
Coates
1987
.-.-.-. .-.-. .-.-.-. .-.-.
Combs
1993
Combs jr
1993
0-1-1-0 2 1-0-0 5 .-.-.-. .-.-.
Comstock
1997
Comstock
1997
0-1-1-0 2 1-1-0 6 1-1-1-1 2 1-1-1 9
Dong
2008
Dong
2008
1-1-1-1 2 1-1-1 9 .-.-.-. .-.-.
Dorgan
1998
Dorgan
1998
0-1-1-1 2 0-1-0 6 1-1-1-1 2 1-1-1 9
Epplein
2009
Epplein
2009
0-1-1-1 2 1-1-0 7 0-1-1-1 2 1-1-1 8
Gill 2009 0-1-1-1 1 1-1-0 6 0-1-1-1 1 1-1-1 7
Garland
1995
Garland
1995
0-1-1-1 2 1-1-1 8 1-1-1-1 2 1-1-1 9
Hunter
1990
0-1-1-1 2 1-1-1 8 1-1-1-1 2 1-1-1 9
Goodman
2001
Goodman
2001
0-1-1-0 2 1-1-0 6 1-1-1-1 2 1-1-1 9
Helzlsouer
2000
Helzlsouer
2000
0-1-1-1 1 1-1-0 6 1-1-1-1 1 1-1-1 8
Karagas
1997
Karagas
1997
0-1-1-1 2 1-1-1 8 1-1-1-1 2 1-1-1 9
Li 2004a Li 2004 0-1-1-1 2 0-1-1 7 1-1-1-1 2 1-1-1 9
Menkes
1986
Menkes
1986
0-1-1-1 2 1-1-0 7 1-1-1-1 2 1-1-1 9
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Table 2. Risk of bias: observational studies (Continued)
Batieha
1993
0-1-1-1 2 1-1-0 7 1-1-1-1 2 1-1-1 9
Breslow
1995
0-1-1-1 2 1-1-0 7 1-0-1-1 2 1-1-1 8
Burney
1989
0-1-1-1 2 1-1-0 7 0-1-1-1 2 1-1-1 8
Helzlsouer
1996
0-1-1-1 2 1-1-0 7 0-1-1-1 2 1-1-1 8
Helzlsouer
1989
0-1-1-1 2 1-1-0 7 1-1-1-1 2 1-1-1 9
Ko 1994 0-1-1-0 2 1-1-0 6 1-1-1-1 2 1-1-1 9
Menkes
1986
.-.-.-. .-.-. .-.-.-. .-.-.
Schober
1987
0-1-1-1 1 1-1-0 6 0-1-1-1 1 1-1-1 7
Schober
1986
.-.-.-. .-.-. .-.-.-. .-.-.
Zheng
1993
0-1-1-1 2 1-1-0 7 0-1-1-1 2 1-1-1 8
Michaud
2005
Michaud
2005
0-1-1-1 2 0-1-0 6 1-1-1-1 2 1-1-1 9
Nomura
1987
Nomura
1987
1-1-1-1 2 1-1-1 9 1-1-1-1 2 1-1-1 9
Nomura
2000
Nomura
2000
1-1-1-1 2 1-1-1 9 1-1-1-1 2 1-1-1 9
Peleg 1985 Peleg 1985 1-1-1-1 1 1-1-0 7 1-1-1-1 1 1-1-1 8
Peters
2007
Peters
2007
0-1-1-1 2 1-1-0 7 1-1-1-1 2 1-1-1 9
Peters
2008
Peters
2008
0-1-1-1 1 1-1-1 7 .-.-.-. .-.-.
Asgari
2009
0-1-1-1 1 1-1-0 6 .-.-.-. .-.-.
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Table 2. Risk of bias: observational studies (Continued)
Thomson
2008
Thomson
2008
0-1-1-1 2 0-1-0 6 .-.-.-. .-.-.
Willett
1983
Willett
1983
1-1-1-0 2 1-1-0 7 1-1-1-1 2 1-1-1 9
Yoshizawa
1998
Yoshizawa
1998
0-1-1-1 2 1-1-1 8 1-0-1-1 2 1-1-1 8
All but one cohort study received five to nine ’stars’ in the NOS.
The exception (two ’stars’) was an early investigation, which was
only available in abstract form for assessment (Clark 1985). For
three items of the NOS cohort assessment, less than 70% of the
included studies were considered adequate: representativeness of
the cohort for the target population (51% of the studies received
a ’star’), demonstration that cancer was not present at study com-
mencement (69%) and completeness of follow-up data (49%).
The representativeness of the cohort for the target population is a
matter of external validity and generalisability of study results, but
a systematic deviation of participants from the target population
might also introduce bias to study results. The target population of
included studies depended on the study objectives and could have
been the general population, but also special occupational groups.
Studies that did not identify their target population or recruited
volunteers were not assigned a ’star’ to this question. Differential
selection of study participants, e.g. volunteers, from the target
population can lead to confounding by factors associated with
selenium status and cancer incidence, e.g. nutritional behaviour
or socio-economic position.
All included studies chose comparison groups (cases/controls or
exposed/non-exposed) from the same study population. This ap-
proach increased the comparability between groups.
The presence of undiagnosed cancer at the beginning of the study,
when specimens for selenium analysis were taken, might influ-
ence selenium levels. People with certain types of cancer have
been found to have lower selenium levels than healthy controls.
This might lead to an overestimation of the protective effect of
higher selenium levels against cancer, if undiagnosed cancer cases
are prevalent. Some studies tried to investigate this source of bias
by excluding cases that occurred within a certain period from the
beginning (mostly one or two years).
Follow-up data were considered either as complete or as missing
data unlikely to introduce bias to study results in 50% of the in-
cluded observational studies. In the other cohorts, losses to follow-
up were more than 5% and a description of losses to follow-up
was not provided. A high attrition may alter the characteristics of
the population under investigation and impede generalisability of
study results to the intended target population (external validity).
The presence of attrition does not necessarily mean that the study
results are biased. However, given the possibility that selenium sta-
tus may be linked to sociodemographic variables and socio-eco-
nomic position which may also influence participation in follow-
up procedures, a differential effect of attrition may introduce bias
towards under- or over-estimation of the true exposure effect.
Thirty-six included observational studies were nested case-control
studies and therefore additionally assessed using the NOS case-
control form. The number of ’stars’ in the NOS assessment of
the case-control part of the studies ranged from six to nine, with
more than 85% having received eight or nine ’stars’. Although the
included prospective case-control studies were generally assessed
as having a low risk of bias, in some studies concern arose due to
case definition and the question of representativeness of the cases.
Definition of cases was considered inadequate in 19%of the nested
case-control studies as cases were identified by self-reporting, link-
age to databases with unclear validity of data or procedures were
not described. The magnitude and direction of bias that might
have been introduced to the study results is unclear.
In 19%of studies, not all identified cases (or an appropriate sample
of them) were included in the trial analyses or selection procedures
for analysed cases were not reported. In some studies, blood spec-
imens were lost due to technical problems (e.g. cooler breakdown
in one study centre), others did not have enough material available
for analysis or cases for analysis were otherwise selected in a non-
random manner. This might bias the estimates of association in
either direction.
There was no obvious asymmetry (as an indicator of publication
bias) in the funnel plots of the studies on total and prostate cancer
risk (Figure 4; Figure 5).
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Figure 4. Funnel plot of comparison: 1 Highest versus lowest selenium exposure, outcome: 1.17 Total
cancer incidence and mortality.
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Figure 5. Funnel plot of comparison: 1 Highest versus lowest selenium exposure, outcome: 1.7 Prostate
cancer risk.
Randomised controlled trials
An overview of the risk of bias in the included randomised con-
trolled trials is presented in Table 3.
Table 3. Risk of bias: randomised controlled trials
Study Sequence
generation
Allocation conceal-
ment
Blinding Completeness of
outcome data
Risk of bias
NPCT 1996 adequate adequate adequate adequate low
Reid 2008 adequate adequate adequate adequate low
Li 2000 unclear unclear adequate adequate unclear
Yu 1997 unclear unclear adequate unclear unclear
Yu 1991 unclear unclear adequate unclear unclear
SELECT 2009 adequate adequate adequate adequate low
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Primary liver cancer
All three trials on liver cancer risk (Li 2000; Yu 1991; Yu 1997)
were considered to have an unclear risk of bias. In these trials, the
generation of allocation sequence and the allocation concealment
were not reported. One study mentioned that the drop-out rate
was similar in the intervention and control group, the remain-
ing two studies did not report the completeness of outcome data.
Blinding was judged as adequate in all three studies as the use of
placebo supplements was reported. We inferred from this proce-
dure that at least the study participants and the physicians directly
involved were blinded towards treatment status.
We would like to point out that we are not entirely convinced
that Li 2000 is a randomised controlled trial. The study investi-
gators used the term ’randomization based on the residence area’
and did not describe the randomisation procedure any further.
As participants were recruited from 17 villages, the villages and
not the individual participants (stratified by village) could have
been randomly assigned to the intervention and control group.
However, we could not make contact with the study investigators
and clarify these questions. A randomisation of villages instead of
individuals would have introduced bias to the study results as the
incidence of liver cancer is known to differ between areas as a result
of environmental factors.
Studies with inadequate or unclear allocation concealment have
been found to overestimate the benefit of interventions in RCTs,
especially in trials with subjective outcomes (Pildal 2007; Wood
2008). In all three liver cancer RCTs, follow-up and case-detection
procedures were not reported, so the influence of subjective factors
on case detection, such as interpretation of bodily symptoms as
trigger of further diagnostic tests, is unknown.Althoughwe judged
blinding as ’adequate’ in all three liver cancer trials, we do not
know whether it was successful in practice for patients, healthcare
providers and outcome assessors.
These uncertainties about study methods seriously weaken our
confidence in the reported RCT results on liver cancer risk.
Non-melanoma skin cancer
Both included RCTs on non-melanoma skin cancer (NPCT1996;
Reid 2008) were considered to have a low risk of bias with ade-
quate generation of allocation sequence, allocation concealment,
blinding and completeness of outcome data. Reid 2008 was a sub-
study of NPCT 1996.
Both studies also reported data for several secondary outcomes that
were introduced post-hoc, such as lung, prostate, colorectal can-
cer and total cancer incidence. Placebo and selenium groups were
similar regarding the distribution of the risk factors smoking, age,
gender and PSA levels at randomisation. New cases were identified
in the biannual participants’ interviews and by documenting can-
cer screening and diagnostic procedures from their medical files.
Detection bias might have been introduced by a different use of
diagnostic procedures in both groups: Men in the placebo group
were, despite similar PSA levels, more likely to have undergone
prostate biopsy (NPCT 1996) than men in the selenium group
(Duffield-Lillico 2003b seeNPCT 1996) which might have led to
an underestimation of prostate cancer incidence in the selenium
group and an overestimation of the treatment effect. As the back-
ground of this difference is unclear, it cannot be ruled out that dif-
ferential health behaviours and diagnostic activities in both study
groups might have affected the detection of lung and colorectal
cancer as well, at least in the 75% male participants.
Prostate cancer
SELECT 2009 was considered to have a low risk of bias with ad-
equate generation of allocation sequence, allocation concealment,
blinding and completeness of outcome data.
Placebo and selenium groups were similar regarding the distribu-
tion of age, education, smoking status, PSA levels and race/eth-
nicity at baseline. No inter-group differences were found in the
utilisation of PSA tests, prostate biopsies or digital rectal exami-
nations during the course of the study.
Ethical criteria
Informed consent and ethics board approval was fulfilled byNPCT
1996, Reid 2008 and SELECT 2009, but not mentioned in Li
2000, Yu 1997, and Yu 1991.
Effects of interventions
1. Observational studies
When comparing the risk of cancer in higher and lower levels
of selenium exposure, a summary risk estimate of 1 suggests that
there is no association between selenium exposure and cancer, a
summary risk estimate below 1 suggests a possible protective effect
of higher selenium exposure and a summary risk estimate above 1
suggests a possible harmful effect of higher selenium exposure.
1.1. Aetiological association: Results from meta-analyses
1.1.1. Any cancer
Results of 13 prospective observational studies on total cancer risk
including data of more than 143,000 participants were meta-anal-
ysed. The cohorts of Salonen 1984 and Salonen 1985 overlapped.
Hence, only data from Salonen 1985 were included in the meta-
analysis. Fex 1987 had to be omitted as the CI value was not re-
ported and could not be calculated from the available data.
In participants in the highest category of pre-diagnostic selenium
exposure, the summary risk estimate was OR 0.69 (95% CI 0.53
to 0.91) for cancer incidence and OR 0.55 (95% CI 0.36 to 0.83)
for cancer mortality in both genders (Analysis 1.17) when com-
pared with participants in the lowest exposure category. Statisti-
cally significant heterogeneity was observed both among studies
on incidence (I² = 49%) and mortality (I² = 58%).
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Analyses by gender found the risk to be lower in men (incidence:
OR 0.66 (95% CI 0.42 to 1.05), mortality 0.56 (95% CI 0.38 to
0.81)) (Analysis 1.20) than in women (incidence: OR 0.90 (95%
CI 0.45 to 1.77), mortality: OR 0.92 (95% CI 0.79 to 1.07)
(Analysis 1.19).
All studies used either serumor serum and plasma biomarker levels
for the assessment of selenium status. Analysis 1.18 shows the
results in ascending order of baseline exposure of those studies
that reported their category borders. The graph does not reveal
a clear pattern of a relationship between baseline biomarker level
and cancer risk.
1.1.2. Female breast cancer
Seven studies were included in the meta-analysis. No association
was seen between baseline selenium levels and incidence of breast
cancer with an overall risk estimate of OR 1.00 (95% CI 0.78 to
1.29) (Analysis 1.1). The heterogeneity of trial results (I² = 5.4%)
was low and not statistically significant.
1.1.3. Bladder cancer
Meta-analysis of bladder cancer incidence in five observational
studies found an inverse association with an overall risk estimate
of 0.67 (95% CI 0.46 to 0.97) suggesting a protective effect of
higher selenium levels against bladder cancer (Analysis 1.2) (overall
heterogeneity: I² = 30%).
Gender-disaggregated data were only available from Michaud
2005 indicating a protective effect in women, but not in men in
this study. However, two studies (Michaud 2002; Nomura 1987)
had only male participants and both found a non-significantly
reduced bladder cancer risk for higher selenium exposure (Analysis
1.2). Heterogeneity was not reduced by gender stratification (I² =
40% in study results for men).
1.1.4. Lung cancer
Eleven studies were included in this meta-analysis. Data from
Menkes 1986 andKnekt 1990 were notmeta-analysed as the study
population of the former overlapped with another meta-analysed
study (Comstock 1997) and results of the latter were presented in
insufficient detail.
The summary risk estimate for lung cancer incidence in both gen-
ders was 0.75 (95% CI 0.54 to 1.03) (Analysis 1.3). Statistically
significant moderate heterogeneity was seen between study results
(I² = 54%).
In the meta-analysis according to gender using gender-stratified
study results (Analysis 1.4), the summary risk estimate for women
was OR 0.83 (95% CI 0.43 to 1.61)) and for men OR 0.88
(95% CI 0.61 to 1.28)). Heterogeneity among study results was
not reduced by stratification. However, we expected the results for
gender-combined data to be more or less a combination of the
separate results for women and men. This was not the case here
with ’gender-neutral’ data suggesting a larger protective effect than
gender-stratified data. This discrepancy might relate to differences
in study designs or populations.
In Knekt 1998, 95% of the lung cancer cases occurred in men.We
repeated the meta-analysis of gender-disaggregated data categoris-
ing Knekt 1998 as ’men-only’ study and found a slightly changed
summary risk estimate for men (OR 0.81 (95%CI 0.56 to 1.18)).
The only study using nutritional intake assessment for exposure
classification (Kromhout 1987) found no association with lung
cancer risk (Analysis 1.6). Two studies measured selenium content
in toenailswith inconsistent results: Participants of the (all women)
Nurses’ Health Study (Garland 1995) showed an increased lung
cancer risk with higher selenium toenail levels, while an inverse
association was observed in the Netherlands’ Cohort Study (vd
Brandt 1993). The remaining eight studies used serum or plasma
selenium levels. The summary OR was 0.84 (95% CI 0.66 to
1.06) with low heterogeneity (I² = 3.5).
We plotted the studies using serum/plasma in ascending order
of baseline exposure level (Analysis 1.5). No clear pattern of a
relationship between baseline exposure levels and lung cancer risk
could be seen in this graph. The two studies, which suggested
the largest protective effect of higher selenium levels, were Knekt
1998 and Kabuto 1994. However, two other studies with quite
similar biomarker levels found discrepant results (Nomura 1987;
Ratnasinghe 2000).
1.1.5. Prostate cancer
Fourteen epidemiological studies on prostate cancer incidence
were included in the meta-analysis. The summary risk estimate
for higher selenium exposure was OR 0.78 (95% CI 0.66 to 0.92)
(heterogeneity: I² = 37%) (Analysis 1.7).
Stratification by the method of selenium assessment showed a re-
duction in prostate cancer risk for higher baseline biochemical
markers (OR 0.74 (95% CI 0.61 to 0.88)), but not for higher esti-
mated selenium intake (OR 1.00 (95%CI 0.73 to 1.36)) (Analysis
1.8). The inverse association between selenium biomarkers and
prostate cancer incidence was stronger for toenail levels (OR 0.53
(95% CI 0.35 to 0.81)) than for blood levels (OR 0.81 (95% CI
0.68 to 0.97)) (Analysis 1.9). Heterogeneity among study results
was slightly reduced with these stratifications.
Stratification by country and continent found the risk reduc-
tion more pronounced in the US than in Europe (Analysis 1.10;
Analysis 1.11).
Overall, the strongest inverse associations were seen in studies
from the US published before 2001. These findings cannot be ex-
plained by differences in baseline selenium levels alone. Analysis
1.12 shows the results for studies using serum or plasma mea-
surements in ascending order of selenium levels. For quite similar
categories of selenium concentration, studies indicated different
effects (Goodman 2001 versus Clark 1985; Nomura 2000 versus
Peters 2007 and Gill 2009 see Epplein 2009).
1.1.6. Stomach cancer
Five observational studies were included in the meta-analysis of
gastric cancer incidence. The summary risk estimate for both gen-
ders was OR 0.66 (95% CI 0.43 to 1.01) in the highest exposure
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category when compared with the lowest (I² = 50.8%) (Analysis
1.13). However, in this meta-analysis one cohort (Mark 2000 in:
Wei 2004) is included twice because the results were reported strat-
ified according to cardia and non-cardia gastric cancer.
We repeated the meta-analyses including alternately the results
of Mark 2000 (see Wei 2004) for cardia and non-cardia gastric
cancer. The summary OR was 0.75 (95% CI 0.47 to 1.21) when
data for non-cardia cancer were included and OR 0.59 (95% CI
0.38 to 0.93) when data for cardia cancer were included.
Using the available gender-stratified results for meta-analysis, the
risk estimate for men was OR 0.43 (95% CI 0.14 to 1.32) (I² =
56.1%) and for women OR 0.73 (95% CI 0.12 to 4.35) (I² =
62.3%) (Analysis 1.14).
1.1.7. Colon/colorectal cancer
Five observational studies reported data on colon or colorectal
cancer incidence. The summary risk estimate was OR 0.89 (95%
CI 0.65 to 1.23) for both genders (I² = 3.8%) (Analysis 1.15), OR
0.69 (95% CI 0.42 to 1.12) for men and OR 1.06 (95% CI 0.57
to 2.00) for women (Analysis 1.16).
1.2. Aetiological association: other results
Results of the observational studies, which were not included in
meta-analyses, are reported in Table 4.
Table 4. Results of observational studies not included in meta-analysis
Organ system Cancer Case
definition
Rel-
ative risk esti-
mate (highest
versus lowest
exposure cat-
egory)
95% CI Selenium
marker
Gender Study
Gynecologic Cervix Incidence 0.89 0.40 to 2.00 serum women Menkes 1986
(Batieha 1993)
1.10 n.r. serum Coates 1988
Gynaeco-
logic (without
breast)
Incidence 0.96 n.r. serum Knekt 1990
Ovary Incidence 0.87 0.25 to 5.26 serum Knekt 1990 (Knekt
1996)
1.22 0.44 to 3.38 toenail Garland 1995
0.58 0.2 to 1.7 serum Menkes 1986 (Hel-
zlsour 1996)
1.00 (HR) 0.73 to 1.37 suppl. intake Thomson 2008
Uterus Incidence 1.38 0.62 to 3.08 toenail Garland 1995
Gastroin-
testinal
Gastrointesti-
nal tract (all)
Incidence 1.00 n.r. serum/plasma both Coates 1988
0.29 0.10 to 0.91 plasma men Persson 2000
Oesophagus Incidence 0.56 0.44 to 0.71 serum both Wei 2004 (Mark
2000)
Mortality 0.62 0.44 to 0.89 serum
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Table 4. Results of observational studies not included in meta-analysis (Continued)
Mortality 0.35 0.16 to 0.81 serum both Wei 2004 (Wei
2004)
Incidence 0.27 0.03 to 2.21 suppl. intake both Dong 2008
Oesophages
and stomach
Incidence 0.45 n.r. serum men Knekt 1990 (Knekt
1988)
Incidence 0.67 n.r. serum women
Liver Incidence 0.62 0.21 to 1.86 plasma men Yu 1999
Incidence 0.50 0.28 to 0.90 toenail both Sakoda 2005
Mortality 0.50 0.28 to 0.90 both
0.57 0.31 to 1.05 men
0.18 0.03 to 1.13 women
Pancreas Incidence 0.08 0.01 to 0.56) serum men Menkes 1986 (Bur-
ney 1989)
0.83 0.4 to 1.67 women
0.58 n.r. serum men Knekt 1990
3.49 n.r. women
Rectum Incidence 0.625 n.r. serum men Nomura 1987
1.05 0.54 to 2.03 toenail both vd Brandt 1993
0.91 0.41 to 2.00 men
1.58 0.59 to 4.22 women
Urinary tract Urinary tract
(all)
Incidence 5.0 0.71 to plasma men Persson 2000
0.81 n.r. serum men Knekt 1990
4.12 n.r. women
Respiratory
tract
Cavum oris/
pharynx
Incidence 5.43 n.r. serum both Menkes 1986
(Zheng 1993)
Respiratory
tract (all)
Incidence 6.0 1.5 to 24.2 plasma men Persson 2000
Skin Melanoma Incidence 1.66 0.71 to 3.85 toenail women Garland 1995
0.90 0.30 to 2.50 serum both Menkes 1986 (Bres-
low 1995)
0.98 0.69 to 1.41 suppl. intake both Peters 2008 (Asgari
2009)
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Table 4. Results of observational studies not included in meta-analysis (Continued)
Any non-
melanoma
cancer
Incidence 0.77 n.r. plasma both Clark 1985
Basal cell car-
cinoma
Incidence 0.54 n.r. serum men Knekt 1990
1.55 n.r. women
0.80 0.10 to 4.5 serum both Menkes 1986 (Bres-
low 1995)
0.86 0.38 to 1.96 serum both McNaughton 2005
0.95 0.59 to 1.50 nutritional in-
take
Squamous cell
carcinoma
Incidence 0.69 0.51 to 0.92 plasma both Combs 1993
0.60 0.20 to 1.50 serum both Menkes 1986 (Bres-
low 1995)
0.86 0.47 to 1.58 plasma both Karagas 1997
1.30 0.77 to 2.3 nutritional in-
take
both McNaughton 2005
0.49 0.24 to 0.99 serum
Other Hematologic Incidence 0.60 n.r. serum/plasma both Coates 1988
Thyroid Incidence 0.15 0.0 to 5.0 serum men Glattre 1989
0.12 0.01 to 1.11 women
0.13 0.02 to 0.77 both
n.r. not reported
2. Randomised controlled trials
2.1. Preventive efficacy: main outcomes
2.1.1. Primary liver cancer
Three RCTs investigated the efficacy of selenium supplementation
for liver cancer prevention. All RCTs were conducted in China
and with participants of different high-risk groups in the Qidong
province.
Yu 1997 investigated a 4-year supplementation period with 200
µg selenium yeast/day in 226 male and female hepatitis B-surface
antigen (HBs-Ag) carriers. Eleven cases (person-time incidence
rate: 1573.03/100,000) were detected in the placebo group and
four cases in the selenium group (RR 0.36 (95% CI 0.12 to 1.11))
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during the 8-year follow-up period. The mean blood selenium
level was 152 ng/ml in the intervention group and 107 ng/ml in
the control group (during the intervention period).
Yu 1991 reported on a trial with 2474 male and female first-degree
relatives of liver cancer patients who also received 200 µg selenium
yeast/day. During the study period of two years, 10 cases in the
selenium and 13 cases in the placebo group were observed (RR
0.55 (95% CI 0.24 to 1.25)).
Li 2000 randomised 2065 male HBs-Ag carriers receiving 0.5 mg
sodium selenite daily for 3 years. Thirty four cases of liver cancer
occurred in the 1112 subjects receiving selenium and 57 cases in
the 953 placebo subjects (RR 0.51 (95% CI 0.34 to 0.77)).
2.1.2. Non-melanoma skin cancer
2.1.2.1. Total non-melanoma skin cancer
A higher risk for non-melanoma skin cancer was seen in the 200
µg/day selenium supplementation group of the NPCT (RR 1.27
(95% CI 1.11 to 1.45)) (Duffield-Lillico 2003 see NPCT 1996).
The increase remained statistically significant after multivariate
adjustment (HR 1.17 (95% CI 1.02 to 1.34)). No variation in
this effect by age, gender or smoking status was statistically sig-
nificant. Mean selenium plasma concentration of the participants
was 114 ng/ml at the time of randomisation. An increased risk for
total non-melanoma skin cancer was seen in all tertiles of base-
line plasma levels (Reid 2008 see NPCT 1996). The increased
risk could be observed more pronouncedly at one study centre
(Macon, Georgia) than at the other study sites. The percentage
of female participants was higher in Macon, but distribution of
other factors, in particular baseline selenium levels, was similar to
the other sites and the reason for the different effect, if not due to
chance alone, remained unclear.
In the sub-studywith 400 µg/day selenium supplementation (Reid
2008), no alteration of non-melanoma skin cancer risk was seen
(HR 0.91 (95% CI 0.69 to 1.20)). Gender-stratified analyses
found a decreased risk in women (RR 0.40 (95%CI 0.20 to 0.80))
and a non-statistically significant increased risk in men (exact data
not reported). Distribution of baseline plasma selenium levels was
similar in this sub-study to the participants of the NPCT main
study and we found no evidence for an effect modification accord-
ing to baseline selenium exposure.
Neither the intervention with 200 µg/day nor with 400 µg/day
found evidence that supported a preventive efficacy of selenium
yeast supplementation against non-melanoma skin cancer in these
populations. The results of theNPCTraised concerns about harm-
ful effects of selenium yeast supplementation.
The comparison of the results of both investigations did not show
a dose-response relationship between the amount of supplemen-
tal selenium intake and outcome: While a harmful effect on non-
melanoma skin cancer risk was seen with the 200 µg/day sup-
plement, the 400 µg/day supplement showed a decreased risk in
women and no effect in men. This might indicate differential bio-
logical mechanisms and health effects of selenium at different lev-
els of supplemental intake by gender. The 400 µg/day supplemen-
tal intake led to a mean selenium level of approximately 250 ng/
ml while 200 µg/day supplemental intake increased plasma levels
to approximately 200 ng/ml.
2.1.2.2. Basal cell carcinoma
At the end of the total blinded treatment period in the NPCT, the
RR 1.17 (95% CI 1.02 to 1.35) for basal cell carcinoma (BCC)
was increased in the 200 µg/day selenium group. Multivariate
adjustment attenuated the effect to a HR of 1.09 (95% CI 0.94
to 1.26). Eliminating the cases that occurred within the first two
years of supplementation had no further effect on the RR. We
found no statistically significant variations in effects according to
age, gender or smoking status.
Reid 2008 found an adjusted HR of 0.95 (95% CI 0.69 to 1.29)
in the 400 µg/day selenium sub-study.
2.1.2.3. Squamous cell carcinoma
In the NPCT, selenium supplementation increased both the (un-
adjusted) risk for squamous cell carcinoma (SCC) (RR 1.32 (95%
CI 1.09 to 1.60)) and the multivariate-adjusted HR 1.25 (95%
CI 1.03 to 1.51). After exclusion of the cases that occurred within
the first two years, a slight decline in the effect of selenium supple-
mentation was seen (leading to statistical non-significance). We
found no statistically significant variations in effects according to
age, gender or smoking status . The adverse effect of selenium
supplementation on SCC risk seemed to increase with increasing
plasma selenium levels at baseline. A higher risk of non-melanoma
skin cancer incidence was seen only in participants with base-
line plasma levels in the highest two tertiles of baseline exposure
(greater or equal to 105.6 ng/ml), which suggested a possible in-
teraction between supplementation and baseline exposure.
In the 400 µg/day selenium sub-study (Reid 2008), we found no
alteration of SCC risk by selenium supplementation (HR 1.05
(95% CI 0.71 to 1.56)).
2.1.3. Prostate cancer
In the SELECT trial, we found no evidence of benefit of L-se-
lenomethionine supplementation (compared to placebo) for ame-
dian of 5.5 years on prostate cancer incidence (HR 1.04, (95%
CI 0.90 to 1.18), (99% CI 0.87 to 1.24)) (SELECT 2009). The
adjusted HR for prostate cancer in the selenium plus vitamin E
group compared to placebo was HR 1.05 ((95% CI 0.91 to 1.20),
(99% CI 0.88 to 1.25)).
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SELECT was terminated early in 2008 following the recommen-
dation of the data and safetymonitoring committee. The commit-
tee had some concern over a statistically non-significant increase
in prostate cancer in the vitamin E-alone group (HR 1.13, (95%
CI 0.99 to 1.29), (99% CI 0.95 to 1.35)).
SELECT failed to replicate the findings of the NPCT, which ob-
served a reduction in prostate cancer incidence in the selenium
yeast group (adjustedHR 0.48 (95%CI 0.28 to 0.80)), and found
no evidence for a statistically significant cancer preventive efficacy
of selenium supplements. NPCT investigators argued that as ran-
domisation worked, bias seemed unlikely to explain the positive
findings for some cancers including prostate cancer in their trial.
Regarding prostate cancer, however, a differential participation of
men with elevated PSA levels in prostate biopsies was observed
in the selenium and placebo group (35% versus 14%; Duffield-
Lillico 2003 see NPCT 1996). This may have occurred by chance
and could have contributed to an overestimation of the effect of
selenium supplementation in the NPCT.
2.2. Preventive efficacy: secondary and other outcomes
The NPCT (NPCT 1996) reported on a number of secondary
outcomes identified post-hoc and other cancers, which had oc-
curred in the trial population.
The total cancer incidence was reduced in the selenium group
(adjusted HR 0.75 (95% CI 0.58 to 0.97)) after a mean follow-
up of 7.4 years (Duffield-Lillico 2002 see NPCT 1996). Cancer
mortality was also reduced (adjusted HR 0.59 (95% CI 0.39 to
0.87)). A gender-stratified analysis revealed that any possibly pro-
tective effect on total cancer incidence in the NPCT was confined
to men (adjusted HR 0.67 (95% CI 0.50 to 0.89)). The adjusted
HR for women was 1.20 (95% CI 0.66 to 2.2). Because of the
predominance of male participants, these gender-differential ef-
fects added up to a net benefit for the total study population.
The observed risk of specific cancers in the selenium group was
lower than in the placebo group for lung cancer (adjusted HR
0.74 (95% CI 0.44 to 1.24)), colorectal cancer (adjusted HR 0.46
(95% CI 0.21 to 1.02)), oesophageal cancer (adjusted HR 0.40
(95% CI 0.08 to 2.07)) and prostate cancer, as mentioned above.
On the contrary, it was higher in the selenium group than in the
placebo group for melanoma (adjusted HR 1.18 (95% CI 0.49 to
2.85)), bladder cancer (adjusted HR 1.28 (95%CI 0.50 to 3.25)),
breast cancer (adjusted HR 1.89 (95% CI 0.69 to 5.14)), head
and neck cancer (adjusted HR 1.27 (95% CI 0.47 to 3.42)) and
lymphoma/leukaemia (adjusted HR 1.25 (95%CI 0.43 to 3.61)).
Reid 2008 found no evidence that selenium supplementation al-
tered total cancer incidence (RR 1.10 (95% CI 0.57 to 2.17)).
2.3. Adverse effects
NPCT 1996 and SELECT 2009 reported on adverse effects of
selenium supplements.
In the NPCT, 35 participants had withdrawn from the study be-
cause of adverse effects, mainly gastrointestinal upset. The RR for
adverse events in the selenium group was 1.51 (95% CI 0.74 to
3.11) (own calculation, based on the number of all randomised
participants).
In SELECT, men in the selenium group had an increased risk
of alopecia (RR 1.28 (99% CI 1.10 to 1.62)) and dermatitis
(grade 1 to 2) (RR 1.17 (99% CI 1.00 to 1.35)), but not of
halitosis, nail changes, fatigue, nausea or dermatitis (grade 3 to 4).
A statistically non-significant increase in diabetes mellitus type II
in the selenium-alone group (HR 1.07 (99% CI 0.94: 1.22)) was
seen.
An increased risk for diabetes mellitus type II was also observed
in the NPCT (Stranges 2007 in: NPCT 1996). A secondary anal-
ysis of participants who did not have diabetes at the start of the
study revealed an excess risk in the selenium group (adjusted HR
1.55 (95% CI 1.03 to 2.33)). We found no statistically significant
interactions with age, gender, smoking status and BMI. The RR
for developing type II diabetes mellitus was higher in participants
in the upper two tertiles of plasma selenium levels, indicating a
possible interaction with baseline exposure status.
Both the SELECT and the NPCT results suggest that long-
term supplementation with selenium may adversely affect glucose
metabolism and increase the risk for diabetes mellitus type II.
The three trials on liver cancer and Reid 2008 did not mention
the occurrence of adverse effects. One paper stated that no case of
selenosis had been observed during the trial.
D I S C U S S I O N
Summary of main results
The aims of this review were to examine the efficacy of selenium
supplements in preventing cancer and possible associations be-
tween selenium exposure and the risk of cancer incidence and
mortality.
Observational studies and aetiological association
From our meta-analyses of 13 prospective observational studies
on total cancer risk, we found a reduced cancer incidence and
mortalitywith higher seleniumexposure. The risk of cancer disease
was 31% (95% CI 9% to 47%) lower in the highest category
of selenium exposure than in the lowest, the risk of death from
cancer was 45% (95% CI 17% to 64%) lower. Subgroup analyses
by gender suggested that a beneficial effect of higher selenium
exposure, if existent, could be higher in men than in women.
The risk of developing bladder cancer was reduced by 33% (95%
CI 3% to 54%) and that of prostate cancer by 22% (95% CI 8%
to 44%). The risk of lung, gastric or colorectal cancers were also
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found to be reduced with higher selenium exposure; however the
confidence intervals of the summary risk estimates overlapped the
1.
No association was seen between selenium and the risk of breast
cancer.
For all other types of cancer, data were only available from less than
five epidemiological studies; thus results were narratively sum-
marised. None of the study results supported an association be-
tween selenium exposure and gynaecological cancer risk, while
results for cancers of the gastrointestinal, respiratory or urologi-
cal tract were inconsistent. For respiratory and urological cancers
(other than bladder, prostate or lung cancer), studies reported ei-
ther no associations or increased risks for participants with a higher
selenium exposure. For gastrointestinal cancers, studies found ei-
ther no associations or reduced risks with a higher selenium expo-
sure.
As is the case with all meta-analyses of epidemiological data, our
findings have potential limitations resulting from study design as
well as quality and heterogeneity of the data. These limitations
can complicate the interpretation of the summary statistics.
RCTs and preventive efficacy
We identified six randomised controlled trials, which investigated
mono-selenium supplements in the prevention of non-melanoma
skin cancer, liver cancer and prostate cancer. There was no con-
vincing evidence that selenium supplementation can prevent non-
melanoma skin cancer or liver cancer in women or men or prostate
cancer. The results of the Nutritional Prevention of Cancer Trial
(NPCT) raised concerns about possible harmful effects of sele-
nium supplements.
The NPCT was considered to have a low risk of bias and found
a statistically significant increase in the incidence of squamous
cell carcinoma as well as a trend towards an increased basal cell
carcinoma incidence with selenium yeast supplementation. The
RR increase was 17% for total non-melanoma skin cancer and
25% for squamous cell carcinoma in both genders after a mean
follow-up of 7.4 years. The number needed to harm in the study
populationwas 19 (95%CI 10 to 143) after a duration of five years
selenium supplementation. A sub-study of the NPCT, which used
supplements with a higher selenium content, found no differences
in non-melanoma skin cancer risk between the active and the
control group in both genders combined (HR 0.91, 95% CI 0.69
to 1.20), but an indication of a possible modification of effect by
sex or gender, which was not seen in the main part of the NPCT.
Secondary outcomes of the NPCT indicated a lower total cancer
incidence and mortality in the selenium group in men, but not
in women. Analyses stratified according to cancer type found a
statistically significantly reduced risk for prostate cancer. These
results were not seen in the sub-study of the NPCT and could not
be replicated in the SELECT trial, although it should be noted
that this trial used a different intervention.
The SELECT trial was a large prostate cancer prevention trial in
the general population of North America. It was considered to
have a low risk of bias and found no alteration of prostate cancer
incidence by L-selenomethionine supplements after a median fol-
low-up of 5.5 years (HR 1.04, 95% CI 0.90 to 1.18).
One out of three liver cancer prevention trials reported a statisti-
cally significantly reduced risk of liver cancer (RR 0.51 (95% CI
0.34 to 0.77)) for male carriers of the hepatitis B surface antigen
taking inorganic selenium supplements (sodium selenite) for three
years. This was in contrast to the other two studies reporting no
statistically significant effect of organic selenium supplements (se-
lenium yeast) for the same cancer site. Due to several methodolog-
ical concerns relating to randomisation and completeness of out-
come data, the risk of bias was unclear for all three RCTs. There-
fore, we cannot conclude that there is strong support for selenium
supplements as agents for the prevention of liver cancer.
Overall completeness and applicability of
evidence
Observational studies and aetiological association
We reviewed data from prospective observational studies, where
selenium exposure was measured in populations without evidence
of cancer, and which were then followed-up for a specified period
of time. This approach minimised the risk of reverse causality if an
association between selenium exposure and cancer was observed
in the study.
The included studies differed in terms of selenium exposure mea-
surement, types of outcomes, study designs and study populations.
The low number of studies for most of the meta-analysed types
of cancers prevented a thorough investigation of the sources of
heterogeneity between study results. In particular, we could not
explore the influence of specific sources of bias or themethodolog-
ical quality of epidemiological studies on heterogeneity.
The investigations included over 1,078,000 individuals from di-
verse study populations predominantly from Europe and the USA
and to a lesser extent, Asia and Australia) (also see: Dennert 2008).
No prospective observational study on selenium and cancer risk
could be identified from Africa or South America. This regional
distribution reflects the under-representation of non-Western and
resource-poor countries in epidemiological research (Pearce 2004).
Differential regional representation in epidemiological studies is
of special interest for this review, as selenium levels in humans vary
significantly around the world. The selenium levels measured in
the included cohorts reflect a broad range of naturally occurring
selenium exposure as measured in cross-sectional studies world-
wide. However, some of the lowest as well as the highest selenium
levels in humans were reported in literature from South American
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populations (Jaffé 1992), a region which was not investigated in
any of the reviewed observational studies.
More than half of the studies included mixed gender populations,
but themajority of themdid not report gender-disaggregated data.
In the available gender-specific results, men are over-represented,
which inhibits the further understanding of a possible gender-
specific association between selenium exposure and cancer risk in
epidemiological data. This also limits the generalisability of the
review results that evidence for a clinically relevant sex or gender-
differential effect exists.
RCTs and preventive efficacy
This review investigated a diverse range of cancers, but cancer
is not a uniform condition and malignant neoplasms show great
differences in tumour biology. Only non-melanoma skin cancer,
liver cancer and prostate cancer were investigated in the included
prevention trials as primary outcomes. The results cannot be gen-
eralised to other types of cancers.
Regarding the three main outcomes, specific characteristics of the
study populations may also limit the generalisability of the results
to non-participants. Participants of the included RCTs on skin
and liver cancer belonged to populations with a high risk for the
outcome under investigation. The participants of the NPCTwere
mostly older and white, predominantly male inhabitants of the
US Mean plasma selenium concentration was in the lower range
of U.S. levels, but still well above the average selenium level of Eu-
ropeans. A possible interaction with baseline selenium levels was
found resulting in an increased risk for developing squamous cell
cancer and diabetes mellitus type II in participants receiving the
selenium supplement who had higher baseline levels. An indica-
tion of interaction and modification of effect was also found for
gender regarding some of the study results. When applying the
study results to other populations, characteristics of the population
regarding gender and selenium exposure should be considered.
Apparently healthy men over 50 years of age from the general
population of North America participated in the SELECT trial
on prostate cancer prevention. The large sample size and the in-
clusion of non-white participants from different socio-economic
backgrounds supported the generalisability of study findings to
other adequately nourished populations.
Selenium supplements contain either organic or inorganic species
of selenium or a mixture of both, e.g. in the form of selenised
yeast. The different species of selenium may exhibit differential
effects on human health. Four included RCTs used selenised yeast
supplements and found either a harmful or no effect of supple-
mentation on the main study outcome. The SELECT trial used
L-selenomethionine supplements, which is the major component
of selenium yeast, and also found no preventive efficacy. The only
RCT investigating sodium selenite supplements found a protective
effect against liver cancer, but was considered to have an unclear
risk of bias. It is also unclear how applicable these results are in
other settings and populations with a different nutritional status.
Interpretation of the results of clinical trials using selenium sup-
plements should consider the different biological forms as well as
their potential differential health effects when supplemented.
Quality of the evidence
Observational studies and aetiological association
The 49 observational studies were heterogenous, not only regard-
ing methodology, but also in the quality and level of detail of re-
porting. The publications included ranged from a congress ab-
stract to a full-text dissertation.
Bias and confounding
Selenium measurement and categorical exposure
classification
Five observational studies measured nutritional or supplemental
selenium intake using questionnaires or interviews. Most studies,
however, relied on selenium biomarkers such as toenail, serum or
plasma selenium levels. Percentile borders, for example quartiles
or quintiles, were usually applied as cut-off points for exposure
categories. Our analyses were based on the comparison of highest
versus lowest baseline exposure category. In ourmeta-analyses, dif-
ferent methods of selenium measurement and different numbers
of exposure categories covering different absolute selenium levels
were combined.
Assessment of total selenium intake with food-frequency ques-
tionnaires (FFQ) or interviews has proven difficult in other in-
vestigations because of the lack of food composition data which
adequately reflects regional and seasonal variations in selenium
concentration. The Duffield 1999 trial compared duplicate diet
collections, dietary logs, FFQ and biomarkers asmeasurements for
selenium intake and status in New Zealand men and women. The
FFQoverestimated themean selenium intake in study participants
when compared with laboratory analyses of duplicate meals. The
ranking in quartiles according to intake for both dietary logs and
FFQ differed from the results from duplicate meals. Correlation
between all three dietary measurements and selenium biomarkers
(whole blood and plasma) were modest (r = 0.1 to 0.4) at the
best. Also Karita 2003 found only a modest correlation between
selenium intake as estimated from FFQ and from a 7-day dietary
log in Japanese men and women. In the same study, a correlation
between both estimates of dietary intake and serum selenium lev-
els could not be seen.
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Validity problems, possibly leading to exposure misclassification,
have also been reported when questionnaires are used to assess
supplement use (Murphy 2002).
Regarding biomarkers for selenium measurement, Ashton 2009
showed in a systematic review that plasma and whole-blood se-
lenium concentrations increased with higher selenium intake in
supplementation studies. Plasma, whole-blood and presumably
serum selenium levels, although Ashton 2009 could not identify
serum studies for their systematic review, were therefore consid-
ered by the authors to adequately reflect a short-term increase in
supplemental selenium intake in healthy adults. However, authors
also found significant, unexplained heterogeneity in the reaction
of participants’ plasma selenium levels to selenium supplementa-
tion.
Concerning the estimation of long-term nutritional intake with
biomarkers, Longnecker 1996 demonstrated a high correlation
between long-term selenium intake as estimated from duplicate
food portions and single measurements from whole blood, serum
and toenail specimens.
These findings support the concern that the ranking of selenium
exposure differs according to the instruments used to assess in-
take and also between intake assessment and biomarkers. Exposure
misclassification may have biased the results of individual studies
and a meta-analysis of observational data is likely to reflect these
biases. Non-differential exposure misclassification might have oc-
curred in all included studies due to measurement errors or as a
result of the gap between the theoretical definition of selenium
exposure and the measurement thereof, which served as a proxy.
Non-differential misclassification might lead to an under- as well
as over-estimation of an effect in the presence of more than two
exposure categories. Our approach of a meta-analysis covering dif-
ferent methods of selenium assessment might have introduced ad-
ditional heterogeneity to review results.
A concern, which we cannot clarify to date, is that biomarkers
do not adequately reflect intake of both organic and inorganic
selenium species. Animal studies indicate that selenium from in-
organic sources is not retained so well in the body as organic se-
lenium. Selenium from organic sources led to higher blood sele-
nium levels and a higher activity of glutathione peroxidase than
equal doses of inorganic supplements in veterinary studies (Slavik
2008; Steen 2008). However, symptoms of acute toxicity were ob-
served in animals with a lower intake of inorganic than organic
selenium species (Kim 2001; Tiwary 2006). Hall 2008 found an
increased genotoxic effect in human cell lines by sodium selenite
in comparison to organic selenium. When considering the pos-
sibly differential effects of selenium species on human health, an
adequate interpretation of the biomarkers representing selenium
exposure would require knowledge of the selenium sources of the
individual.
The observation in our review that cancer risks only show an as-
sociation with biomarker levels, but not with nutritional intake
might therefore be a consequence of an invalid measurement of
nutritional intake, which biased the results towards the null. Alter-
natively, it might likewise reflect that there truly is no association
and that the findings from the biomarker studies were the result of
chance and measurements of nutritional intake may provide bet-
ter estimates of the exposure situation than do biomarkers, which
may misclassify the exposure to inorganic selenium sources.
Furthermore, the comparison of risks between the highest and the
lowest exposure category is most suitable to identify an effect when
there is a consistent decrease or increase across absolute exposure
levels. Other associations (e.g. threshold effects or U-shaped rela-
tionships) may be missed by this method of meta-analyses or the
true effect might be diminished.
Comparability of cases and controls and detection of cancer
All included studies recruited participants pre-diagnostically and
cases and control subjects stemmed from the same popula-
tion. This approach decreased potential differences between both
groups, which could have influenced cancer disease or death due to
factors other than selenium exposure.We included the results from
each study in meta-analyses which were adjusted for the highest
number of additional variables.
Any cancer
All studies on total cancer risk identified cases by using registry
links or a combination of several methods and losses to follow-
up were low. Two studies on cancer incidence and two studies
on cancer mortality analysed less than 80% of all identified cases
(incidence: Persson 2000: 76%;Coates 1988: 79%;mortality: Kok
1987: 71%; Kornitzer 2004: 57%). The main reason for this was
samples missing for selenium measurement. Not all studies that
assessed mortality as a measure of cancer risk excluded participants
with cancer disease at study inception. This might have led to an
overestimation of a protective effect when selenium levels were
lowered by the presence of cancer.
We therefore consider the results for cancer incidence to provide
the more valid estimation for the relationship between selenium
exposure and cancer risk than the mortality data.
Prostate cancer
All but two of the studies on prostate cancer risk identified cases
by using links to cancer registries or a combination of personal
follow-up interviews with PSA screening. Two studies with health
professionals used self-reporting for case identification, followed
by confirmation through medical records. The number of peo-
ple lost to follow-up was low in all studies included. Two studies,
however, included less than 80% of all identified cases in their
analyses (Brooks 2001: 39%; van den Brandt 2003 in: vd Brandt
1993: 77%) because samples were not available for selenium mea-
surement or diagnosis was not confirmed. In Brooks 2001, bias
might have been introduced to the results to some extent, as the
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demographic variables differed between the identified and anal-
ysed cases.
Bladder cancer
Losses to follow-up were low in three studies (Michaud 2002;
Nomura 1987; Zeegers 2002 in: vd Brandt 1993) and unclear in
two on bladder cancer risk (Helzlsouer 1986 in: Menkes 1986;
Michaud 2005). Endpoints were ascertained in elaborate ways in
four studies including linkages to registries and regional and na-
tional databases; one study relied on the self-reporting of study par-
ticipants (Michaud 2005). The latter investigation compared blad-
der cancer in the Nurses’ Health Study (women) and the Health
Professionals Follow-Up Study (men) and was the only one to re-
port gender disaggregated data. A gender-differential association
between selenium exposure and bladder cancer risk was found, but
the role of potential biases due to possible different self-reporting
behaviour in these two distinct cohorts remained unclear.
The second study which found a statistically inverse association
between selenium exposure and bladder cancer risk was Zeegers
2002, which could only analyse 70% of the identified bladder
cancer cases as specimens for selenium measurement were not
available for the remainder.
Residual confounding and effect modification
Most of the studies included controls for smoking and age, either
by matching or by using multivariate techniques. However, only a
few considered the potential effect of other factors. Possible con-
founding factors could be another food nutrient or a certain be-
haviour, which exhibits cancer protective effects and is associated
with higher intake of selenium-rich foods. Furthermore, intake
of heavy metals and other dietary factors may modify selenium
health effects or the relationship between selenium exposure and
biomarker concentration (overview in: Vinceti 2000). Metabolic
interactions, for example, are known for arsenic (Zeng 2005).
Even in studies that considered the influence of a specific factor,
validity of the assessment of the potential confounder can be chal-
lenging and is not commonly reported in study publications. For
example, control for smoke exposure as a known risk factor for sev-
eral types of cancer seems a crucial issue in epidemiologic studies
on cancer risk. Cigarette smokers, for example, tend to have lower
selenium biomarker levels, though cigarette smoking is a source of
selenium exposure itself. Therefore an inverse association between
selenium and lung cancer risk might also be the result of residual
confounding and effect modification by smoking. Exposure to en-
vironmental and household smoking, which has been shown to be
associated with increased risks of cancer (Gorlova 2006; Nishino
2001), might also be associated with selenium status due to dif-
ferential nutritional behaviours or other mechanisms. We are not
aware of any study that investigated this issue. Unknown factors
may influence an observed selenium - cancer association and thus
pose a challenge as to causal inferences.
Some of these factors cluster in population groups according to
socio-economic position (SEP). Only a few studies attempted to
control for indicators of adult SEP as potential confounders, e.g.
education, occupation or income. None used a composite index
of indicators or considered childhood SEP. Some studies restricted
their cohorts to certain subgroups of a population, such as occu-
pational groups, and were likely only to include people of a similar
adult socio-economic background.
It has been claimed that associations between vitamins and dis-
eases are the result of confounding by social and behavioural fac-
tors acting over the course of a lifetime (Lawlor 2004). Lawlor
2004 argued that the divergent results from epidemiological and
randomised controlled studies on the prevention of cardiovascular
diseases can be explained by unmeasured confounding due to SEP.
Risk of most cancers is - like cardiovascular morbidity - known
to decrease with higher SEP. Research also indicated a positive as-
sociation between higher SEP and selenium biomarkers (Barany
2002; Niskar 2003). However, other investigations did not con-
firm these findings: Kant 2007, for example, did not find an as-
sociation between a measure of household poverty and selenium
status.
The hypothesis of possible confounding due to SEP leading to an
indirect association between selenium and cancer in epidemiolog-
ical research would be consistent with the results for all types of
cancers in this review - including the null association with breast
cancer - with the exception of prostate cancer findings. Prostate
cancer has been found to be more often diagnosed in men of
a higher SEP (Dalton 2008) while we saw a protective associa-
tion with higher selenium exposure. However, it remains unclear
whether the more frequent diagnoses of prostate cancer in men
with higher SEP reflects an excess of prostate cancer incidence in
this population. It might also result from differential health and
screening behaviours leading to a detection of otherwise symptom-
free cases while men with a lower SEP tend to be overrepresented
in diagnoses of advanced stages of the disease (Rapiti 2009). More
information on screening and diagnostic behaviour of the male
cohort participants would be necessary to further elucidate these
findings.
For prostate cancer, studies published before 2000 and especially
those from the US found a larger protective effect with higher
selenium levels than did later studies. We consistently observed
this in the studies on lung cancer.
This might be attributable to differences in study design or popu-
lations (with the later studies being the larger studies including the
general population) or changing health and screening behaviours
over time in the case of prostate cancer studies. It could also reflect
publication bias in earlier years favouring positive results.
An alternative explanation could be a ’threshold’ effect for a pos-
sible protective effect of selenium against prostate cancer around
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a certain level, which has been diminishing due to the increasing
use of selenium supplements in the US. Brooks 2001 reportedly
observed results consistent with a threshold effect at a level of 108
µg/l serum selenium. Conversely, a threshold effect was not seen in
another study with almost the same percentile limits (Goodman
2001) in a population of asbestos workers, who may have had
other sources of selenium exposure than the participants of Brooks
2001 from the general population. It has been frequently suggested
that an increase in selenium intake might be beneficial only for
men with lower selenium levels as glutathione peroxidase activity
reaches a plateau above approximately 95 (range 89 to 114) µg/l
(Rayman 2000).
We found no clear indication of a threshold effect in either lung
or prostate cancer in the overview of study results. Heterogeneity
between studies might therefore not reflect a consistent biological
threshold effect of baseline selenium exposure levels, but a cluster
of known and unknown influences of factors related to study de-
sign, population and potential biases.
The role of chance
Large epidemiological studies are not designed to test for a specific
aetiological hypothesis, but enable research to investigate a large
number of possible associations. Given the multiplicity of possible
comparisons, associations between selenium exposure and cancer
endpoints may have resulted from chance alone.
Summary
Factors which seemed to account partially for the inter-study het-
erogeneity were type of outcomemeasure (incidence ormortality),
assessment of exposure and gender.
Considering the possible influences of bias, residual confounding
and modifying factors on the selenium-cancer relationship, the
summary estimates frommeta-analyses should be interpreted with
caution. Meta-analyses of spurious findings in observational stud-
ies increase the precision of a summary risk estimate, which does
not itself get nearer to the true value and may suggest an non-
existent association (Egger 1998).
RCTs and preventive efficacy
The NPCT, its sub-study and the SELECT trial were considered
to have a low risk of bias with adequate sequence generation,
allocation concealment, blinding and reporting of findings.
In the three trials on liver cancer prevention, quality of report-
ing was an issue and they were considered to have an unknown
risk of bias. The individual trials were - in some cases discrepantly
- reported in several papers and essential questions regarding se-
quence generation, allocation concealment, handling of drop-outs
andwithdrawals anddetectionof outcomes remainedunanswered.
This might be due to inadequate reporting, but might also hint
to flaws in trial design and implementation. We were uncertain
that the only trial which found positive results for selenium sup-
plements in liver cancer prevention randomised participants in-
dividually. A cluster randomisation of participants who lived in
the same area/village, which may have been the procedure in this
investigation, might have introduced additional bias to the study
results, e.g. due to different environmental factors contributing to
liver cancer development or detection, and might have led to an
overestimation of the protective efficacy of selenium. A duplica-
tion of results with a rigorous study design would be necessary to
assess the effect of sodium selenite on liver cancer incidence.
Potential biases in the review process
RCTs and preventive efficacy & observational studies
and aetiological association
The literature search included the major international databases
in the English and German language and we applied a broad
search strategy supplemented by hand searching for references.We
assume that we identified all randomised controlled studies and
prospective observational studies relevant to our review questions.
As we did not search databases in other languages, e.g. Chinese or
Russian, we cannot rule out that we missed smaller studies which
were not published in international journals. There is also a chance
that we might have missed observational studies whose results on
selenium exposure and cancer were reported in the body of a paper
but not mentioned in the paper’s title or abstract, even if the paper
is indexed in the searched databases.
Although we tried to contact all investigators for missing or ad-
ditional data on their studies, we were unable to retrieve answers
to questions we had regarding methodology or outcomes in some
studies. This applied particularly to earlier epidemiological studies
where primary investigators may have relocated, died, or where
data were not available in a current electronic format. Similarly,
we could not make contact with the primary investigators of the
Chinese RCTs.
The risk of bias assessment was based on the included publications.
The risk of bias of studies that did not adequately describe the
study design in the included publication but gave a reference to
another paper, might therefore have been overestimated in this
review.
Another concern, especially with the epidemiological studies, is
publication bias. Cohort and nested case-control studies are not
exclusively designed to test for a specific exposure-outcome asso-
ciation, but enable researchers to investigate a range of questions.
It is conceivable that unfavourable results were less likely to be
published.
We decided a priori to conduct meta-analyses only when five or
more studies were available for a study outcome. As a result of this
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cut-off, we did not conduct meta-analyses for a number of obser-
vational study outcomes with two to four studies available (see:
Table 1). Our primary intention was to facilitate the investigation
of heterogeneity between studies that were included in meta-anal-
yses, in order to avoid producing more precise, but still unexplain-
ably biased results. However, results of this review revealed that
the cut-off at five studies did not guarantee this possibility and
could therefore be reconsidered in future updates.
Regarding the question of the efficacy of selenium for cancer pre-
vention, the cut-off point led to the situation that nometa-analytic
procedures were conducted for RCTs. Looking out our results,
however, only liver cancer results would have pooled without the
cut-off. Results for this meta-analysis of liver cancer have already
been published in another systematic review (Bjelakovic 2008)
and were included in the discussion here. Replicating the meta-
analysis of liver cancer trials would not have changed the results
of this systematic review.
The authors of this review came from different disciplines and
have different focuses, e.g. epidemiology, clinical medicine and
nutrition. We consider this internal variety of expertise to be a
strength of this review and made use of it by applying double-
checking procedures during the entire review process whenever
possible.
Agreements and disagreements with other
studies or reviews
The idea of selenium supplementation for cancer prevention re-
ceived broad support following the NPCT and the publication
of several large epidemiological studies which supported the hy-
pothesis of an aetiological relationship between low selenium sta-
tus and cancer development. Combs 2005 stated that “the hy-
pothesis that Se (selenium) can affect cancer risk is supported by a
remarkably consistent body of scientific evidence” (Combs 2005,
p346). These ideas stimulated the largest ever cancer prevention
trial SELECT, which failed to provide support for this hypothesis.
Disagreement between the results of this systematic review and
other publications may partly be explained by the differentiation
between aetiology and efficacy in the research questions of this
review.
Observational studies and aetiological association
A number of systematic reviews with and without meta-analyses
have been conducted on selenium and the risk of different types
of cancer. Overall, our combined risk estimates are consistent with
their results and slight discrepancies in numbers are attributable to
different inclusion criteria. However, some of the previous publi-
cations arrived at more favourable conclusions regarding a possible
protective association of higher selenium exposure against cancer.
Our meta-analyses of epidemiological studies suggested an inverse
association between selenium exposure and risk of several cancers
in men, which was reflected in a reduced overall cancer incidence
and mortality. Associations with toenail selenium levels tended to
be larger thanwith serum or plasma levels and in general no associ-
ations were seen with selenium intake. These findings were consis-
tent with the secondary outcomes of the NPCT, which suggested
a preventive efficacy of selenium supplements against several types
of cancers in men, the strongest of which was prostate cancer.
However, the large-scale SELECT trial failed to confirm any ben-
eficial effects of supplemental selenium intake on prostate cancer
risk. An earlier ecological analysis of a nationwide program to in-
crease selenium intake with fortification in Finland also found no
evidence of any protective effect against prostate cancer (Vinceti
2000).
Overall, there is little evidence for an association between selenium
exposure and cancer risk in women and, if existent, it is likely to
be small. Our meta-analyses do not support a protective associ-
ation between higher selenium exposure and breast or colorectal
cancer in women. These findings are consistent with the results
of the NPCT trial, where all protective effects of selenium yeast
supplementation were confined to men.
It has been argued that gender-related outcomes may reflect dif-
ferent exposure levels at baseline possibly related to gender-spe-
cific nutritional behaviour, which might be true for comparisons
of distinct women-only and men-only cohorts (Michaud 2005).
However, comparisons by gender within studies also pointed to
a differential effect at similar exposure levels. We cannot rule out
that sex or gender differences are observed by chance only, but
laboratory and animal research have suggested sex differences in
selenium metabolism and biology. Also sex-specific tumour biol-
ogy and the predominance of specific cancer types may contribute
to differential health outcomes in women and men. However, we
cannot estimate the magnitude sex or gender differences possibly
contribute to the observed differential health outcomes in men
and women.
These considerations are of special interest as selenium supple-
ments are aggressively marketed especially to women with regard
to breast cancer prevention and treatment, which is not supported
by data from observational or clinical investigations.
Heterogeneity between studies was not largely reduced by gender
stratification in our meta-analyses. Furthermore, we expected that
non-gender stratified data from observational studies would more
or less reflect a combination of gender-stratified results for a spe-
cific tumour type, which was not always the case. In lung cancer
meta-analysis, for example, the risk reduction by higher selenium
levels seems to be larger in data for both genders combined than
it was in data for women and men separately. This underlines the
influence of other sources of heterogeneity on study outcomes. Re-
porting of gender-stratified results in mixed-gender cohort stud-
ies, which has become increasingly common over the years, might
therefore reflect other factors related to study design, such as a
better evaluation of possible confounders in more recently pub-
lished studies. Socioeconomic position could be one such possible
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confounder, leading to an overestimation of a protective effect of
selenium. Several studies have found selenium levels to be posi-
tively associated with adult socioeconomic position in both men
and women (Gundacker 2006; Niskar 2003).
Doubts seem therefore justified that the observed associations
point to a causal relationship between selenium biomarker levels
and cancer risk.
RCTs and preventive efficacy
Non-melanoma skin cancer
The risk increase in non-melanoma skin cancer by selenium sup-
plements in the NPCT raises concerns about the safety of sele-
nium yeast supplementation in both men and women.
The overall lack of a protective effect of selenium yeast against non-
melanoma skin cancer is consistent with the results of the French
SU.VI.M.AX trial. However, an increased risk (non-statistically
significant) of non-melanoma skin cancer was only seen in women
in the SU.VI.M.AX trial, not inmen. These discrepancies between
the results of both trials might relate to differences in intervention
and characteristics of the study populations. Increased risk of non-
melanoma skin cancer could be more pronounced in or restricted
to high-risk populations or observable only at certain selenium
levels.
Liver and other gastrointestinal cancers
Bjelakovic 2008 conducted a systematic review of antioxidant
supplements for the prevention of gastrointestinal (GIT) cancers.
They meta-analysed RCT data for liver cancer prevention with
selenium-containing supplements and reported a protective effect
in both genders (RR 0.56 (95%CI (95%CI 0.42 to 0.76)). Three
of the four trials in their meta-analysis were also included in this
systematic review (Li 2000; Yu 1991; Yu 1997). The remaining
RCT (Li 2004b) used a combination of selenium with allitridum,
a synthetic garlic extract, in the intervention and therefore did not
meet our inclusion criteria. Li 2004b found a preventive efficacy
of high-dose allitridum/100 µg sodium selenite supplementation
on total and gastric cancer incidence in men, but not in women.
No effect on liver cancer was seen in either gender. Allitridum was
considered the main intervention by Li and colleagues in their pa-
per and the contribution of selenium to the overall effect remained
unclear. The more recent RCT by Qu 2007 found no effect of 50
µg selenium yeast in combination with beta-carotene and alpha-
tocopherol on liver cancer mortality.
We did not calculate a summary risk estimate for the included
RCTs on liver cancer in this review. The minimum number of
studies required for meta-analyses was set a priori to five in the
protocol because we expected large heterogeneity between inter-
ventions and study populations and a high risk of bias in stud-
ies using selenium supplements. Considering the methodological
constraints of the studies, the summary risk estimate of Bjelakovic
2008 may have overestimated the preventive efficacy of selenium
against liver cancer.
We could not identify RCTs that investigated other GIT cancers
as primary outcomes. The NPCT reported a (statistically non-
significant) reduced risk of colorectal and oesophageal cancer as
a secondary outcome in the selenium group. Other studies using
multi-component selenium-containing supplements found diver-
gent results, which also indicated potential sex or gender differ-
ences (Blot 1993; Hercberg 2004; see Background)
We consider that a replication of study results in adequately con-
ducted randomised controlled trials is necessary before the pre-
ventive efficacy of selenium supplements against liver or other gas-
trointestinal cancers can be further evaluated or any recommen-
dation made regarding supplements for GIT cancer prevention.
However, the indication that nutritional supplementsmay prevent
GIT cancers in borderline nutrient-deficient populations of devel-
oping countries should not be ignored in future research. Special
consideration should be given to sex or gender-specific effects, se-
lenium specification and possible interactions with other nutrients
and the presence of risk factors for gastrointestinal cancers.
Prostate cancer
The SELECT trial failed to provide evidence for the preventive
efficacy of oral L-selenomethionine and alpha-tocopherol either
alone or in combination against prostate cancer.
The SELECT results contrasted with findings of the NPCT on
prostate cancer. This might have occurred because of an overesti-
mation of the real effect in the NPCT, where prostate cancer was
not the primary outcome. It has also been argued that selenome-
thionine was the wrong supplement to replicate the NPCT results
(Goossens 2009; El-Bayoumy 2009) and future trials should in-
vestigate selenium yeast as the active intervention.
SELECT participants had a higher selenium level at randomisa-
tion than men in the NPCT. While the mean plasma selenium
concentration was 113 to 114 µg/l in the NPCT, median serum
concentration was 135 to 138 µg/l in the different study arms in
SELECT. Lower prostate cancer incidence in the NPCT trial was
confined to men with baseline selenium levels in the lower two
thirds (below 121 µg/l). Subgroup analyses of the SELECT trial
are underway to investigate a possible modification by pre-inter-
vention selenium levels.
The SU.VI.M.AX trial, which used a multivitamin and mineral
supplement containing 100 µg selenised yeast, found a reduction
in the rate of prostate cancers only in men with normal PSA levels
at baseline (HR 0.52 (95%CI 0.29 to 0.92)), but an increased risk
in men with elevated PSA (> 3 ng/ml) (HR 1.54 (95% CI 0.87
to 2.72) (Meyer 2005). There was no interaction with serum sele-
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nium levels at baseline in this study and authors hypothesised that
their multi component supplement might be beneficial in healthy
men, but might promote prostate cancer development in men at
higher risk. However, an interaction with baseline PSA levels was
not seen in the NPCT. In SELECT, only men with normal PSA
levels (less than 4 ng/ml) were eligible for participation.
Other cancers and diseases
Data for a variety of other cancers were reported in theNPCT trial.
Notably, the results for the primary outcome of theNPCT, i.e. the
incidence of non-melanoma skin cancer, received less attention in
the public debate than those for secondary outcomes, especially
those in favour of selenium supplementation. As they were based
on a post-hoc analysis, the question of confounding and bias arose.
Also the role of chance was unclear because of the uncontrolled
procedures for detection of secondary outcomes. Under-represen-
tation of women in the NPCT decreased the power to detect sex-
/gender-specific effects (Duffield-Lillico 2002, in: NPCT 1996)
and is a concern as the highest hazard ratio for a single cancer
type in the selenium group was seen for breast cancer (HR 1.89
(95% CI 0.69 to 5.14), non-statistically significant). All possible
beneficial effects on cancer incidence were confined to men in this
study.
In the SU.VI.M.AX trial, the selenium yeast-containing sup-
plement did not alter breast cancer risk in female participants
(Hercberg 2004). Overall, the SU.VI.M.AX trial detected no ef-
fect on total cancer incidence by its multivitamin/nutrient sup-
plement in both genders combined (RR 0.90 (95% CI 0.76 to
1.06). Gender-stratified analyses showed a protective efficacy in
men (RR 0.60 (95%CI 0.53 to 0.91), but not in women (RR 1.04
(95% CI 0.85 to 1.29)), with a reduction of cases mainly seen in
gastrointestinal and respiratory cancers in men. Women had the
higher baseline levels of antioxidants and study authors hypothe-
sised that differences in outcomes between men and women may
be attributable to gender differences in nutritional behaviour and
consequent antioxidant status.
Also the Linxian General Population Trial (Blot 1993) found no
statistically significant protective effect of the selenium contain-
ing supplement on total cancer incidence in either gender(RR
0.93 (95% CI 0.83 to 1.03); gender stratified results were not re-
ported). Cancer deaths were marginally significantly reduced (RR
0.87 (95% CI 0.75 to 1.00)) in participants receiving the sele-
nium/beta-carotene/vitamin E supplement.
For lung cancer, the Linxian trial found no alteration in mortality
by selenium-containing study supplements (RR 0.98 (95% CI
0.71 to 1.35); Kamangar 2006).
One study currently in progress investigates the efficacy of sele-
nium for the recurrence of early stage non-small cell lung cancer
after initial surgery (RCT˙ECOG 2002).
The SELECT trial reported a slightly elevated risk (statistically
non-significant) for diabetes mellitus type II in the selenium group
(RR 1.07 99% CI (95% CI 0.94 to 1.22)). Secondary analysis of
the NPCT also indicated that long-term selenium supplementa-
tion may increase the risk for developing type II diabetes mellitus
(Stranges 2007).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
For women, there is little evidence for lower or higher nutritional
intake of selenium exhibiting a major impact on cancer risk. The
only RCT results that have a low risk of bias support concerns of
an increased risk of non-melanoma skin cancer by selenium yeast
supplements in womenwho had already suffered from this disease.
For men, there is evidence for an inverse association between
higher selenium biomarker levels and cancer risk. However, we
cannot exclude that this effect may well be the result of other fac-
tors related to higher selenium biomarker levels than caused by
selenium exposure itself. Results from two randomised controlled
trials (NPCT and SELECT) have failed to provide evidence that
non-melanoma skin cancer or prostate cancer can be prevented by
selenium supplementation in men.
Additionally, concerns have been raised about possible toxicities
from long-term intake of supplemental selenium.
Currently, regular intake of selenium supplements for cancer pre-
vention cannot be recommended to either the selenium-replete or
deficient populations.
Implications for research
Selenium may have different effects on specific types of cancer.
The results from randomised controlled trials for the prevention of
liver cancer need to be replicated in studies with a rigorous design.
Potential differential effects of sex or gender and the use of sele-
nium supplements in populations with a high burden of specific
types of cancer diseases and differing selenium exposure levels, e.g.
known low nutritional selenium intake, require further examina-
tion.
Future prospective epidemiological studies as well as intervention
trials should be adequately designed to detect sex or gender dif-
ferences on specific types of cancer. Results of gender-stratified
analyses should be reported even when statistically significant dif-
ferences cannot be found.
Further research should aim to clarify why biomarkers of selenium
exposure failed to reliably predict the results of RCTs with low risk
of bias.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Akbaraly 2005
Methods Cohort/sub-cohort controlled cohort study
Country: France
Participants Name of parent cohort: Etude du Vieillissement Antériel Study (EVA study)
Participants: 1389 participants (41% male, 59% female)
Inclusion criteria: 59 to 71 years of age; residents of Nantes; able to undergo examination at study centre
Recruitment: 1991 to 1993
Outcome assessment: December 2001
Number of cases:
Any cancer: 45 (male/female: n.r.)
Case definition:mortality
Years of follow-up: 9.0 years
Type of selenium marker: plasma
Interventions d.n.a.
Outcomes Statistical methods: Cox proportional hazard model
Variables controlled in analysis: gender, smoking, alcohol intake, medication use, obesity, diabetes mellitus, hyperten-
sion, CVD, age, education, dyslipidaemia, low cognitive function
Notes
Allen 2008
Methods Matched, nested case-control study
Countries: Denmark, Germany, Greece, Italy, the Netherlands, Spain, Sweden, the UK
Participants Participants: approximately 130,000 men
Inclusion criteria: male participants of the EPIC study
Name of parent cohort: European Prospective Investigation into Cancer and Nutrition (EPIC)
Recruitment: 1992 to 2000
Outcome assessment: at each country’s study closure date (between June 1999 and January 2003)
Number of cases:
Prostate cancer: 959 (male/female: 959/0)
Case definition: incidence
Years of follow-up: median 2.6 years (Greece) to 9.2 years (Sweden)
Type of selenium marker: plasma
Interventions d.n.a.
Outcomes Statistical methods: conditional logistic regression
Variables controlled in analysis: BMI, smoking, alcohol consumption, physical activity, marital status, education
Variables controlled by matching: age, study centre, time of day of blood collection, time between blood collection and
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Allen 2008 (Continued)
last meal, sex
Notes
Bleys 2008
Methods Cohort Study
Country: US
Participants Participants: 13,887 men and women
Inclusion criteria:male and female adults, aged 20 to 90 years, participating in theNHANES III: “stratified, multistage
probability cluster to provide data representing the noninstitutionalized US population” (Bleys 2008, p. 404)
Name of parent cohort: Third National Health and Nutrition Examination Survey (NHANES III)
Recruitment: 1988 to 1994
Outcome assessment: 15 December 2000
Number of cases:
Cancer deaths: 457 (male/female: n.r.)
Case definition:mortality
Years of follow-up: 6 to 12 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, sex, race, education, annual family income, post-menopausal status (women),
cigarette smoking, serum cotinine level, alcohol consumption
Notes
Brooks 2001
Methods Matched, nested case-control study
Country: US
Participants Name of parent cohort: Baltimore Longitudinal Study of Aging
Participants: 1555 men
Inclusion criteria: n.r.
Recruitment: n.r.
Outcome assessment: n.r.
Number of cases:
prostate cancer: 52 (male/female: 52/0)
Case definition: incidence
Years of follow-up: n.r.
Type of selenium marker: plasma
Interventions d.n.a.
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Brooks 2001 (Continued)
Outcomes Analysed cases: analysis for 52 of 133 cases (reason for non-inclusion: plasma and/or histological confirmation of
diagnosis not available)
Statistical methods: logistic regression
Variables controlled in analysis: years between blood donation and diagnosis/follow-up, age, age by years before
diagnosis interaction, BMI, smoking history, alcohol use
Variables controlled by matching: age
Notes
Clark 1985
Methods Cohort/sub-cohort-controlled cohort study
Country: US
Participants Participants: 177 participants; no information on gender
Inclusion criteria: persons at high risk of non-melanoma skin cancer
Recruitment: n.r.
Outcome assessment: n.r.
Number of cases:
skin (non-melanoma): 19 (male/female: n.r.)
Case definition: incidence
Years of follow-up: mean: 3.0 years
Type of selenium marker: plasma
Interventions d.n.a.
Outcomes Statistical methods: Cox proportional hazard model
Notes
Coates 1988
Methods Matched, nested case-control study
Country: US
Participants Participants: number of participants n.r.; both genders
Inclusion criteria: employees of two Seattle companies
Recruitment: 1972 to 1973 and 1976
Outcome assessment: not stated
Number of cases:
Any cancer: 154 (male/female: n.r.)
Gastrointestinal cancer: 28 (male/female: n.r.)
Breast cancer: 20 (male/female: 0/20)
Prostate cancer: 13 (male/female: 13/0)
Haematological cancers: 12 (male/female: n.r.)
Cervical cancer: 12 (male/female: 0/12)
Lung cancer: 11 (male/female: n.r.)
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Coates 1988 (Continued)
Other: 58 (male/female: n.r.)
Case definition: incidence
Years of follow-up: n.r.
Type of selenium marker: serum and plasma
Interventions d.n.a.
Outcomes Analysed cases: 154 (133 serum, 21 plasma) of 195 cases analysed (reason for non-inclusion: no sample available for
analysis or no control available)
Statistical methods: conditional logistic regression
Variables controlled by matching: age, gender, race/ethnicity, year/month of sample collection, employer, plasma or
serum sample
Notes Primary publication: Coates 1988
Secondary publication: Coates 1987
Combs 1993
Methods Cohort/sub-cohort-controlled cohort study
Country: US
Participants Participants: 1239 men and women
Inclusion criteria: participants of the NPCT with valid selenium measurement at baseline
Name of parent cohort: Nutritional Prevention of Cancer Trial (NPCT)
Recruitment: see: Nutritional Prevention of Cancer Trial
Outcome assessment: not stated
Number of cases:
Squamous cell cancer: 204 (male/female: n.r.)
Case definition: incidence
Years of follow-up: 2.0 years
Type of selenium marker: plasma
Interventions d.n.a.
Outcomes Statistical methods: Cox proportional hazard model
Variables controlled in analysis: age, gender, current smoking, alcohol drinking
Notes
Comstock 1997
Methods Matched, nested case-control study
Country: US
Participants Participants: number of participants n.r.; both genders
Inclusion criteria: residents of Washington County
Name of parent cohort: CLUE I and II Cohort
Recruitment: 1974/75 or 1989
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Comstock 1997 (Continued)
Outcome assessment: n.r.
Number of cases:
Lung cancer: 258 (male/female: 157/101)
Case definition: incidence
Years of follow-up: n.r.
Type of selenium marker: serum/plasma
Interventions d.n.a.
Outcomes Statistical methods: conditional logistic regression
Variables controlled by matching: age, gender, race/ethnicity, year and month of sample collection, participant of Clue
I or Clue II cohort
Notes
Dong 2008
Methods Cohort study
Country: US
Participants Participants: 339 participants (275 men; 64 women)
Inclusion criteria: participants of a surveillance programme for men and women with Barrett’s oesophagus, no prior
history of oesophageal cancer or diagnosis of cancer within first three months of baseline
Name of parent cohort: Seattle Barrett’s Esophagus Program
Recruitment: 1983 to 2004, baseline assessment for this study: 1 February 1995 to 1 July 2004
Outcome assessment: n.r.
Number of cases: oesophageal adenocarcinoma: 37 (32 men, 5 women)
Case definition: incidence
Years of follow-up: mean: 5 years
Type of selenium marker: intake of selenium supplements (self administered food frequency questionnaire)
Interventions d.n.a.
Outcomes Statistical methods: Cox proportional hazards regression
Variables controlled in analysis: age, sex, fruit and vegetable consumption, percent energy from fat, waist-hip ratio,
cigarette smoking, non-steroidal anti-inflammatory drug use
Notes
Dorgan 1998
Methods Matched, nested case-control study
Country: US
Participants Participants: 6426 women
Inclusion criteria: female volunteers with serum available at the Breast Cancer Serum Bank in Columbia (Missouri)/
U.S.A; no history of cancer at baseline; missing serum sample for analysis excluded
Recruitment: 1987 to 1997
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Dorgan 1998 (Continued)
Outcome assessment: 1982 to 1983, 1989
Number of cases:
Breast cancer: 105 (male/female: 0/105)
Case definition: incidence
Years of follow-up: median: 2.7 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: conditional logistic regression
Variables controlled in analysis: serum cholesterol, packs of cigarettes / day, BMI
Variables controlled by matching: age, year and month of sample collection, diagnosis of benign breast disease within
two years prior to study enrolment, “sequence number of blood draw” for women who donate blood more than one
time
Notes
Epplein 2009
Methods Matched, nested case-control study (Epplein 2009, Gill 2009)
Country: US
Participants Inclusion criteria: participants of the Multiethnic Cohort, aged 45 to 75 years (native Hawaiians: aged 42 years and
older), blood sample provided before cancer diagnosis between 1997 and 2006
Name of parent cohort: Multiethnic Cohort
Recruitment: 1993 to 1996
Case definition: incidence
Type of selenium marker: serum
Epplein 2009:
Participants: 67,594 (male: 29,009 / female: 38,585) men and women
Outcome assessment: 2006
Number of cases:
Lung cancer: 207 (male/female: 136/71)
Years of follow-up: 0 to 10 years
Gill 2009:
Participants: 29,009 men
Outcome assessment: n.r.
Number of cases:
Prostate cancer: 467 (male/female: 467/0)
Years of follow-up: n.r.
Interventions d.n.a.
Outcomes Statistical methods: conditional logistic regression
Epplein 2009:
Variables controlled in analysis: age, fasting hours, pack-years, pack-years squared, years of schooling, family history
of lung cancer
Variables controlled by matching: age, sex, race/ethnicity, date of sample collection, time of day of sample collection,
fasting status, smoking
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Epplein 2009 (Continued)
Gill 2009:
Analysed cases: 450 of 467 cases analysed
Variables controlled in analysis: age, fasting hours, BMI, family history of prostate cancer, education
Variables controlled by matching: age, race/ethnicity, date of sample collection, geographic site (California, Hawaii),
time of day of sample collection, fasting status
Notes Primary publication: Epplein 2009
Other publications: Gill 2009
Fex 1987
Methods Matched, nested case-control study
Country: Sweden
Participants Participants: 7935 men
Inclusion criteria: 46 to 48 years of age; residents of Malmo/Sweden; no restriction regarding malignant disease at
baseline (11 of 35 cases were diagnosed with cancer at baseline screening examination and/or died during first year
of follow-up)
Name of parent cohort: Malmo Preventive Programme
Recruitment: 1975 to 1979
Outcome assessment: June 1981
Number of cases:
Any cancer: 35 (male/female: 35/0)
Case definition:mortality
Years of follow-up: 3.5 to 8.0 years
Type of selenium marker: plasma
Interventions d.n.a.
Outcomes Analysed cases: 35 of 61 cases analysed (reason for non-inclusion: no plasma sample available)
Statistical methods: logistic regression, Mantel-Haenszel
Variables controlled by matching: age, month of sample collection
Notes
Garland 1995
Methods Matched, nested case-control study
Country: US
Participants Participants: 62,641 women
Inclusion criteria: female registered nurses in 11 U.S. states; aged 30 to 55 years at baseline; completed questionnaire
in 1976 and provision of toenail sample in 1982; no history of cancer at baseline
Name of parent cohort: Nurses’ Health Study (NHS)
Recruitment: 1976 (toenail sample collection in 1982)
Outcome assessment: 1 June 1986
Garland 1995:
Number of cases:
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Garland 1995 (Continued)
Any cancer (without breast): 503 (male/female: 0/503)
Colon and rectal cancer: 89 (male/female: 0/89)
Melanoma: 63 (male/female: 0/63)
Ovarian cancer: 58 (male/female: 0/58)
Lung cancer: 47 (male/female: 0/47)
Other: 155 (male/female: 0/155)
Uterine cancer: 91 (male/female: 0/91)
Hunter 1990:
Number of cases:
Breast cancer: 434 (0/434)
Case definition: incidence
Years of follow-up: 2.0 to 4.4 years
Type of selenium marker: toenail
Interventions d.n.a.
Outcomes Statistical methods: logistic regression, conditional logistic regression
Variables controlled in analysis: smoking status
Variables controlled by matching: age, year and month of sample collection
Hunter 1990 additionally controlled in analysis for: age at first birth, age at menarche, alcohol use, history of benign
breast disease, menopausal status, maternal breast cancer, breast cancer in sister(s), oral contraceptive use, parity,
relative weight
Notes Primary publication: Garland 1995
Other publications: Hunter 1990
Glattre 1989
Methods Matched, nested case-control study
Country: Norway
Participants Participants: 100,000 men and women
Inclusion criteria: serum available at Janus serum bank (Norwegian serum bank which is consolidated from several
sources and maintained by the Norwegian Cancer Society for research purposes)
Recruitment: 1972 to 1985
Outcome assessment: end of 1985
Number of cases:
thyroid cancer: 43 (male/female: 12/31)
Case definition: incidence
Years of follow-up: 0.0 to 14.0 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: conditional logistic regression
Variables controlled by matching: age, gender, year of sample collection, county of residence
Notes
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Goodman 2001
Methods Matched, nested case-control study
Country: US
Participants Participants: 18,314 men and women
Inclusion criteria: asbestos workers: 45 to 74 years of age; smokers > 20 pack-years: 50 to 69 years of age; cohort of a
RCT for lung cancer prevention in high risk populations
Name of parent cohort: Caret (Carotene and Retinol Efficacy Trial)
Recruitment: 1988 to 1994
Outcome assessment: April 1999
Number of cases:
Lung cancer: 235 (male/female: n.r.)
Prostate cancer: 356 (male/female: 356/0)
Case definition: incidence
Years of follow-up: 6.0 to 12.0 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Analysed cases: 235 of 236 prostate cancer cases analysed (reason for non-inclusion: no sample available for analysis
or no control available); 356 of 385 lung cancer cases analysed (reason for non-inclusion: missing selenium values
for case-control pairs)
Statistical methods: conditional logistic regression
Variables controlled bymatching: age, smoking status at randomisation, year of randomisation, year of sample collection,
treatment arm, exposure population
Notes
Hartman 1998
Methods Cohort/sub-cohort-controlled cohort study
Country: Finland
Participants Participants: 29,133 men
Inclusion criteria: 50 to 69 years of age; smokers; no history of cancer (other than non-melanoma skin cancer) at
baseline; no severe physical or psychiatric illness; intake of vitamin E/A/beta-carotene supplements in excess of defined
amounts
Name of parent cohort: Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study
Recruitment: 1985 to 1988
Outcome assessment: 30 April 1993
Number of cases:
Prostate cancer: 302 (male/female: 302/0)
Case definition: incidence
Years of follow-up: 5.0 to 8.0 years
Type of selenium marker: intake (food use questionnaire)
Interventions d.n.a.
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Hartman 1998 (Continued)
Outcomes Analysed cases: 302 of 317 cases included in analysis (reason for non-inclusion: no dietary information available)
analysis stratified by randomisation status according to active interventions or placebo interventions in the RCT
results reported separately for total selenium intake and non-supplemental selenium intake
Statistical methods: Cox regression
Variables controlled in analysis: age, living in urban area, beta-carotene intervention, total energy, BPH
Notes
Helzlsouer 2000
Methods Matched, nested case-control study
Country: US
Participants Participants: 10,456 men
Inclusion criteria: residents of Washington county; cases with second malignancy or missing pathologic confirmation
excluded
Name of parent cohort: CLUE II Cohort
Recruitment: 1989
Outcome assessment: September 1996
Number of cases:
prostate cancer: 117 (male/female: 117/0)
Case definition: incidence
Years of follow-up: 6.8 to 7.8 years
Type of selenium marker: toenail
Interventions d.n.a.
Outcomes Analysed cases: 117 of 145 cases analysed (reason for non-inclusion: no toenail clipping available)
Statistical methods: conditional logistic regression
Variables controlled in analysis: BMI at age 21, education, hours since last meal
Variables controlled by matching: age, race/ethnicity, year and month of sample collection, size of toenail clipping
Notes
Kabuto 1994
Methods Matched, nested case-control study
Country: Japan
Participants Participants: 20,000 men and women
Inclusion criteria: survivors of the atomic bomb in Hiroshima or Nagasaki; serum available for analysis
Name of parent cohort: Adult Health Study Hiroshima and Nagasaki
Recruitment: 1960 (blood samples drawn in 1970 to 1972)
Outcome assessment: 1983
Number of cases:
Stomach cancer: 201 (male/female: 113/88)
Lung cancer: 77 (male/female: 43/34)
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Kabuto 1994 (Continued)
Case definition: incidence
Years of follow-up: 12.0 to 14.0 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: conditional logistic regression
Variables controlled in analysis: radiation dose, smoking, age, gender
Variables controlled by matching: age, gender, year/month of sample collection, city
Notes
Karagas 1997
Methods Matched, nested case-control study
Country: US
Participants Participants: 1805 men and women
Inclusion criteria: at least one basal cell or squamous cell cancer before study entry; participants of an RCT for non-
melanoma skin cancer prevention with oral beta-carotene supplementation
Name of parent cohort: Skin Cancer Prevention Study
Recruitment: February 1983 to February 1986
Outcome assessment: 30 September 1989
Number of cases:
Squamous cell cancer: 131 (89% male/11% female)
Case definition: incidence
Years of follow-up: 3.0 to 5.0 years
Type of selenium marker: plasma
Interventions d.n.a.
Outcomes Statistical methods: conditional logistic regression
Variables controlled in analysis: cigarette smoking
Variables controlled by matching: age, gender, study centre of RCT, time in study (diagnosis date)
Notes
Knekt 1990
Methods Matched, nested case-control study (Knekt 1990, Hakama 1990, Knekt 1988, Knekt 1996)
Cohort study (Knekt 1991)
Country: Finland
Participants Inclusion criteria: no history of cancer at baseline
Name of parent cohort: Social Insurance Institution’s Mobile Clinic Health Examination Survey
Recruitment: 1968 to 1972
Knekt 1990:
Participants: 39,268: 21,172 men and 18,096 women
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Knekt 1990 (Continued)
Outcome assessment: 31 December 1980
Number of cases:
Any cancer: 1096 (male/female: 597/499)
Stomach cancer: 95 (male/female: 58/37)
Colon and rectal cancer: 91 (male/female: 32/59)
Lung cancer: 198 (male/female: 189/9)
Prostate cancer: 51 (male/female: 51/0)
Urinary tract cancer: 47 (male/female: 34/13)
Pancreatic cancer: 45 (male/female: 22/23)
Breast cancer: 90 (male/female: 0/90)
Gynaecological cancer (without breast): 86 (male/female: 0/86)
Basal cell carcinoma (skin): 126 (male/female: 64/62)
Other: 267 (male/female: 147/120)
Hakama 1990:
Participants: number of participants n.r.; both genders
Inclusion criteria: aged 15 years and older
Outcome assessment: 1977
Number of cases:
Any cancer: 766 (male/female: n.r.)
Lung cancer: 151 (male/female: 151/0)
Breast cancer: 67 (male/female: 0/67)
Stomach cancer: 76 (male/female: n.r.)
Prostate cancer: 37 (male/female: 37/0)
Knekt 1988:
Participants: 36,265: 21,172 men and 15,093 women
Outcome assessment: 31 December 1977
Number of cases:
Oesophageal and stomach cancer: 86 (male/female: 51/35)
Colon and rectal cancer: 57 (male/female: 21/36)
Knekt 1991:
Participants: 4538 men
Inclusion criteria: aged 20 to 69 years, with dietary history taken
Outcome assessment: 1986
Number of cases:
Lung cancer: 117 (male/female: 117/0)
Knekt 1996:
Participants: 1896 women
Outcome assessment: 1980
Number of cases:
Ovarian cancer: 24 (male/female: 0/24)
Case definition: incidence
Years of follow-up: 9 to 20 years
Type of selenium marker: serum (Knekt 1990, Hakama 1990, Knekt 1988, Knekt 1996), intake (Knekt 1991: dietary
history)
Interventions d.n.a.
Outcomes Knekt 1990:
Statistical methods: conditional logistic regression
Variables controlled in analysis: smoking
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Knekt 1990 (Continued)
Variables additionally controlled in analysis of highest four quintiles versus lowest quintile: occupation, BMI, parity,
cholesterol, haematocrit
Variables controlled bymatching: age, gender, municipality, time of baseline examination, duration of storage of sample
Hakama 1990:
Analysed cases: 766 of 864 cases analysed (reason for non-inclusion: no serum sample)
Statistical methods: conditional logistic regression
Variables controlled in analysis: smoking
Variables additionally controlled in analysis of highest four quintiles versus lowest quintile: retinol level, alpha-tocopherol
level
Variables controlled bymatching: age, gender, municipality, time of baseline examination, duration of storage of sample
Knekt 1988:
Statistical methods: n.r.
Variables controlled in analysis: smoking, serum cholesterol
Variables controlled bymatching: age, gender, municipality, time of baseline examination, duration of storage of sample
Knekt 1991:
Statistical methods: Cox-proportional hazards model
Variables controlled in analysis: age, smoking (data stratified according to smoking status)
Knekt 1996:
Statistical methods: conditional logistic regression
Variables controlled bymatching: age, gender, municipality, time of baseline examination, duration of storage of sample
Notes Primary publication: Knekt 1990
Other publications: Hakama 1990, Knekt 1988, Knekt 1991, Knekt 1996
Knekt 1998
Methods Matched, nested case-control study
Country: Finland
Participants Participants: 9101 men and women
Inclusion criteria: 19 years or older; no history of cancer at baseline; serum sample available for analysis
Name of parent cohort: Social Insurance Institution’s Mobile Clinic Health Examination Survey
Recruitment: 1973 to 1976
Outcome assessment: end of 1991
Number of cases:
Lung cancer: 91 (male/female: approximately 95%/5%)
Case definition: incidence
Years of follow-up: 16.0 to 19.0 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Analysed cases: 91 of 95 (male/female: 90/5) cases analysed
Statistical methods: conditional logistic regression
Variables controlled in analysis: smoking, alpha-tocopherol, serum cholesterol, copper, orosomucoid, BMI
Variables controlled by matching: age, gender, municipality, season of sample collection, length of storage of sample
Notes
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Kok 1987
Methods Matched, nested case-control study
Country: the Netherlands
Participants Participants: 10,532 men and women
Inclusion criteria: inhabitants of Zoetermeer; 5 years or older
Name of parent cohort: EPOZ Cohort (Epidemiologisch onderzoek naar risico-indicatoren voor hart- en vaatziekten)
Recruitment: 1975 to 1978
Outcome assessment: 31 December 1983
Number of cases:
Any cancer: 69 (male/female: 40/29)
Case definition:mortality
Years of follow-up: 6.0 to 9.0 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Analysed cases: 69 of 114 cases analysed (reason for non-inclusion: serum or baseline data not available, deaths in first
year of follow-up excluded)
Statistical methods: not specified
Variables controlled in analysis: age, smoking, serum cholesterol, serum vitamin A and E, systolic and diastolic blood
pressure, BMI, week of blood collection, years of education, gender (in group of both genders)
Variables controlled by matching: age, gender, smoking status
Notes Primary publication: Kok 1987b
Other publication: Kok 1987a
Kornitzer 2004
Methods Matched, nested case-control study
Country: Belgium
Participants Participants: cohort size not reported; men and women
Inclusion criteria: 25 to 74 years of age
Name of parent cohort: Belgian Interuniversity Study on Nutrition and Health
Recruitment: 1980 to 1984
Outcome assessment: n.r.
Number of cases:
Any cancer: 193 (male/female: 143/50)
Case definition:mortality
Years of follow-up: 10.0 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Analysed cases: 143 male/50 female cases analysed from 252 male/91 female cases (reason for non-inclusion: no
selenium measurement available)
Statistical methods: not specified
Variables controlled in analysis: BMI, total energy, total fat, saturated fat, alcohol intake, fibre, retinol, vitamin C,
smoking, beta-carotene
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Kornitzer 2004 (Continued)
Variables controlled by matching: age, gender
Notes
Kromhout 1987
Methods Cohort/sub-cohort-controlled cohort study
Country: the Netherlands
Participants Participants: 878 men
Inclusion criteria: 40 to 59 years of age; random sample of general male population at specific age in Zutphen
Name of parent cohort: Zutphen Study
Recruitment: 1960
Outcome assessment: 1985
Number of cases:
lung cancer: 63 (male/female: 63/0)
Case definition:mortality
Years of follow-up: 25.0 years
Type of selenium marker: intake (interview)
Interventions d.n.a.
Outcomes Statistical methods: Cox proportional hazard model
Variables controlled in analysis: age, pack years of smoking
Notes
Li 2000
Methods Randomised controlled trial
Allocation: randomised, “based on their residence area”
Sequence generation: unclear, not described
Concealment: unclear, not described
Blinding: of participants: adequate (placebo), of investigators and doctors: unclear, not described
Dropouts/withdrawals: no significant difference between percentage of drop-outs in intervention and control group
(absolute numbers not reported)
Intention-to-treat-analysis: unclear
Recruitment period: unclear, not described
Observation period: 3 years, started in 1996
Study period: unclear, not described
Detection of cases: unclear, the study followed the diagnostic menu published by the National Cancer Control and
Prevention Center, follow-up procedures not described
Informed consent: unclear, not described
Participants Country: China
Number of participants: 2065 (selenium group: 1112; placebo group: 953)
Condition: HBsAg carriers with negative AFP and normal ALT living in Qidong, Jiangsu province
Demographics:men only; aged 20 to 65 years (screening group)
65Selenium for preventing cancer (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Li 2000 (Continued)
Recruitment and setting: recruitment of 2065 HBsAg carriers from 17 villages out of a screening group of 18,000 men
Interventions Intervention: 0.5 mg sodium selenite p.o. daily for 3 years
Control: placebo
Outcomes Primary outcome measure: incidence of primary liver cancer
Other: blood selenium levels, activity of glutathione peroxidase
Results: person-year incidence rate (number of cases/total number of persons) in intervention and control group:
1st year of follow-up: selenium group 899.25/100,000 (10/1112); placebo group: 1,888.77/100,000 (18/953)
2nd year of follow-up: selenium group 1,708.60/100,000 (19/1112); placebo group: 4,302.20/100,000 (41/953)
3rd year of follow-up: selenium group 3,057.55/100,000 (34/1112); placebo group: 5,981.11/100,000 (57/953)
Notes adverse effects were not mentioned
Li 2004a
Methods Matched, nested case-control study
Country: US
Participants Participants: 14,916 men
Inclusion criteria: participants of Physicians’ Health Study who provided blood sample (healthy male physicians); no
history of cancer at baseline; several physical conditions excluded at baseline: chronic renal failure, unstable angina
pectoris, liver disease, peptic ulcer, history of TIA/stroke/myocardial infarction/gout; no use of vitamin A or beta-
carotene supplements
Name of parent cohort: Physicians’ Health Study
Recruitment: 1982
Outcome assessment: 1995
Number of cases:
Prostate cancer: 586 (male/female: 586/0)
Case definition: incidence
Years of follow-up: 13.0 years
Type of selenium marker: plasma
Interventions d.n.a.
Outcomes Statistical methods: logistic regression
Variables controlled in analysis: age at baseline, smoking status, duration of follow-up
Variables controlled by matching: age, smoking status
Notes
66Selenium for preventing cancer (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
McNaughton 2005
Methods Matched, nested case-control study (McNaughton 2005b)
Cohort study (Heinen 2007, van der Pols 2009)
Country: Australia
Participants Name of parent cohort: Nambour Skin Cancer Study
Recruitment: 1992 to 1996
Case definition: incidence
McNaughton 2005b :
Participants: approximately 1000 men and women
Inclusion criteria: randomly selected adults, aged 20 to 69 years; recruited for participation in a randomised controlled
trial for skin cancer prevention with beta-carotene supplements and sunscreen application in 1992; living in the
Nambour community; free of SCC at baseline; with blood sample and FFQ provided in 1996; participants with
extreme energy intakes in FFQ excluded
Outcome assessment:December 2001
Number of cases:
Basal cell carcinoma of the skin: 90 (male/female: 39/51)
Years of follow-up: 5.5 years
Type of selenium marker: serum and nutritional intake (FFQ)
Heinen 2007:
Participants: 1001 men and women
Inclusion criteria: randomly selected adults, aged 20 to 69 years; recruited for participation in randomised controlled
trial for skin cancer prevention with beta-carotene supplements and sunscreen application in 1992; living in the
Nambour community; with blood sample and FFQ provided in 1996; participants with extreme energy intakes in
FFQ and missing consumption frequencies for more than 10% of food items excluded
Outcome assessment: 31 December 2004
Number of cases:
Basal cell carcinoma of the skin: 149 (male/female: 87/62) participants with 321 BCC tumours
Squamous cell carcinoma of the skin: 116 (male/female: 70/46) participants with 221 SCC tumours,
Case definition: incidence (tumour-based incidence and person-based incidence)
Years of follow-up: 8 years
Type of selenium marker: nutritional intake (FFQ)
van der Pols 2009:
Participants: 485 (male/female: 223/262) men and women
Inclusion criteria: randomly selected adults, aged 20 to 69 years; recruited for participation in randomised controlled
trial for skin cancer prevention with beta-carotene supplements and sunscreen application in 1992; randomised to
placebo in the intervention trial; living in the Nambour community; free of SCC at baseline; with blood sample and
FFQ provided in 1996; participants with extreme energy intakes in FFQ excluded
Outcome assessment: 31 December 2004
Number of cases:
Basal cell carcinoma of the skin: 77 (male/female: 46/31) participants with 173 BCC tumours
Squamous cell carcinoma of the skin: 59 (male/female: 38/21) participants with 124 SCC tumours,
Years of follow-up: 8 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes McNaughton 2005b :
Statistical methods: conditional logistic regression
Variables controlled in analysis: age, gender
Variables controlled by matching: age, gender
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McNaughton 2005 (Continued)
Heinen 2007:
Statistical methods: generalised linear models
Variables controlled in analysis: age, sex, intervention arm in RCT, energy intake, skin colour, elastosis of the neck,
smoking, use of dietary supplements, history of skin cancer
van der Pols 2009:
Statistical methods: generalised linear models
Variables controlled in analysis: age, sex, pack-years of smoking, alcohol intake, time spent outdoors on weekdays,
history of skin cancer before 1996
Notes Primary publication: McNaughton 2005b
Other publication: Heinen 2007, van der Pols 2009
tumour-based incidence: number of newly developed histologically confirmed BCC or SCC divided by the person-
years of follow-up accumulated over follow-up period
person-based incidence: number of persons newly affected by BCC or SCC during the same person-years of follow-
up time as calculated for the tumour-based analysis
Menkes 1986
Methods Matched, nested case-control study
Country: US
Participants Participants: 25,804 men and women
Inclusion criteria: female andmale inhabitants ofWashington county/Maryland; history of cancer at baseline excluded
Name of parent cohort: CLUE I Cohort
Recruitment: September to November 1974
Menkes 1986b:
Outcome assessment: 1983
Number of cases:
Lung cancer: 99 (69% male/31% female)
Helzlsour 1996:
Inclusion criteria: women only; women who used hormones at baseline excluded
Outcome assessment: 1989
Number of cases:
Ovarian cancer: 35 (male/female: 0/35)
Breslow 1995:
Outcome assessment: 1994
Number of cases:
Melanoma: 23 (male/female: n.r.)
Basal cell carcinoma (skin): 17 (male/female: n.r.)
Squamous cell cancer: 37 (male/female: n.r.)
Zheng 1993:
Outcome assessment: 1990
Number of cases:
Oral and pharyngeal: 28 (male/female: n.r.)
Batieha 1993:
Inclusion criteria: 15,161 women
Outcome assessment: 31 May 1990
Number of cases:
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Menkes 1986 (Continued)
Cervical cancer: 50 (male/female: 0/50)
Helzlsour 1989:
Inclusion criteria: 20,305 men and women
Outcome assessment: 1986
Number of cases:
Bladder cancer: 35 (male/female: n.r.)
Burney 1989:
Outcome assessment: 1986
Number of cases:
Pancreatic cancer: 22 (male/female: 9/13)
Ko 1994:
Outcome assessment: 25 September 1991
Number of cases:
Colon cancer: 121 (male/female: 50/71)
Case definition: incidence
Years of follow-up: 8.0 to 16.8 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Menkes 1986b:
Statistical methods: conditional logistic regression
Variables controlled by matching: age, gender, race/ethnicity, smoking status, year and month of sample collection
Helzlsour 1986:
Statistical methods: conditional logistic regression
Variables controlled by matching: Age, race/ethnicity, day time of blood sample collection, hours since last meal, time
since last menstrual period (post-menopausal: years, pre-menopausal: days)
Breslow 1995:
Statistical methods: conditional logistic regression
Analysed cases: 17 of 98 basal cell carcinoma cases, and 23 of 30 melanoma cases (and all squamous cell carcinoma
cases) included in analysis
Variables controlled by matching: age, gender, race/ethnicity
Zheng 1993:
Statistical methods: n.r.
Variables controlled in analysis: smoking
Variables controlled by matching: age, gender, race/ethnicity, year and month of sample collection, hours between
previous meal and blood collection
Batieha 1993:
Statistical methods: conditional logistic regression
Analysed cases: 50 of 60 cases (CIS and invasive cervical cancer) analysed (reason for non-inclusion: no matched
control available)
Variables controlled by matching: age, race/ethnicity, year and month of blood collection, hours since last meal, time
since last menstrual period
Helzlsour 1989:
Statistical methods: n.r.
Variables controlled in analysis: cigarette smoking, use of vitamin supplements
Variables controlled by matching: age, gender, race/ethnicity, hours since last meal (all samples collected in same year)
Burney 1989:
Statistical methods: n.r.
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Menkes 1986 (Continued)
Variables controlled by matching: age, gender, race/ethnicity, hours since last meal
Ko 1994:
Analysed cases: 121 of 154 cases analysed (reason for non-inclusion: no serum sample available, tumour pathology or
localisation unclear)
Statistical methods: conditional logistic regression
Variables controlled by matching: age, gender, race/ethnicity, year and month of sample collection, hours since last
meal, women: time since last menstrual period, women: use of hormones/hormonal contraceptives
Notes Primary publication: Menkes 1986b
Other publications: Helzlsour 1996, Breslow 1995, Zheng 1993, Batieha 1993, Helzlsour 1989, Burney 1989, Ko
1994, Schober 1987 (cases included in Ko 1994), Menkes 1986a (cases included in Menkes 1986b)
Michaud 2002
Methods Matched, nested case-control study
Country: Finland
Participants Participants: 29,133 men
Inclusion criteria: 50 to 69 years of age; smokers; no history of cancer (other than non-melanoma skin cancer) at
baseline; no severe physical or psychiatric illness; intake of vitamin E/A/beta-carotene supplements in excess of defined
amounts
Name of parent cohort: Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study
Recruitment: 1985 to 1988
Outcome assessment: 30 April 1993
Number of cases:
Bladder cancer: 133 (male/female: 133/0)
Case definition: incidence
Years of follow-up: 5.0 to 8.0 years
Type of selenium marker: toenail
Interventions d.n.a.
Outcomes Statistical methods: conditional logistic regression
Variables controlled in analysis: smoking dose and duration
Variables controlled by matching: age, year/month of sample collection, intervention group status in RCT (only male
smokers included in cohort)
Notes
Michaud 2005
Methods Matched, nested case-control study
Country: US
Participants Participants: 101,950: 33,737 men, 68,213 women
Inclusion criteria: cohort of HPFS (men) and NHS (women); no history of cancer at baseline
Name of parent cohort: Health Professional Follow-Up Study (HPFS) and Nurses’ Health Study (NHS)
Recruitment: 1987 (HPFS), 1983 (NHS)
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Michaud 2005 (Continued)
Outcome assessment: 2000
Number of cases:
Bladder cancer: 337 (male/female: 221/116)
Case definition: incidence
Years of follow-up: 13.0 to 17.0 years
Type of selenium marker: toenail
Interventions d.n.a.
Outcomes Statistical methods: conditional logistic regression
Variables controlled in analysis: pack-years of smoking, heavy smoking at baseline
Variables controlled by matching: age, gender, smoking status, month of sample collection
Notes
Nomura 1987
Methods Unmatched, nested case-control study
Country: US
Participants Participants: 6860 men
Inclusion criteria: born 1900 to 1919; Japanese ancestry; inhabitants of Oahu/Hawaii; participants in the Honolulu
Heart Program (1965 to 68)
Name of parent cohort: Honolulu Heart Program
Recruitment: 1971 to 1975
Outcome assessment: n.r.
Number of cases:
Any cancer: 280 (male/female: 280/0)
Stomach cancer: 66 (male/female: 66/0)
Rectal cancer: 32 (male/female: 32/0)
Lung cancer: 71 (male/female: 71/0)
Colon cancer: 82 (male/female: 82/0)
Bladder cancer: 29 (male/female: 29/0)
Case definition: incidence
Years of follow-up: 11.0 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: proportional hazards regression/Cox regression
Variables controlled in analysis:
age at examination, cigarettes/day (any cancer, lung cancer, bladder cancer)
age at examination (stomach, rectum, colon)
Notes N.B.: “Any cancer” in this study comprises all cancer cases for stomach, rectal, lung, colon and bladder cancer.
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Nomura 2000
Methods Matched, nested case-control study
Country: US
Participants Participants: 9345 men
Inclusion criteria: no cancer diagnosis at baseline, blood sample available for analysis, men from two cohorts: sub-
cohort one: participants of Nomura 1987; sub-cohort 2: brothers of participants in Nomura 1987
Recruitment: 1971 to 1977
Outcome assessment: 1995
Number of cases:
Prostate cancer: 249 (male/female: 249/0)
Case definition: incidence
Years of follow-up: 19.0 to 25.0 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Analysed cases: random sample of 249 (out of 360) cases analysed because of limited resources
Statistical methods: generalised linear model
Variables controlled in analysis: cigarette smoking history, age
Variables controlled by matching: age, year/month of sample collection, recruitment in sub-cohort 1 or 2
Notes
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NPCT 1996
Methods Randomised controlled trial
Nutritional Prevention of Cancer Trial (NPCT)
Allocation: random, block/stratified by clinic
Sequence generation: computer generated random numbers
Concealment: central assignment (sealed pill bottles)
Blinding:participant blinded, doctor blinded, outcome assessor/pathologist unclear, review/coding of medical records
blinded
Dropouts/withdrawals: “9 patients (5 in the selenium group and 4 in the placebo group) declined to provide additional
illness information” (Clark 1996, p. 1959) - 0 participants lost to vital follow-up
Intention-to-treat-analysis: yes
Recruitment period: 1983 to 1991
End of predefined study period: 31 December 1993
Blinded intervention continued until the end of the blinded period: 31 January 1996
Intervention duration:
31 December 1993 (end of study period): mean = 4.5 years
31 January 1996 (end of blinded period): mean = 7.9 years
Observation period/dermatologic follow-up:
31 December 1993 (end of study period): mean = 6.4 years
31 January 1996 (end of blinded period): mean = 7.4 years
Detection of cases: dermatologic examination and interview every 6 months during follow-up; incident BCC and SCC
were diagnosed by biopsy and confirmed by another dermatopathologist
Informed consent: written informed consent forms, approval by institutional review board of participating institutions
Participants Country: US
Number of participants: 1312 (randomised to selenium group: 653, to placebo group: 659)
Condition: male and female participants with history of 2 or more squamous cell or basal cell skin cancers
Demographics:mean age 63.4 years (selenium)/63.0 years (placebo); 73.8% men (selenium). 75.6% men (placebo)
Recruitment and setting: seven dermatological clinics (three academic units, four private practices) in the US
Interventions Intervention: 200 µg selenium supplied as 500 mg selenium yeast tablets p.o./daily.
Control: placebo
Outcomes Primary outcome measure: incidence of basal and squamous cell carcinoma of the skin:
all analyses were based on 1250 participants with initial blood collection within four days after randomisation (621
in the selenium group and 629 in the placebo group)
Other reported outcomes and secondary outcome measures:
Reported in Clark 1996: Incidence of lung cancer, prostate cancer, colorectal cancer, any cancer, head and neck
cancer, bladder cancer, oesophageal cancer, breast cancer, melanoma, haematologic cancer,
Reported in Duffield-Lillico 2002: Overall cancer mortality
Notes Adverse effects: Clark 1996: 35 participants (21 in selenium and 14 in control group) complained of adverse effects,
mostly involving gastrointestinal upset, and withdrew treatment.
Post-hoc introduced secondary outcomes were: all-cause mortality, total cancer mortality, total cancer incidence and
incidence of lung / prostate / colorectal cancers
HR: adjusted for sex, age, smoking status, clinic site, plasma selenium concentration, clinical sun damage, sunscreen
use at baseline and number of BCCs/SCCs/NMSCs in the 12 months before randomisation
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Overvad 1991
Methods Cohort/sub-cohort-controlled cohort study
Country: Channel Islands
Participants Participants: 5162 women
Inclusion criteria: ≥ 35 years of age; ostensibly healthy inhabitants of Guernsey
Name of parent cohort: Channel Island Cohort
Recruitment: 1967 to 1976
Outcome assessment: end of 1985
Number of cases:
Breast cancer: 46 (male/female: 0/46)
Case definition: incidence
Years of follow-up: mean: 11 years for cases
Type of selenium marker: plasma
Interventions d.n.a.
Outcomes Analysed cases: 46 of 88 cases analysed (reason for non-inclusion: no plasma available)
Statistical methods: logistic regression
Variables controlled in analysis: age, age at menarche, age at first baby, parity, BMI
Notes
Peleg 1985
Methods Matched, nested case-control study
Country: US
Participants Participants: 2530 men and women
Inclusion criteria: 15 years of age and older; residents of Evans county; cases within first two years of follow-up
excluded
Name of parent cohort: Evans County Study
Recruitment: 1967 to 1969
Outcome assessment: January 1981
Number of cases:
Any cancer: 130 (male/female: 78/52)
Case definition: incidence
Years of follow-up: 11.0 to 14.0 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: n.r.
Variables controlled by matching: age, gender, race/ethnicity, year/month of sample collection
Notes
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Persson 2000
Methods Matched, nested case-control study
Country: Sweden
Participants Participants: approximately 9500 men (exact figure not reported)
Inclusion criteria: 46 to 48 years; residents of Malmo/Sweden
Name of parent cohort: Malmö Preventive Programme
Recruitment: 1974 to 1982
Outcome assessment: end of 1988
Number of cases:
Any cancer: 302 (male/female: 302/0)
Gastrointestinal cancer: 115 (male/female: 115/0)
Respiratory tract cancer: 69 (male/female: 69/0)
Other: 61 (male/female: 61/0)
Urinary tract cancer: 57 (male/female: 57/0)
Case definition: incidence
Years of follow-up: 6.0 to 15.0 years
Type of selenium marker: plasma selenium P
Interventions d.n.a.
Outcomes Analysed cases: 302 of 400 cases analysed (reason for non-inclusion: no sample available)
Statistical methods: logistic regression, Mantel-Haenszel
Variables controlled in analysis: smoking
Variables controlled by matching: age, year/month/date of sample collection
Notes Arbitrary unit: Concentration of selenoprotein P was expressed in arbitrary units (AU) relative to a standard of pooled
plasma. 0.3 AU equal one standard deviation.
Peters 2007
Methods Matched, nested case-control study
Country: US
Participants Participants: 26,975 white non-Hispanic men
Inclusion criteria: 55 to 74 years of age; excluded: no baseline questionnaire/informed consent/blood sample, no
further contact after screening
Name of parent cohort: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
Recruitment: September 1993 to June 2001
Outcome assessment: 1 October 2001
Number of cases:
Prostate cancer: 724 (male/female: 724/0)
Case definition: incidence
Years of follow-up: 0.3 to 8.0 years
Type of selenium marker: serum
Interventions d.n.a.
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Peters 2007 (Continued)
Outcomes Analysed cases: 724 of 803 cases included in analysis (reason for non-inclusion: no selenium measurement available)
Statistical methods: n.r.
Variables controlled in analysis: age, time since initial screening, year of blood collection, study centre
Variables controlled by matching: age, month of sample collection, time since initial screening
Notes
Peters 2008
Methods Cohort study
Country: US
Participants Inclusion criteria: aged 50 to 76 years, participants recruited from subscribers of commercial mailing list, residents of
western Washington state, non-whites excluded, no malignant disease at baseline
Name of parent cohort: Vitamins and lifestyle (VITAL) study
Recruitment: 1 October 2000 to 31 December 2002
Type of selenium marker: supplemental intake (questionnaire: use of supplements over the last 10 years, mean supple-
mental intake / day calculated)
Case definition: incidence
Peters 2008:
Participants: 35,242 men
Outcome assessment: 31 December 2004
Number of cases:
Prostate cancer: 818 (male/female: 818/0)
Years of follow-up: 2 to 4 years
Asgari 2009:
Participants: 69,671 men and women
Outcome assessment: 31 December 2006
Number of cases:
Melanoma: 461 (male/female: n.r.)
Years of follow-up: 4 to 5 years
Interventions d.n.a.
Outcomes Peters 2008:
Analysed cases: 818 of 830 cases analysed (reason for non-inclusion: not reported)
Statistical methods: Cox proportional hazard regression analysis
Variables controlled in analysis: age, family history of prostate cancer, BPH, income, multivitamin use
Asgari 2009:
Analysed cases: one case not analysed (reason for non-inclusion: not reported)
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, sex, education, family history of melanoma, personal history of non-melanoma
skin cancer, mole removal, freckles, sunburns, hair colour, reaction to sunlight exposure
Notes
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Ratnasinghe 2000
Methods Matched, nested case-control study
Country: China
Participants Participants: 9143 men
Inclusion criteria: 35 years or older; tin miners employed by the Yunnan Tin Corporation; 10 or more years of
underground mining / smelting; no history of cancer at baseline
Recruitment: 1992 to 1997
Outcome assessment: 1997
Number of cases:
Lung cancer: 108 (male/female: 108/0)
Case definition: incidence
Years of follow-up: 3 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Analysed cases: plasma was available for 108 of a total of 339 identified cases
Statistical methods: logistic regression, conditional logistic regression, Wilcoxon rank sum test
Variables controlled in analysis: radon exposure, smoking
Variables controlled by matching: age, year and month of sample collection
Notes
Reid 2008
Methods Randomised controlled trial
Sub-study of the Nutritional Prevention of Cancer Trial (NPCT 1996)
Allocation: random
Sequence generation: computer generated random numbers
Concealment: central assignment (sealed pill bottles)
Blinding:participant blinded, doctor blinded, outcome assessor/pathologist unclear, review/coding of medical records
blinded
Dropouts/withdrawals: two participants declined to provide additional illness information, no participant lost to vital
follow -up
Intention-to-treat-analysis: yes
Recruitment period: 1989-1992
Treatment duration:
Blinded intervention continued until the end of the blinded period; 1 February 1996.
Observation period/dermatologic follow-up:
1 February 1996
Detection of cases: dermatological examination and interview every 6 months during follow-up; incident BCC and
SCC were diagnosed by biopsy and confirmed by another dermatopathologist
Informed consent: written informed consent forms, approval by institutional review board of participating institutions
Participants 423 male and female participants with prior non-melanoma skin cancer
Country: US
Number of patients: 423 (randomised to selenium group: 210, to placebo group: 213)
Condition: male and female patients with history of 2 or more squamous cell or basal cell skin cancers
Demographics:mean age 63.8 years (selenium)/63.8 years (placebo); 66.2% men (selenium). 68.2% men (placebo)
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Reid 2008 (Continued)
Recruitment and setting: dermatologic clinic in Macon, Georgia
Interventions Intervention: 400 µg selenium supplied as selenium yeast tablets p.o./daily. Control: placebo
400 µg/day of selenium yeast or identical-appearing low selenium yeast placebo
Recruitment: 12 September 1989 to 3 April 1992
End of the blinded treatment period: 2 February 1996
Outcomes Primary outcome measure: incidence of basal and squamous cell carcinoma of the skin:
all analyses were based on n = 423 participants with initial blood collection within 4 days after randomizations
Other reported outcomes:
total internal cancer incidence
Notes Information on study design, which was not reported in Reid 2008, was taken from the information available on the
Nutritional Prevention of Cancer Trial.
Adverse effects: not reported
HR: adjusted for: age (continuous), smoking status (never, former, current), gender
Ringstad 1988
Methods Matched, nested case-control study
Country: Norway
Participants Participants: 9364 men and women
Inclusion criteria: 20 to 54 years of age (men), 20 to 49 years of age (women); inhabitants of Tromso; blood sample
provided in 1979; no history of cancer at baseline
Name of parent cohort: Tromso Heart Study II
Recruitment: 1979 to 1980
Outcome assessment: 1985
Number of cases:
Any cancer: 60 (male/female: 26/34)
Case definition: incidence
Years of follow-up: 5.0 to 7.0 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Analysed cases: 60 of 72 cases analysed (reason for non-inclusion: no sample available)
Statistical methods: n.r.
Variables controlled by matching: age, gender, smoking status, month of sample collection, place of residence (district
of Tromso)
Notes
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Sakoda 2005
Methods Matched, nested case-control study
Country: China
Participants Participants: 41,563 men and women
Inclusion criteria: inhabitants of Haiman city of Chinese origin; written consent; toenail clipping available
Recruitment: January 1993 to December 1993
Outcome assessment: 30 September 2000
Number of cases:
Primary liver cancer: 166 (male/female: 154/12)
Case definition:mortality
Years of follow-up: 6.8 to 7.8 years
Type of selenium marker: toenail
Interventions d.n.a.
Outcomes Analysed cases: 166 of 455 observed cases included in analysis (only cases with questionnaire, blood sample and toenail
specimen analysed after 2000 due to different methods of selenium analysis)
Statistical methods: not specified
Variables controlled in analysis:
both genders: age, gender, HBsAg-status, alcohol intake, history of acute hepatitis, occupation
men: age, HBsAg-status, alcohol intake, history of acute hepatitis, family history of HCC, occupation
women: HBsAg-status, age, history of acute hepatitis
Variables controlled by matching: age, gender, township of residence
Notes
Salonen 1984
Methods Matched, nested case-control study
Country: Finland
Participants Participants: 8113 men and women
Inclusion criteria: 31 to 59 years of age; random sample of inhabitants of two Finnish provinces; initially free of cancer
Name of parent cohort: North Karelia Project
Recruitment: February to April 1972
Outcome assessment: 31 December 1978
Number of cases:
Any cancer: 128 (male/female: n.r.)
Case definition: incidence
Years of follow-up: 8.5 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: logistic regression / paired-sample OR
Variables controlled in analysis: tobacco consumption, serum cholesterol, beer consumption, dietary saturated fats,
years of education, study area
Variables controlled by matching: age, gender, smoking (tobacco use/day), total serum cholesterol
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Salonen 1984 (Continued)
Notes
Salonen 1985
Methods Matched, nested case-control study
Country: Finland
Participants Participants: 12,155 men and women
Inclusion criteria: 30 to 64 years of age; random sample of residents of two Finnish provinces; initially free of cancer
Name of parent cohort: North Karelia Project
Recruitment: January to March 1977
Outcome assessment: 31 December 1980
Number of cases:
Any cancer: 51 (male/female: 30/21)
Case definition:mortality
Years of follow-up: 3.7 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Analysed cases: 51 out of 56 cases (reason for non-inclusion: no serum sample available)
Statistical methods: logistic regression
Variables controlled by matching: age, gender, smoking (tobacco use/day)
Notes
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SELECT 2009
Methods Randomised controlled trial
SELECT (Selenium and Vitamin E Cancer Prevention Trial)
Allocation: random, block/stratified by clinic
Sequence generation: computer-generated random numbers
Concealment: central assignment (pill bottles)
Blinding: participant blinded, doctor blinded, outcome assessor/pathologist blinded, review/coding ofmedical records
blinded
Dropouts/withdrawals: of 35,533 randomised participants, 645 were excluded from analysis because they had prior
prostate cancer, did not give informed consent or participated at two study sites, which were excluded due to
management and regulatory issues
Intention-to-treat-analysis: yes
Recruitment period: 22 August 2001 to 24 June 2004
End of study period: 1 August 2009
Blinded intervention was discontinued on 23 October 2008 following the recommendation of the data safety and
monitoring committee after the second formal interim analysis in September 2008
Detection of cases: Participants had clinic visits once every 6 months and reported prostate cancers to the study staff.
Study staff obtained medical records to verify the diagnosis. Tissue and the corresponding pathology report were sent
to the central pathology laboratory for confirmation.
Informed consent: yes
Participants Countries: US, Canada, Puerto Rico
Number of participants: 34,888 men, randomised to four groups: placebo (8696), vitamin E (8737), selenium (8752)
, selenium + vitamin E (8703)
Condition: healthy men, aged 50 years or older (African American) or 55 years or older (all other), no prior diagnosis
of prostate cancer, 4 ng/ml or less of PSA in serum, a digital rectal examination not suspicious for cancer, no current
use of anticoagulant therapy other than 175 mg/day or less of acetylsalicylic acid or 81 mg/day or less of acetylsalicylic
acid with clopidogrel bisulphate, no history of haemorrhagic stroke, normal blood pressure.
Demographics:median age: 62.3-62.6 years in all four intervention groups, 79% white in all four intervention groups
Recruitment and setting: 427 participating sites
Interventions Group 1: placebo + placebo
Group 2: 400 IU/day all rac-alpha-tocopheryl acetate + placebo
Group 3: 200 µg/day L-selenomethionine + placebo
Group 4: 400 IU/day all rac-alpha-tocopheryl acetate + 200 µg/day L-selenomethionine
Outcomes Primary outcome: incidence of prostate cancer as determined by routine clinical management
Secondary outcomes: incidence of any cancer / lung cancer / colorectal cancer, diabetes mellitus, cardiovascular events,
death from any cause
Notes Adverse effects:
alopecia RR 1.28, (99% CI 1.01 to 1.62)
dermatitis grade 1-2 RR 1.17, (99% CI 1.00 to 1.35)
dermatitis grade 3-4 RR 1.74, (99% CI 0.56 to 5.44)
halitosis RR 1.17, (99% CI 0.99 to 1.38)
nail changes RR 1.04, (99% CI 0.94 to 1.16)
fatigue grade 1-2 RR 1.09, (99% CI 0.95 to 1.26)
fatigue grade 3-4 RR 0.87, (99% CI 0.40 to 1.88)
nausea grade 1-2 RR 1.19, (99% CI 0.94 to 1.52)
nausea grade 3 RR 0.99, (99% CI 0.30 to 3.34)
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Thomson 2008
Methods Cohort Study
Country: US
Participants Participants: 133,614 women
Inclusion criteria: post-menopausal participants (aged 50 to 79 years) of the WHI clinical trial and observational
study
Name of parent cohort: Women’s Health Initiative (WHI)
Recruitment: n.r.
Outcome assessment: December 2004
Number of cases: ovarian cancer: 451 (0/451)
Case definition: incidence
Years of follow-up: mean: 7 years
Type of selenium marker: supplemental selenium intake (food frequency questionnaire)
Interventions d.n.a.
Outcomes Statistical methods: Cox logistic regression
Variables controlled in analysis: participation in observational or intervention study, age, log calories, number of
relatives with breast/ovarian cancer, dietary modification randomisation arm, hysterectomy, minority race, pack-years
of smoking, physical activity, NSAID use, parity, infertility, duration of oral contraceptive use, number of lifetime
ovulatory cycles, partial oophorectomy, age at menopause, hormone therapy at study entry
Notes
van Noord 1987
Methods Matched, nested case-control study
Country: the Netherlands
Participants Participants: 8760 women
Inclusion criteria: 42 to 52 years of age; pre-menopausal; inhabitants of Utrecht
Name of parent cohort: DOM (Diagnostic onderzoek mammacarcinoom) Study
Recruitment: n.r.
Outcome assessment: 1 February 1986
Number of cases:
Breast cancer (pre-menopausal): 27 (male/female: 0/27)
Case definition: incidence
Years of follow-up: 0.6 to 3.5 years, mean: 2.1 years
Type of selenium marker: toenail
Interventions d.n.a.
Outcomes Analysed cases: 7 cases were detected in the initial mammography screening in this study and not included in the
analysis of incident cases
Statistical methods: n.r.
Variables controlled by matching: age, date of birth, pre-menopausal status
Notes
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vd Brandt 1993
Methods Cohort/sub-cohort-controlled cohort study
Country: the Netherlands
Participants Name of parent cohort: Netherlands Cohort Study (NLCS)
Recruitment: 1986
van den Brandt 1993b:
Participants: 120,852: 58,279 men and 62,573 women; aged 55 to 69 years; returned baseline questionnaire; no
history of cancer at baseline
Outcome assessment: n.r.
Number of cases:
Stomach cancer: 104 (male/female: 84/20)
Colon cancer: 234 (male/female: 121/113)
Rectal cancer: 113 (male/female: 77/36)
van den Brandt 1993a:
Participants: 120,852: 58,279 men and 62,573 women; age 55 to 69 years; returned baseline questionnaire; no history
of cancer at baseline
Outcome assessment: n.r.
Number of cases:
Lung cancer: 370 (male/female: 335/35)
van den Brandt 1994:
Participants: 62,573 post-menopausal women
Outcome assessment: 1989
Number of cases:
Breast cancer (post-menopausal): 355 (male/female: 0/355)
Breast cancer (post-menopausal), multivariate analysis: 270 (male/female: 0/270)
Zeegers 2002:
Participants: 120,852: 58,279 men and 62,573 women
Outcome assessment: December 1992
Number of cases:
Bladder cancer: 431 (male/female: 372/59)
van den Brandt 2003:
Participants: 58,279 men
Outcome assessment: n.r. (probably December 1992)
Number of cases:
Prostate cancer: 540 (male/female: 540/0)
Case definition: incidence
Years of follow-up:
3.3 years (Brandt 1993a; Brandt 1993b; Brandt 1994),
6.3 years (Zeegers 2002; Brandt 2003)
Type of selenium marker: toenail
Interventions d.n.a.
Outcomes van den Brandt 1993b:
Analysed cases: 234 of 351 colon cancer cases / 104 of 176 stomach cancer cases / 113 of 185 rectal cancer cases
analysed (reasons for non-inclusion: history of cancer at baseline not available, no pathological confirmation or CIS,
no toenail clipping available)
Statistical methods:Mantel-Haenszel
Variables controlled in analysis: age, gender
van den Brandt 1993a:
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vd Brandt 1993 (Continued)
Analysed cases: 370 of 617 cases analysed (reasons for non-inclusion: history of cancer at baseline not available, no
toenail clipping, no pathological confirmation, problems with selenium measurement)
Statistical methods:
Statistical methods:Mantel-Haenszel
Variables controlled in analysis: age, gender
van den Brandt 1994:
Analysed cases: 355 of 553 cases analysed (reasons for non-inclusion: history of cancer at baseline not available, CIS,
no toenail sample or problems with selenium detection)
Statistical methods: multivariate case-cohort analysis
Variables controlled in analysis: age, history of benign breast disease, maternal breast cancer, breast cancer in sister(s)
, age at menarche, age at menopause, oral contraceptive use, parity, age at first birth, body mass index, education,
current cigarette smoking, alcohol intake, energy intake
Zeegers 2002:
Analysed cases: 431 of 619 cases analysed (reason for non-inclusion: no toenails available)
Statistical methods: exponentially distributed failure time regression models
Variables controlled in analysis: age, gender, number of cigarettes/day, years of cigarette smoking
van den Brandt 2003:
Analysed cases: 540 of 704 cases analysed (reason for non-inclusion: no toenail samples or selenium detection not
possible)
Statistical methods: exponentially distributed failure time regression models
Variables controlled in analysis: age, family history of prostate cancer, number of cigarettes/day, years of cigarette
smoking, level of education
Notes Primary publication: van den Brandt 1993b
Other publications: Zeegers 2002, van den Brandt 1993a, van den Brandt 1994, van den Brandt 2003
Virtamo 1987
Methods Cohort/sub-cohort-controlled cohort study
Country: Finland
Participants Participants: 1110 men
Inclusion criteria: 55 to 74 years of age; inhabitants of Finnish rural areas; participants of prior study on CHD; serum
sample available: cases within first year of follow-up excluded
Name of parent cohort: Men in rural East and West Finland
Recruitment: 1974
Outcome assessment: 31 December 1983
Number of cases:
Any cancer: 109 (male/female: 109/0)
Case definition: incidence
Years of follow-up: 10.0 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: conditional logistic regression
Variables controlled in analysis: age, area of residence, smoking, serum cholesterol, alcohol intake
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Virtamo 1987 (Continued)
Notes
Wei 2004
Methods Frequency-matched cohort controlled study
Country: China
Participants Participants: Mark 2000: 29,584 men and women; Wei 2004: 1103 people who were originally selected as disease-
free controls in Mark 2000
Inclusion criteria: 40 to 69 years of age; healthy inhabitants of 4 Linxian communities; participants of a randomised
controlled trial
Name of parent cohort: General Population Trial Linxian
Recruitment: 1985
Outcome assessment:May 1991 (Mark 2000); n.r. (Wei 2004)
Number of cases:
Wei 2004:
oesophageal cancer: 75 (male/female: 49/26) mortality
stomach, cardia cancer: 36 (male/female: 22/14) mortality
stomach, non-cardia cancer: 24 (male/female: 20/4) mortality
other: 32 (male/female: 22/10) mortality
Mark 2000:
oesophageal cancer: 590 (male/female: 286/304) incidence
oesophageal cancer: 332 (male/female: n.r.) mortality
stomach, cardia cancer: 402 (male/female: 239/163) incidence
stomach, cardia cancer: 232 (male/female: n.r.) mortality
stomach, non-cardia cancer: 87 (male/female: 66/21) incidence
stomach, non-cardia cancer: 68 (male/female: n.r.) mortality
Case definition:mortality, incidence
Years of follow-up: unclear/approximately 9 years (Wei 2004), 6 years (Mark 2000)
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: cox-proportional hazard model
Variables controlled in analysis:Wei 2004: age, cholesterol, smoking, alcohol intake, BMI; Mark 2000: age
Variables controlled by matching: age category, gender
Notes Primary publication: Wei 2004
Other publication: Mark 2000
Remark:
Wei 2004 measured serum selenium in a sub-cohort derived from 29,584 male and female participants of the Linxian
Population Trial. The earlier publication of this study, Mark 2000 reported 332 fatal cases and 590 incident cases.
The later publication, Wei 2004 reported deaths from oesophageal cancer in the disease-free controls of Mark 2000
and analysed 75 fatal cases.
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Willett 1983
Methods Matched, nested case-control study
Country: US
Participants Participants: 10,940 men and women
Inclusion criteria: 30 to 69 years of age; serum sample available (only 4480 samples of cohort were available because
of freezer breakdown); participants of an RCT on hypertension; institutionalised and bedfast people were excluded
Name of parent cohort: Hypertension Detection Follow-Up Programme (HDFP)
Recruitment: 1973 to 1974
Outcome assessment: n.r.
Number of cases:
Any cancer: 111 (male/female: 60/51)
Case definition: incidence
Years of follow-up: 5.0 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: logistic regression of unmatched data
Variables controlled by matching: age, gender, race/ethnicity, smoking status, year/month of sample collection, initial
blood pressure, use of antihypertensive medication, randomisation group
in women: parity, menopausal status
Notes
Yoshizawa 1998
Methods Matched, nested case-control study
Country: US
Participants Participants: 33,737 men
Inclusion criteria: 40 to 75 years of age; physicians from all 50 U.S. states; provision of toenails in 1987 and completed
baseline questionnaire in 1986; exclusion of histologically confirmed prostate cancer at baseline and cases within first
2 years of follow-up
Name of parent cohort: Health Professionals Follow-Up Study (HPFS)
Recruitment: 1986 to 1987
Outcome assessment: 1994
Number of cases:
Prostate cancer: 181 (male/female: 181/0)
Case definition: incidence
Years of follow-up: 8.0 to 9.0 years
Type of selenium marker: toenail
Interventions d.n.a.
Outcomes Statistical methods: logistic regression, conditional logistic regression
Variables controlled in analysis: quintiles of lycopene, saturated fat, calcium, family history of prostate cancer, BMI,
vasectomy
Variables controlled by matching: age, smoking status, year/month of sample collection
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Yoshizawa 1998 (Continued)
Notes
Yu 1991
Methods Randomised controlled trial
Allocation: random
Sequence generation: unclear, not described
Concealment: unclear, not described
Blinding: described as double-blind; blinding of participants: adequate, placebo tablets; blinding of investigators and
doctors: unclear
Dropouts/withdrawals: unclear, not described
Intention-to-treat-analysis: unclear, not described
Recruitment period: unclear, not described
Observation period: 2 years
Study period: 2 years
Detection of cases: unclear, use of “national standards” for the diagnosis of liver cancer
Informed consent: unclear, not described
Participants Country: China
Number of participants: 2,474
Condition: first-degree relatives within three generations of families with 2 or more cases of liver cancer during the
period 1972 to 1985
Demographics: gender distribution not reported; age: 15 to 75 years
Recruitment and setting: participants were residents in Qidong province
Interventions Intervention: 200 µg selenium as selenised yeast p.o. daily, intervention period unclear
Control: placebo
Outcomes Primary outcome measure: incidence of primary liver cancer within 2 years after start of intervention
Results:
13 cases in 1030 placebo subjects
10 cases in 1444 selenium subjects
Notes Data were extracted from Yu 1991.
We identified two later publications (Li 2002, Yu 1993), which we assumed to report on the same trial as Yu 1991.
However, total number of participants differed from the initial report (N = 3849 in the later publications with 1485
receiving placebo and 2364 receiving selenium). The total number of cases was not reported in either Li 1992 or Yu
1993.
The reported results were:
Li 1992:
person-year incidence rate in intervention and control group:
within one year of follow-up: selenium group 175.36/100,000; placebo group: 414.65/100,000
within two years of follow-up: selenium group 219.37/100,000; placebo group: 553.15/100,000
Yu 1993:
cumulated incidence:
after one year: selenium group 1.75/1000; placebo group: 4.15/1000
after two years: selenium group 2.19/1000; placebo group: 5.53/1000
We could not make contact with the study investigators to clarify these discrepancies. As we could not clarify the
87Selenium for preventing cancer (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Yu 1991 (Continued)
actual number of liver cancer cases in the later publications, we decided to use the data of Yu 1991 for this review.
Adverse effects were not mentioned in Yu 1991 or Li 1992. Yu 1993 stated that no cases of selenosis were observed
in the trial.
Yu 1997
Methods Randomised controlled trial
Allocation: random
Sequence generation: unclear, not described
Concealment: unclear, not described
Blinding: of participants: adequate (placebo), of investigators and doctors: unclear, not described
Dropouts/withdrawals: unclear, not described
Recruitment period: unclear, not described
Intention-to-treat-analysis: unclear, not described
Observation period: 1987 to 1994
Intervention period: 1987 to 1990
Detection of cases: unclear, monthly blood sample during follow-up for liver enzymes (SGPT, ZnTT), use of “national
standards” for the diagnosis of liver cancer
Informed consent: unclear, not described
Participants Country: China
Number of participants: 226 (selenium group: 113; placebo group 113)
Condition: HBs-antigen carriers with normal liver function
Demographics: 95 men, 131 women; age: 21 to 63 years
Recruitment and setting: recruitment “through screening in a village in the city Qidong” (Li 1992)
Interventions Intervention: 200 µg selenium as selenised yeast p.o. daily for 4 years
Control: placebo
Outcomes Primary outcome measure: incidence of primary liver cancer (defined as increase of SGPT and ZnTT)
Results: at the end of the intervention period: 0 cases in the selenium group; 7 cases in the placebo group in a total of
445 person years of observation (person-time incidence rate: 1,573.03/100,000)
Notes Adverse effects: “No side effects have been found in these trials.” (Yu 1997, p124)
further data reported in: Li 1992 (Chinese, translated); Yu 1991
In Yu 1991 a different incidence in the selenium group was reported (5 cases). We could not clarify this discrepancy
to the later papers Li 1992 and Yu 1997.
Yu 1999
Methods Matched, nested case-control study
Country: China (Taiwan)
Participants Participants: 4841 men
Inclusion criteria: 30 to 65 years of age; HBsAg-positive or/and HCV-positive; recruited at two centres: Government
Employee Central Clinics or Liver Unit of Chang-Gung Memorial Hospital
Recruitment: August 1988 to June 1992
Outcome assessment: 31 December 1996
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Yu 1999 (Continued)
Number of cases:
Primary liver cancer: 69 (male/female: 69/0)
Case definition: incidence
Years of follow-up: 4.5 to 8.3 years
Type of selenium marker: plasma
Interventions d.n.a.
Outcomes Analysed cases: 69 of 73 cases analysed (reason for non-inclusion: no sample available)
Statistical methods: conditional logistic regression
Variables controlled in analysis: age, cigarette smoking, alcohol intake, plasma levels of retinol/alpha-tocopherol/alpha-
carotene/beta-carotene/lycopene
Variables controlled by matching: age, year and season of sample collection, recruitment clinic
Notes
(lower border; upper border) lower and upper border of the 95% CI (if not otherwise specified)
µ micro
AFP alpha-fetoprotein
ALT alanine aminotransferase
ATBC Alpha-tocopherol, beta-carotene cancer prevention study
AU arbitrary unit
BCC basal cell carcinoma
BMI body-mass-index
BPH benign prostate hyperplasia
CARET Carotene and Retinol Efficacy Trial
CHD coronary heart disease
CI confidence interval
CIS carcinoma in situ
CVD cardiovascular disease
dl deciliter
d.n.a. does not apply
DOM Diagnostic onderzoek mammacarcinoom
EVA Etude du Vieillissement Antériel
EPOZ Epidemiologisch onderzoek naar risico-indicatoren voor hart- en vaatziekten
FFQ food-frequency questionnaire
g gram
HBsAg Hepatitis B surface antigen
HCC hepatocellular carcinoma
HCV hepatitis C virus
HPFP Hypertension Detection Follow-up Programme
HPFS Health Professionals Follow-up Study
HR hazard ratio
IU international unit
l litre
m milli
max. adj. maximally adjusted
MHC Mobile Health Clinic
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n nano
NHS Nurses‘ Health Study
NLCS Netherlands Cohort Study
NMSC non-melanoma skin cancer
NPCT Nutritional Prevention of Cancer Trial
n.r. not reported
NSAID non-steroidal antiinflammatory drugs
OR Odds ratio
p. page
p.o. per os
ppm parts per million
PSA prostate-specific antigen
RCT randomised controlled trial
RR relative risk
SCC squamous cell carcinoma
SGPT alanine aminotransferase
TIA transient ischemic attack
UK United Kingdom
US United States of America
VITAL Vitamins and Lifestyle Study
ZnTT zinc turbidity test
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bostick 1993 Cohort study: Iowa Women’s Health Study Cohort.
Selenium exposure not assessed according to eligibility: only intake of selenium supplements yes/no in ques-
tionnaire assessed
Brock 1991 Case-control study with pre-cancerous condition (carcinoma in situ of the cervix)
Chen 1988 Case-control study
Chen 2003 Case-control study
Connelly-Frost 2009 Case-control study
Costello 2001 APPOSE (Australian Prostate Cancer Prevention Trial Using Selenium): publication describes study design,
trial was not started
Criqui 1991 Population-based prospective case-control study: Lipid Research Clinic Prevalence and Follow-Up Study
Results not reported according to inclusion criteria: differences in mean selenium levels were reported
Cui 2007 Nested case-control study
Selenium exposure not assessed according to eligibility: selenium measurement was conducted in tissue of
benign breast diseases
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(Continued)
Davies 2002 Nested case-control study: EPIC Norfolk Study Cohort
Results not reported according to inclusion criteria: RR estimate per unit increase in selenium level reported
Fleshner 2003 Randomised Study of Vitamin E, Selenium, and Soy Protein Isolate in Patients with High-Grade Prostatic
Intraepithelial Neoplasia:
Multicomponent intervention
Hagmar 1992 Historical cohort study
Hartman 2002 Nested case-control study: ATBC Cohort
Results not reported according to inclusion criteria: differences inmean selenium levels reported;OR reported
as graph and could not be calculated from reported data
Huzarski 2006 Interventional studywithout control groupwith 1489 female participantswithBRCA1mutationwho received
a selenium-containing nutritional supplement
Joniau 2007 Intervention study without control group with male participants with high-grade intraepithelial neoplasia of
the prostate who received a selenium-containing nutritional supplement
Kellen 2008 Case-control study
Kilander 2001 Cohort study in Uppsala/Sweden
Results not reported according to inclusion criteria: RR estimate per unit increase in selenium level reported
Knekt 1988a Nested case-control study: Mobile Health Clinic Cohort
Results not reported according to inclusion criteria: differences in mean selenium levels reported
Knekt 1988c Nested case-control study: Mobile Health Clinic Cohort
Results not reported according to inclusion criteria: differences in mean selenium levels reported
Knekt 1991b Nested case-control study: Mobile Health Clinic Cohort
Results not reported according to inclusion criteria: differences in mean selenium levels reported
Kok 1987c Nested case-control study: Zoetermeer Cohort
Results not reported according to inclusion criteria: differences in mean selenium levels reported
Kune 2006 Case-control study
Kuroda 1988 Case-control study
Lawson 2007 Cohort study on multivitamin use and risk of prostate cancer
Le Marchand 2006 Case-control study
Li 2004b RCT for gastric cancer prevention with multi component intervention (200 mg synthetic allitridum and 100
µg selenium per day)
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Limburg 2005 Randomised controlled trial: primary endpoint in this 2 by 2 factorial design trial with selenomethionine 200
µg daily and/or celecoxib 200 mg twice daily was the per-subject change (regression, stable, progression) of
pre-existing oesophageal dysplasia - cancer incidence or mortality were not endpoints in this study
Linxian Pilot 2000 Randomised controlled trial with selenium supplements and celecoxib in participants with oesophageal
squamous dysplasia in Linxian, China
Endpoint was “regression of disease”, cancer was not an endpoint in this investigation
Neuhouser 2009 Cohort study (Women’s Health Initiative) on multivitamin use and risk of cancer and cardiovascular disease.
No data for selenium and cancer risk reported.
Ray 2006 Cohort study (Women’s Health and Aging Studies I and II) on selenium and carotenoid serum levels and
mortality.
No data for selenium and cancer mortality reported
Rayman 2001 PRECISE trial (Prevention of Cancer by Intervention with Selenium): trial has been stopped
Rendon Randomised controlled trial: Vitamin E, Selenium, and Soy Protein in Preventing Cancer in Patients with
High-Grade Prostate Neoplasia. Multicomponent intervention
Thompson 2009 Cohort study: Iowa Women’s Health Study Cohort.
Selenium exposure not assessed according to eligibility: only intake of selenium supplements yes/no in ques-
tionnaire assessed
Tsugane 1996 Case-control and cross-sectional studies
Ujiie 2002 A part of this study is a prospective cohort study in Miyagi/Japan
Results not reported according to inclusion criteria: differences in mean selenium levels reported
van Noord 1992 Nested case-control study: DOM Cohort
Results not reported according to inclusion criteria: differences in mean selenium levels reported
van Noord 1993 Nested case-control study: DOM II Cohort
Results not reported according to inclusion criteria: RR estimate per unit increase of selenium level reported
van’t Veer 1996 Case-control study
Wallace 2009 Case-control study
Watters 2009 Cohort study on smoking and prostate cancer risk. Selenium not reported as independent variable.
Wright 2004 Cohort study: ATBC Cohort
Exposure to antioxidants was assessed using a self-developed index
You 2005 Randomised controlled trial to test retardation of the progression of pre-cancerous gastric lesions among 3400
adults in Shandong, China. Intervention: vitamin C, vitamin E, selenium, garlic preparation.
Multicomponent intervention.
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Yuan 2006 Nested case-control study: Shanghai Cohort Study
No data on selenium and cancer risk reported
Zeegers 2009 Cohort study on factors influencing recurrence or progression of bladder cancer: West Midlands Bladder
Cancer Prognosis Programme
µ micro
APPOSE Australian Prostate Cancer Prevention Trial Using Selenium
ATBC Alpha-tocopherol, beta-carotene cancer prevention study
BRCA breast cancer
DOM Diagnostic onderzoek mammacarcinoom
EPIC European Prospective Investigation of Cancer
m milli
g gram
OR Odds ratio
PRECISE Prevention of Cancer by Intervention with Selenium
RCT randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
Characteristics of ongoing studies [ordered by study ID]
Epi˙Nomura 2002
Trial name or title Cancer Sero Epidemiology Among the Japanese in Hawaii
Methods This is a sero-epidemiologic prospective study to identify biochemical markers related to common cancers.
Among the aims are: (a) to see if low serum selenium levels increase prostate cancer risk (b) to determine
whether low serum selenium levels increase urinary bladder cancer risk in men
Participants 9,345 male American Japanese subjects, examined in Hawaii
Interventions d.n.a.
Outcomes risk of prostate and urinary bladder cancer
Starting date Project Start: 15 September 1983, Project End planned for: 30 June 2004
Contact information Abraham M. Nomura
Kuakini Medical Center
347 N Kuakini St
Honolulu, HI 96817
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Epi˙Nomura 2002 (Continued)
Notes
RCT˙Cheng 2003
Trial name or title Selenium supplementation for the prevention of hepatocellular carcinomas in HBsAg positive patients (pilot
study)
Methods Randomised controlled trial
Participants Men aged 45 to 64 years with positive HBsAg test, negative AFP test and normal ALT values
Interventions Placebo or 200 mg (sic!)/day selenium as selenised yeast
Outcomes Primary liver cancer
Starting date 2003
Contact information Prof Kar Keung Cheng, University of Birmingham, UK
Notes Author contacted for further information, but no reply received.
Should probably say 200 µg/day selenium yeast as intervention in the publication.
RCT˙Cheng 2006
Trial name or title
Methods Double-blinded, placebo-controlled, 2 by 2 factorial, randomised controlled trial (SELENIB), nested within
a prospective observational cohort study (Bladder Cancer Prognosis Programme BCPP)
Participants 1200 participants of the Bladder Cancer Prognosis Programme in the United Kingdom
Inclusion criteria:
Histopathologically confirmed non-muscle invasive transitional cell carcinoma. Solitary grade 1 pTa larger
than 3 cm and all other stage pTa, pT1 or pTcis
Exclusion criteria:
1. Disease characteristics - solitary grade 1 pTa < 3 cm or stage pT2 and above
2. Patients that are pregnant or breastfeeding
3. Patients diagnosed with human immunodeficiency virus (HIV) infection
4. Patients who are on immunosuppressive therapy following organ transplantation
5. Patients taking cyclosporin
6. Any condition, which, in the opinion of the local investigator, might interfere with the safety of the patient
or evaluation of the trial objectives
Interventions Four study arms:
1) selenium
2) alpha-tocopherol
3) selenium and alpha-tocopherol
4) placebo
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RCT˙Cheng 2006 (Continued)
Outcomes Primary outcomes: recurrence-free survival, progression-free survival
SELENIB trial - secondary outcomes
1. All cause mortality
2. Incidence of transitional cell carcinoma (TCC) outside the bladder
3. Incidence of all other malignancies clinically diagnosed
4. Incidence of cardiovascular events: myocardial infarction,. stroke, death from cardiovascular causes,
5. Quality of life - as assessed by the quality of life instruments: European Organisation for Research and
Treatment of Cancer (EORTC) QLQ-C30, QLQ-BLS24 and QLQ-BLM30
Starting date
Contact information
Notes Ongoing trial
Contact details:
Prof K. K. Cheng
The Public Health Building
University of Birmingham
Edgbaston
Birmingham
United Kingdom
B15 2TT
http://www.bcpp.bham.ac.uk
RCT˙ECOG 2002
Trial name or title Phase III Randomised Chemoprevention Study of Selenium in Participants With Previously Resected Stage
I Non-Small Cell Lung Cancer
Methods Randomised controlled trial
Participants Disease Characteristics:
Histologically confirmed, completely resected stage IA (pT1, N0) or IB (pT2, N0) non-small lung cancer
(except carcinoid)
Completion of treatment for stage I lung cancer within the past 6 to 36 months and currently disease free
At least one mediastinal lymph node sampled at resection
Age: 18 years and over
Performance status: ECOG 0-1
A total of 1,960 participants (980 per arm) will be accrued for this study within 4 years.
Interventions Arm I: Participants receive oral selenium yeast daily for 6 months. Treatment repeats every 6 months for 8
courses for a total of 4 years in the absence of unacceptable toxicity
Arm II: Participants receive an oral yeast placebo as in arm I
Participants are followed annually
Outcomes Second incidence/recurrence of primary lung tumours
Toxicity
Incidence of specific cancers, mortality from cancer, and overall survival
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RCT˙ECOG 2002 (Continued)
Starting date October 2000
Contact information Eastern Cooperative Oncology Group
Daniel Karp, MD, Protocol chair Phone: 713-745-7398; 800-392-1611
Southwest Oncology Group
Omer Kucuk, MD, Protocol chair Phone: 313-576-8739; 800-527-6266
Email: kucuko@karmanos.org
Notes Recruiting
RCT˙HGPIN˙Marshall 2006
Trial name or title L-selenium-based chemoprevention of prostate cancer among men with high-grade prostatic intraepithelial
neoplasia (HGPIN)
Methods Randomised controlled trial
Participants Country: US
465 men, age 40 years and over with diagnosis of HGPIN with no evidence of cancer
Interventions Placebo or 200 µg/day selenium
Outcomes Incidence of prostate cancer
Starting date February 2000
Contact information James R. Marshall, Roswell Park Cancer Institute, Buffalo, New York, US
Notes No longer recruiting
RCT˙NBT˙Stratton 2003
Trial name or title Negative Biopsy Trial (NBT)
Methods The study is a Phase III cancer chemoprevention study among men at high risk of prostate cancer because of
a persistent elevation in PSA above 4 ng/ml and a negative initial biopsy.
Participants The trial will randomise at least 700 patients with persistently elevated PSA levels (greater 4 ng/ml) and at
least one negative biopsy for prostate cancer. The principal purpose of this trial is to assess the potential for
treatment with the essential trace element selenium (Se) to prevent prostate cancer (PCa).
Interventions The trial will randomise patients to either placebo or one of two selenium dosages, 200 µg/day or 400 µg/
day.
Outcomes The primary endpoints for the trial are the incidence of PCa and the velocity of the primary serum marker
of prostate cancer progression, prostate specific antigen (PSA). Safety endpoints for the trial include onset of
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RCT˙NBT˙Stratton 2003 (Continued)
mild symptoms of selenium toxicity as well as significant changes in liver and kidney enzyme levels.
Starting date 30 September 1999
Contact information M. Suzanne Stratton, Ph.D.
Research Assistant Professor
Arizona Cancer Center
Prostate Cancer Prevention Program
2504 E Elm Street.
Tucson, AZ 85716
http://www.selenium.arizona.edu
Notes
µ micro
AARP American Association of Retired Persons
AFP alpha-fetoprotein
ALT alanine aminotransferase
BCC basal cell carcinoma
BCPP Bladder Cancer Prognosis Programme
BRCA breast cancer
cm centimeter
d.n.a. does not apply
ECG electrocardiogram
ECOG Eastern Cooperative Oncology Group
EORTC European Organisation for Research and Treatment of Cancer
EPIC European Prospective Investigation of Cancer
g gram
HBsAg Hepatitis B surface antigen
HGPIN high-grade prostatic intraepithelial neoplasia
HIV human immunodeficiency virus
iU international unit
l liter
m milli
n nano
n.r. not reported
NHANES National Health and Nutrition Examination Survey
NIH National Institute of Health
p. page
PSA prostate specific antigen
pT tumour after pathological assessment, according to the tumour/nodules/metastases TNM-staging system
QLQ Quality of Life Questionnaire
RCT randomised controlled trial
SCC squamous cell carcinoma
SELECT Selenium and Vitamin E Cancer Prevention Trial
SELENIB (randomised controlled trial of selenium and vitamin E in the recurrence and progression of non muscle invasive bladder
cancer)
TCC transitional cell carcinoma
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UK United Kingdom
US United States of America
WHAS Women’s Health and Aging Study
WHI Women’s Health Initiative
WHO World Health Organization
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D A T A A N D A N A L Y S E S
Comparison 1. Highest versus lowest selenium exposure
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Breast cancer risk (women) 7 Odds Ratio (Random, 95% CI) 1.00 [0.77, 1.29]
1.1 Breast cancer (all) 6 Odds Ratio (Random, 95% CI) 1.01 [0.74, 1.36]
1.2 Breast cancer
(premenopausal)
1 Odds Ratio (Random, 95% CI) 1.10 [0.46, 2.65]
2 Bladder cancer risk 5 Odds Ratio (Random, 95% CI) 0.67 [0.46, 0.97]
2.1 all (male + female) 2 Odds Ratio (Random, 95% CI) 0.65 [0.46, 0.92]
2.2 male 3 Odds Ratio (Random, 95% CI) 0.82 [0.41, 1.62]
2.3 female 1 Odds Ratio (Random, 95% CI) 0.36 [0.14, 0.92]
3 Lung cancer risk
(gender-aggregated data)
11 Odds Ratio (Random, 95% CI) 0.76 [0.57, 1.03]
3.1 incidence 10 Odds Ratio (Random, 95% CI) 0.75 [0.54, 1.03]
3.2 mortality 1 Odds Ratio (Random, 95% CI) 0.98 [0.41, 2.35]
4 Lung cancer risk
(gender-disaggregated data)
11 Odds Ratio (Random, 95% CI) 0.77 [0.60, 0.98]
4.1 all (female + male) 4 Odds Ratio (Random, 95% CI) 0.58 [0.39, 0.86]
4.2 female 4 Odds Ratio (Random, 95% CI) 0.83 [0.43, 1.61]
4.3 male 6 Odds Ratio (Random, 95% CI) 0.88 [0.61, 1.28]
5 Lung cancer risk (ascending
order of selenium levels)
7 1756 Odds Ratio (Random, 95% CI) 0.90 [0.69, 1.16]
6 Lung cancer risk 11 Odds Ratio (Random, 95% CI) 0.76 [0.57, 1.03]
6.1 intake 1 Odds Ratio (Random, 95% CI) 0.98 [0.41, 2.35]
6.2 serum or plasma 8 Odds Ratio (Random, 95% CI) 0.84 [0.66, 1.06]
6.3 toenail 2 Odds Ratio (Random, 95% CI) 1.05 [0.11, 10.36]
7 Prostate cancer risk 14 Odds Ratio (Random, 95% CI) 0.78 [0.66, 0.92]
8 Prostate cancer risk (by selenium
measurement)
14 Odds Ratio (Random, 95% CI) 0.78 [0.66, 0.92]
8.1 biochemical selenium level 12 Odds Ratio (Random, 95% CI) 0.74 [0.61, 0.88]
8.2 estimated selenium intake 2 Odds Ratio (Random, 95% CI) 1.00 [0.73, 1.36]
9 Prostate cancer risk (by exposure
assessment)
14 Odds Ratio (Random, 95% CI) 0.78 [0.66, 0.92]
9.1 intake 2 Odds Ratio (Random, 95% CI) 1.00 [0.73, 1.36]
9.2 serum or plasma 9 Odds Ratio (Random, 95% CI) 0.81 [0.68, 0.97]
9.3 toenail 3 Odds Ratio (Random, 95% CI) 0.53 [0.35, 0.81]
10 Prostate cancer risk (by
continent)
14 Odds Ratio (Random, 95% CI) 0.78 [0.66, 0.92]
10.1 Europe 4 Odds Ratio (Random, 95% CI) 0.91 [0.70, 1.17]
10.2 North America 10 Odds Ratio (Random, 95% CI) 0.71 [0.58, 0.88]
11 Prostate cancer risk (by
country)
14 Odds Ratio (Random, 95% CI) 0.78 [0.66, 0.92]
11.1 Several European
countries
1 Odds Ratio (Random, 95% CI) 0.96 [0.70, 1.31]
11.2 Finland 2 Odds Ratio (Random, 95% CI) 1.24 [0.75, 2.05]
11.3 The Netherlands 1 Odds Ratio (Random, 95% CI) 0.69 [0.48, 0.99]
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11.4 U.S.A. 10 Odds Ratio (Random, 95% CI) 0.71 [0.58, 0.88]
12 Prostate cancer risk (ascending
order of selenium levels)
9 2112 Odds Ratio (Random, 95% CI) 0.81 [0.68, 0.97]
13 Stomach cancer risk 5 Odds Ratio (Random, 95% CI) 0.66 [0.43, 1.01]
13.1 stomach 4 Odds Ratio (Random, 95% CI) 0.65 [0.35, 1.19]
13.2 stomach: cardia cancer 1 Odds Ratio (Random, 95% CI) 0.47 [0.33, 0.66]
13.3 stomach: non-cardia
cancer
1 Odds Ratio (Random, 95% CI) 1.07 [0.55, 2.08]
14 Stomach cancer risk (by gender) 5 Odds Ratio (Random, 95% CI) 0.66 [0.42, 1.04]
14.1 all (female + male) 2 Odds Ratio (Random, 95% CI) 0.75 [0.41, 1.36]
14.2 female 2 Odds Ratio (Random, 95% CI) 0.73 [0.12, 4.35]
14.3 male 3 Odds Ratio (Random, 95% CI) 0.43 [0.14, 1.32]
15 Colorectal cancer risk 5 Odds Ratio (Random, 95% CI) 0.89 [0.65, 1.23]
15.1 colon and rectal cancer 2 Odds Ratio (Random, 95% CI) 1.11 [0.50, 2.46]
15.2 colon cancer 3 Odds Ratio (Random, 95% CI) 0.80 [0.56, 1.15]
16 Colorectal cancer risk (by
gender)
5 Odds Ratio (Random, 95% CI) 0.89 [0.65, 1.23]
16.1 all (female + male) 1 Odds Ratio (Random, 95% CI) 1.22 [0.52, 2.86]
16.2 female 3 Odds Ratio (Random, 95% CI) 1.06 [0.57, 2.00]
16.3 male 3 Odds Ratio (Random, 95% CI) 0.69 [0.42, 1.12]
17 Total cancer incidence and
mortality
13 Odds Ratio (Random, 95% CI) Subtotals only
17.1 incidence 8 Odds Ratio (Random, 95% CI) 0.69 [0.53, 0.91]
17.2 mortality 5 Odds Ratio (Random, 95% CI) 0.55 [0.36, 0.83]
18 Total cancer incidence and
mortality (ascending order of
selenium levels)
11 Odds Ratio (Random, 95% CI) Subtotals only
18.1 incidence 6 1297 Odds Ratio (Random, 95% CI) 0.69 [0.52, 0.91]
18.2 mortality 5 1032 Odds Ratio (Random, 95% CI) 0.55 [0.36, 0.83]
19 Total cancer incidence and
mortality (women)
5 Odds Ratio (Random, 95% CI) Subtotals only
19.1 incidence 2 Odds Ratio (Random, 95% CI) 0.90 [0.45, 1.77]
19.2 mortality 3 Odds Ratio (Random, 95% CI) 0.92 [0.79, 1.07]
20 Total cancer incidence and
mortality (men)
8 Odds Ratio (Random, 95% CI) Subtotals only
20.1 incidence 5 Odds Ratio (Random, 95% CI) 0.66 [0.42, 1.05]
20.2 mortality 3 Odds Ratio (Random, 95% CI) 0.56 [0.38, 0.81]
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Analysis 1.1. Comparison 1 Highest versus lowest selenium exposure, Outcome 1 Breast cancer risk
(women).
Review: Selenium for preventing cancer
Comparison: 1 Highest versus lowest selenium exposure
Outcome: 1 Breast cancer risk (women)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Breast cancer (all)
Overvad 1991 0.22314354 (0.51575917) 6.3 % 1.25 [ 0.45, 3.43 ]
vd Brandt 1993 -0.17435342 (0.21348313) 32.6 % 0.84 [ 0.55, 1.28 ]
Dorgan 1998 -0.10536054 (0.3836932) 11.1 % 0.90 [ 0.42, 1.91 ]
Garland 1995 0.0953102 (0.22933655) 28.8 % 1.10 [ 0.70, 1.72 ]
Coates 1988 1.2237755 (0.59689179) 4.7 % 3.40 [ 1.06, 10.95 ]
Knekt 1990 -0.44628712 (0.44815248) 8.2 % 0.64 [ 0.27, 1.54 ]
Subtotal (95% CI) 91.8 % 1.01 [ 0.74, 1.36 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 6.29, df = 5 (P = 0.28); I2 =21%
Test for overall effect: Z = 0.04 (P = 0.97)
2 Breast cancer (premenopausal)
van Noord 1987 0.0953102 (0.44843315) 8.2 % 1.10 [ 0.46, 2.65 ]
Subtotal (95% CI) 8.2 % 1.10 [ 0.46, 2.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
Total (95% CI) 100.0 % 1.00 [ 0.77, 1.29 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 6.34, df = 6 (P = 0.39); I2 =5%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.85), I2 =0.0%
0.01 0.1 1 10 100
Favours experimental Favours control
101Selenium for preventing cancer (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.2. Comparison 1 Highest versus lowest selenium exposure, Outcome 2 Bladder cancer risk.
Review: Selenium for preventing cancer
Comparison: 1 Highest versus lowest selenium exposure
Outcome: 2 Bladder cancer risk
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 all (male + female)
Menkes 1986 -0.72270596 (0.57370723) 9.1 % 0.49 [ 0.16, 1.49 ]
vd Brandt 1993 -0.40047754 (0.19032388) 36.7 % 0.67 [ 0.46, 0.97 ]
Subtotal (95% CI) 45.8 % 0.65 [ 0.46, 0.92 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 2.39 (P = 0.017)
2 male
Michaud 2005 0.15700371 (0.29159795) 24.4 % 1.17 [ 0.66, 2.07 ]
Nomura 1987 -1.1314021 (0.64600567) 7.4 % 0.32 [ 0.09, 1.14 ]
Michaud 2002 -0.13926206 (0.54291624) 10.0 % 0.87 [ 0.30, 2.52 ]
Subtotal (95% CI) 41.9 % 0.82 [ 0.41, 1.62 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 3.32, df = 2 (P = 0.19); I2 =40%
Test for overall effect: Z = 0.57 (P = 0.57)
3 female
Michaud 2005 -1.0216512 (0.47750056) 12.3 % 0.36 [ 0.14, 0.92 ]
Subtotal (95% CI) 12.3 % 0.36 [ 0.14, 0.92 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.14 (P = 0.032)
Total (95% CI) 100.0 % 0.67 [ 0.46, 0.97 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 7.10, df = 5 (P = 0.21); I2 =30%
Test for overall effect: Z = 2.11 (P = 0.035)
Test for subgroup differences: Chi2 = 1.96, df = 2 (P = 0.38), I2 =0.0%
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Analysis 1.3. Comparison 1 Highest versus lowest selenium exposure, Outcome 3 Lung cancer risk (gender-
aggregated data).
Review: Selenium for preventing cancer
Comparison: 1 Highest versus lowest selenium exposure
Outcome: 3 Lung cancer risk (gender-aggregated data)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 incidence
Nomura 1987 -0.0953102 (0.42360895) 7.7 % 0.91 [ 0.40, 2.09 ]
Coates 1988 -0.22314354 (0.948341) 2.3 % 0.80 [ 0.12, 5.13 ]
vd Brandt 1993 -0.91629072 (0.19941339) 14.3 % 0.40 [ 0.27, 0.59 ]
Kabuto 1994 -0.58778664 (0.50155941) 6.3 % 0.56 [ 0.21, 1.48 ]
Garland 1995 1.4655675 (1.0612346) 1.9 % 4.33 [ 0.54, 34.66 ]
Comstock 1997 -0.43078295 (0.26193982) 12.2 % 0.65 [ 0.39, 1.09 ]
Knekt 1998 -0.89159813 (0.43624526) 7.5 % 0.41 [ 0.17, 0.96 ]
Ratnasinghe 2000 0.1823216 (0.35364652) 9.4 % 1.20 [ 0.60, 2.40 ]
Goodman 2001 0.1823216 (0.22771341) 13.4 % 1.20 [ 0.77, 1.88 ]
Epplein 2009 -0.35667496 (0.32638552) 10.2 % 0.70 [ 0.37, 1.33 ]
Epplein 2009 -0.02020269 (0.43266643) 7.6 % 0.98 [ 0.42, 2.29 ]
Subtotal (95% CI) 92.7 % 0.75 [ 0.54, 1.03 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 21.54, df = 10 (P = 0.02); I2 =54%
Test for overall effect: Z = 1.75 (P = 0.080)
2 mortality
Kromhout 1987 -0.02020269 (0.44649482) 7.3 % 0.98 [ 0.41, 2.35 ]
Subtotal (95% CI) 7.3 % 0.98 [ 0.41, 2.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
Total (95% CI) 100.0 % 0.76 [ 0.57, 1.03 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 22.06, df = 11 (P = 0.02); I2 =50%
Test for overall effect: Z = 1.76 (P = 0.078)
Test for subgroup differences: Chi2 = 0.31, df = 1 (P = 0.57), I2 =0.0%
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Analysis 1.4. Comparison 1 Highest versus lowest selenium exposure, Outcome 4 Lung cancer risk (gender-
disaggregated data).
Review: Selenium for preventing cancer
Comparison: 1 Highest versus lowest selenium exposure
Outcome: 4 Lung cancer risk (gender-disaggregated data)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 all (female + male)
Coates 1988 -0.22314354 (0.948341) 1.6 % 0.80 [ 0.12, 5.13 ]
Kabuto 1994 -0.58778664 (0.50155941) 5.2 % 0.56 [ 0.21, 1.48 ]
Comstock 1997 -0.43078295 (0.26193982) 13.3 % 0.65 [ 0.39, 1.09 ]
Knekt 1998 -0.89159813 (0.43624526) 6.5 % 0.41 [ 0.17, 0.96 ]
Subtotal (95% CI) 26.5 % 0.58 [ 0.39, 0.86 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.94, df = 3 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 2.71 (P = 0.0066)
2 female
vd Brandt 1993 -0.91629072 (0.57533986) 4.1 % 0.40 [ 0.13, 1.24 ]
Garland 1995 1.4655675 (1.0612346) 1.3 % 4.33 [ 0.54, 34.66 ]
Goodman 2001 -0.27443686 (0.49387987) 5.3 % 0.76 [ 0.29, 2.00 ]
Epplein 2009 -0.02020269 (0.43266643) 6.6 % 0.98 [ 0.42, 2.29 ]
Subtotal (95% CI) 17.3 % 0.83 [ 0.43, 1.61 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 4.21, df = 3 (P = 0.24); I2 =29%
Test for overall effect: Z = 0.54 (P = 0.59)
3 male
Kromhout 1987 -0.02020269 (0.44649482) 6.2 % 0.98 [ 0.41, 2.35 ]
Nomura 1987 -0.0953102 (0.42360895) 6.8 % 0.91 [ 0.40, 2.09 ]
vd Brandt 1993 -0.69314718 (0.25651067) 13.6 % 0.50 [ 0.30, 0.83 ]
Ratnasinghe 2000 0.1823216 (0.35364652) 8.9 % 1.20 [ 0.60, 2.40 ]
Goodman 2001 0.42526772 (0.31200675) 10.6 % 1.53 [ 0.83, 2.82 ]
Epplein 2009 -0.35667496 (0.32638552) 10.0 % 0.70 [ 0.37, 1.33 ]
Subtotal (95% CI) 56.2 % 0.88 [ 0.61, 1.28 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 9.26, df = 5 (P = 0.10); I2 =46%
Test for overall effect: Z = 0.65 (P = 0.52)
Total (95% CI) 100.0 % 0.77 [ 0.60, 0.98 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 16.96, df = 13 (P = 0.20); I2 =23%
Test for overall effect: Z = 2.08 (P = 0.037)
Test for subgroup differences: Chi2 = 2.46, df = 2 (P = 0.29), I2 =19%
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Analysis 1.5. Comparison 1 Highest versus lowest selenium exposure, Outcome 5 Lung cancer risk
(ascending order of selenium levels).
Review: Selenium for preventing cancer
Comparison: 1 Highest versus lowest selenium exposure
Outcome: 5 Lung cancer risk (ascending order of selenium levels)
Study or subgroup Lowest level Highest level log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Ratnasinghe 2000 39 55 0.1823216 (0.35364652) 13.9 % 1.20 [ 0.60, 2.40 ]
Knekt 1998 45 -0.89159813 (0.43624526) 61 9.2 % 0.41 [ 0.17, 0.96 ]
Kabuto 1994 99 -0.58778664 (0.50155941) 128 6.9 % 0.56 [ 0.21, 1.48 ]
Goodman 2001 106 129 0.1823216 (0.22771341) 32.8 % 1.20 [ 0.77, 1.88 ]
Nomura 1987 103 133 -0.0953102 (0.42360895) 9.7 % 0.91 [ 0.40, 2.09 ]
Epplein 2009 128 -0.02020269 (0.43266643) 139 9.3 % 0.98 [ 0.42, 2.29 ]
Epplein 2009 128 -0.35667496 (0.32638552) 144 16.2 % 0.70 [ 0.37, 1.33 ]
Coates 1988 148 171 -0.22314354 (0.948341) 2.0 % 0.80 [ 0.12, 5.13 ]
Total (95% CI) 100.0 % 0.90 [ 0.69, 1.16 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 7.08, df = 7 (P = 0.42); I2 =1%
Test for overall effect: Z = 0.83 (P = 0.40)
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Analysis 1.6. Comparison 1 Highest versus lowest selenium exposure, Outcome 6 Lung cancer risk.
Review: Selenium for preventing cancer
Comparison: 1 Highest versus lowest selenium exposure
Outcome: 6 Lung cancer risk
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 intake
Kromhout 1987 -0.02020269 (0.44649482) 7.3 % 0.98 [ 0.41, 2.35 ]
Subtotal (95% CI) 7.3 % 0.98 [ 0.41, 2.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
2 serum or plasma
Nomura 1987 -0.0953102 (0.42360895) 7.7 % 0.91 [ 0.40, 2.09 ]
Coates 1988 -0.22314354 (0.948341) 2.3 % 0.80 [ 0.12, 5.13 ]
Kabuto 1994 -0.58778664 (0.50155941) 6.3 % 0.56 [ 0.21, 1.48 ]
Comstock 1997 -0.43078295 (0.26193982) 12.2 % 0.65 [ 0.39, 1.09 ]
Knekt 1998 -0.89159813 (0.43624526) 7.5 % 0.41 [ 0.17, 0.96 ]
Ratnasinghe 2000 0.1823216 (0.35364652) 9.4 % 1.20 [ 0.60, 2.40 ]
Goodman 2001 0.1823216 (0.22771341) 13.4 % 1.20 [ 0.77, 1.88 ]
Epplein 2009 -0.35667496 (0.32638552) 10.2 % 0.70 [ 0.37, 1.33 ]
Epplein 2009 -0.02020269 (0.43266643) 7.6 % 0.98 [ 0.42, 2.29 ]
Subtotal (95% CI) 76.5 % 0.84 [ 0.66, 1.06 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 8.29, df = 8 (P = 0.41); I2 =3%
Test for overall effect: Z = 1.47 (P = 0.14)
3 toenail
vd Brandt 1993 -0.91629072 (0.19941339) 14.3 % 0.40 [ 0.27, 0.59 ]
Garland 1995 1.4655675 (1.0612346) 1.9 % 4.33 [ 0.54, 34.66 ]
Subtotal (95% CI) 16.2 % 1.05 [ 0.11, 10.36 ]
Heterogeneity: Tau2 = 2.25; Chi2 = 4.87, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.04 (P = 0.97)
Total (95% CI) 100.0 % 0.76 [ 0.57, 1.03 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 22.06, df = 11 (P = 0.02); I2 =50%
Test for overall effect: Z = 1.76 (P = 0.078)
Test for subgroup differences: Chi2 = 0.15, df = 2 (P = 0.93), I2 =0.0%
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Analysis 1.7. Comparison 1 Highest versus lowest selenium exposure, Outcome 7 Prostate cancer risk.
Review: Selenium for preventing cancer
Comparison: 1 Highest versus lowest selenium exposure
Outcome: 7 Prostate cancer risk
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Epplein 2009 -0.19845095 (0.16802577) 11.6 % 0.82 [ 0.59, 1.14 ]
vd Brandt 1993 -0.37106368 (0.18467318) 10.6 % 0.69 [ 0.48, 0.99 ]
Helzlsouer 2000 -0.96758404 (0.4105709) 3.5 % 0.38 [ 0.17, 0.85 ]
Coates 1988 -1.2039728 (1.118034) 0.6 % 0.30 [ 0.03, 2.68 ]
Brooks 2001 -1.4271164 (0.61170797) 1.7 % 0.24 [ 0.07, 0.80 ]
Hartman 1998 0.23901689 (0.2921256) 6.0 % 1.27 [ 0.72, 2.25 ]
Peters 2008 -0.10536054 (0.18887756) 10.4 % 0.90 [ 0.62, 1.30 ]
Knekt 1990 0.13976192 (0.5352475) 2.2 % 1.15 [ 0.40, 3.28 ]
Goodman 2001 0.01980261 (0.2297925) 8.3 % 1.02 [ 0.65, 1.60 ]
Peters 2007 -0.17435342 (0.15537348) 12.5 % 0.84 [ 0.62, 1.14 ]
Yoshizawa 1998 -0.94160858 (0.39297066) 3.8 % 0.39 [ 0.18, 0.84 ]
Allen 2008 -0.04082202 (0.15987297) 12.2 % 0.96 [ 0.70, 1.31 ]
Nomura 2000 -0.69314718 (0.28025822) 6.4 % 0.50 [ 0.29, 0.87 ]
Li 2004a -0.2484614 (0.1883683) 10.4 % 0.78 [ 0.54, 1.13 ]
Total (95% CI) 100.0 % 0.78 [ 0.66, 0.92 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 20.63, df = 13 (P = 0.08); I2 =37%
Test for overall effect: Z = 3.00 (P = 0.0027)
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Analysis 1.8. Comparison 1 Highest versus lowest selenium exposure, Outcome 8 Prostate cancer risk (by
selenium measurement).
Review: Selenium for preventing cancer
Comparison: 1 Highest versus lowest selenium exposure
Outcome: 8 Prostate cancer risk (by selenium measurement)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 biochemical selenium level
Coates 1988 -1.2039728 (1.118034) 0.6 % 0.30 [ 0.03, 2.68 ]
Knekt 1990 0.13976192 (0.5352475) 2.2 % 1.15 [ 0.40, 3.28 ]
Yoshizawa 1998 -0.94160858 (0.39297066) 3.8 % 0.39 [ 0.18, 0.84 ]
Nomura 2000 -0.69314718 (0.28025822) 6.4 % 0.50 [ 0.29, 0.87 ]
Helzlsouer 2000 -0.96758404 (0.4105709) 3.5 % 0.38 [ 0.17, 0.85 ]
Brooks 2001 -1.4271164 (0.61170797) 1.7 % 0.24 [ 0.07, 0.80 ]
Goodman 2001 0.01980261 (0.2297925) 8.3 % 1.02 [ 0.65, 1.60 ]
vd Brandt 1993 -0.37106368 (0.18467318) 10.6 % 0.69 [ 0.48, 0.99 ]
Li 2004a -0.2484614 (0.1883683) 10.4 % 0.78 [ 0.54, 1.13 ]
Peters 2007 -0.17435342 (0.15537348) 12.5 % 0.84 [ 0.62, 1.14 ]
Allen 2008 -0.04082202 (0.15987297) 12.2 % 0.96 [ 0.70, 1.31 ]
Epplein 2009 -0.19845095 (0.16802577) 11.6 % 0.82 [ 0.59, 1.14 ]
Subtotal (95% CI) 83.7 % 0.74 [ 0.61, 0.88 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 17.44, df = 11 (P = 0.10); I2 =37%
Test for overall effect: Z = 3.31 (P = 0.00092)
2 estimated selenium intake
Hartman 1998 0.23901689 (0.2921256) 6.0 % 1.27 [ 0.72, 2.25 ]
Peters 2008 -0.10536054 (0.18887756) 10.4 % 0.90 [ 0.62, 1.30 ]
Subtotal (95% CI) 16.3 % 1.00 [ 0.73, 1.36 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
Total (95% CI) 100.0 % 0.78 [ 0.66, 0.92 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 20.63, df = 13 (P = 0.08); I2 =37%
Test for overall effect: Z = 3.00 (P = 0.0027)
Test for subgroup differences: Chi2 = 2.71, df = 1 (P = 0.10), I2 =63%
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Analysis 1.9. Comparison 1 Highest versus lowest selenium exposure, Outcome 9 Prostate cancer risk (by
exposure assessment).
Review: Selenium for preventing cancer
Comparison: 1 Highest versus lowest selenium exposure
Outcome: 9 Prostate cancer risk (by exposure assessment)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 intake
Hartman 1998 0.23901689 (0.2921256) 6.0 % 1.27 [ 0.72, 2.25 ]
Peters 2008 -0.10536054 (0.18887756) 10.4 % 0.90 [ 0.62, 1.30 ]
Subtotal (95% CI) 16.3 % 1.00 [ 0.73, 1.36 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
2 serum or plasma
Coates 1988 -1.2039728 (1.118034) 0.6 % 0.30 [ 0.03, 2.68 ]
Knekt 1990 0.13976192 (0.5352475) 2.2 % 1.15 [ 0.40, 3.28 ]
Nomura 2000 -0.69314718 (0.28025822) 6.4 % 0.50 [ 0.29, 0.87 ]
Goodman 2001 0.01980261 (0.2297925) 8.3 % 1.02 [ 0.65, 1.60 ]
Brooks 2001 -1.4271164 (0.61170797) 1.7 % 0.24 [ 0.07, 0.80 ]
Li 2004a -0.2484614 (0.1883683) 10.4 % 0.78 [ 0.54, 1.13 ]
Peters 2007 -0.17435342 (0.15537348) 12.5 % 0.84 [ 0.62, 1.14 ]
Allen 2008 -0.04082202 (0.15987297) 12.2 % 0.96 [ 0.70, 1.31 ]
Epplein 2009 -0.19845095 (0.16802577) 11.6 % 0.82 [ 0.59, 1.14 ]
Subtotal (95% CI) 65.8 % 0.81 [ 0.68, 0.97 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 10.32, df = 8 (P = 0.24); I2 =23%
Test for overall effect: Z = 2.34 (P = 0.019)
3 toenail
vd Brandt 1993 -0.37106368 (0.18467318) 10.6 % 0.69 [ 0.48, 0.99 ]
Yoshizawa 1998 -0.94160858 (0.39297066) 3.8 % 0.39 [ 0.18, 0.84 ]
Helzlsouer 2000 -0.96758404 (0.4105709) 3.5 % 0.38 [ 0.17, 0.85 ]
Subtotal (95% CI) 17.9 % 0.53 [ 0.35, 0.81 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 2.97, df = 2 (P = 0.23); I2 =33%
Test for overall effect: Z = 2.91 (P = 0.0036)
Total (95% CI) 100.0 % 0.78 [ 0.66, 0.92 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 20.63, df = 13 (P = 0.08); I2 =37%
Test for overall effect: Z = 3.00 (P = 0.0027)
Test for subgroup differences: Chi2 = 5.44, df = 2 (P = 0.07), I2 =63%
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Analysis 1.10. Comparison 1 Highest versus lowest selenium exposure, Outcome 10 Prostate cancer risk
(by continent).
Review: Selenium for preventing cancer
Comparison: 1 Highest versus lowest selenium exposure
Outcome: 10 Prostate cancer risk (by continent)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Europe
Knekt 1990 0.13976192 (0.5352475) 2.2 % 1.15 [ 0.40, 3.28 ]
vd Brandt 1993 -0.37106368 (0.18467318) 10.6 % 0.69 [ 0.48, 0.99 ]
Allen 2008 -0.04082202 (0.15987297) 12.2 % 0.96 [ 0.70, 1.31 ]
Hartman 1998 0.23901689 (0.2921256) 6.0 % 1.27 [ 0.72, 2.25 ]
Subtotal (95% CI) 31.0 % 0.91 [ 0.70, 1.17 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 3.83, df = 3 (P = 0.28); I2 =22%
Test for overall effect: Z = 0.74 (P = 0.46)
2 North America
Coates 1988 -1.2039728 (1.118034) 0.6 % 0.30 [ 0.03, 2.68 ]
Epplein 2009 -0.19845095 (0.16802577) 11.6 % 0.82 [ 0.59, 1.14 ]
Peters 2007 -0.17435342 (0.15537348) 12.5 % 0.84 [ 0.62, 1.14 ]
Brooks 2001 -1.4271164 (0.61170797) 1.7 % 0.24 [ 0.07, 0.80 ]
Yoshizawa 1998 -0.94160858 (0.39297066) 3.8 % 0.39 [ 0.18, 0.84 ]
Peters 2008 -0.10536054 (0.18887756) 10.4 % 0.90 [ 0.62, 1.30 ]
Helzlsouer 2000 -0.96758404 (0.4105709) 3.5 % 0.38 [ 0.17, 0.85 ]
Li 2004a -0.2484614 (0.1883683) 10.4 % 0.78 [ 0.54, 1.13 ]
Nomura 2000 -0.69314718 (0.28025822) 6.4 % 0.50 [ 0.29, 0.87 ]
Goodman 2001 0.01980261 (0.2297925) 8.3 % 1.02 [ 0.65, 1.60 ]
Subtotal (95% CI) 69.0 % 0.71 [ 0.58, 0.88 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 15.29, df = 9 (P = 0.08); I2 =41%
Test for overall effect: Z = 3.15 (P = 0.0016)
Total (95% CI) 100.0 % 0.78 [ 0.66, 0.92 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 20.63, df = 13 (P = 0.08); I2 =37%
Test for overall effect: Z = 3.00 (P = 0.0027)
Test for subgroup differences: Chi2 = 1.98, df = 1 (P = 0.16), I2 =49%
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Analysis 1.11. Comparison 1 Highest versus lowest selenium exposure, Outcome 11 Prostate cancer risk
(by country).
Review: Selenium for preventing cancer
Comparison: 1 Highest versus lowest selenium exposure
Outcome: 11 Prostate cancer risk (by country)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Several European countries
Allen 2008 -0.04082202 (0.15987297) 12.2 % 0.96 [ 0.70, 1.31 ]
Subtotal (95% CI) 12.2 % 0.96 [ 0.70, 1.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.80)
2 Finland
Knekt 1990 0.13976192 (0.5352475) 2.2 % 1.15 [ 0.40, 3.28 ]
Hartman 1998 0.23901689 (0.2921256) 6.0 % 1.27 [ 0.72, 2.25 ]
Subtotal (95% CI) 8.2 % 1.24 [ 0.75, 2.05 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
3 The Netherlands
vd Brandt 1993 -0.37106368 (0.18467318) 10.6 % 0.69 [ 0.48, 0.99 ]
Subtotal (95% CI) 10.6 % 0.69 [ 0.48, 0.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.01 (P = 0.045)
4 U.S.A.
Coates 1988 -1.2039728 (1.118034) 0.6 % 0.30 [ 0.03, 2.68 ]
Peters 2007 -0.17435342 (0.15537348) 12.5 % 0.84 [ 0.62, 1.14 ]
Brooks 2001 -1.4271164 (0.61170797) 1.7 % 0.24 [ 0.07, 0.80 ]
Peters 2008 -0.10536054 (0.18887756) 10.4 % 0.90 [ 0.62, 1.30 ]
Helzlsouer 2000 -0.96758404 (0.4105709) 3.5 % 0.38 [ 0.17, 0.85 ]
Yoshizawa 1998 -0.94160858 (0.39297066) 3.8 % 0.39 [ 0.18, 0.84 ]
Goodman 2001 0.01980261 (0.2297925) 8.3 % 1.02 [ 0.65, 1.60 ]
Li 2004a -0.2484614 (0.1883683) 10.4 % 0.78 [ 0.54, 1.13 ]
Nomura 2000 -0.69314718 (0.28025822) 6.4 % 0.50 [ 0.29, 0.87 ]
Epplein 2009 -0.19845095 (0.16802577) 11.6 % 0.82 [ 0.59, 1.14 ]
Subtotal (95% CI) 69.0 % 0.71 [ 0.58, 0.88 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 15.29, df = 9 (P = 0.08); I2 =41%
Test for overall effect: Z = 3.15 (P = 0.0016)
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(. . . Continued)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Total (95% CI) 100.0 % 0.78 [ 0.66, 0.92 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 20.63, df = 13 (P = 0.08); I2 =37%
Test for overall effect: Z = 3.00 (P = 0.0027)
Test for subgroup differences: Chi2 = 6.00, df = 3 (P = 0.11), I2 =50%
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Analysis 1.12. Comparison 1 Highest versus lowest selenium exposure, Outcome 12 Prostate cancer risk
(ascending order of selenium levels).
Review: Selenium for preventing cancer
Comparison: 1 Highest versus lowest selenium exposure
Outcome: 12 Prostate cancer risk (ascending order of selenium levels)
Study or subgroup Upper border/lowest level Lower border/highest leve log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Knekt 1990 49 78 0.13976192 (0.5352475) 2.7 % 1.15 [ 0.40, 3.28 ]
Allen 2008 62 -0.04082202 (0.15987297) 84 19.6 % 0.96 [ 0.70, 1.31 ]
Li 2004a 92 124 -0.2484614 (0.1883683) 15.8 % 0.78 [ 0.54, 1.13 ]
Goodman 2001 101 126 0.01980261 (0.2297925) 11.8 % 1.02 [ 0.65, 1.60 ]
Brooks 2001 107 133 -1.4271164 (0.61170797) 2.1 % 0.24 [ 0.07, 0.80 ]
Nomura 2000 119 -0.69314718 (0.28025822) 147 8.6 % 0.50 [ 0.29, 0.87 ]
Peters 2007 127 -0.17435342 (0.15537348) 158 20.4 % 0.84 [ 0.62, 1.14 ]
Epplein 2009 127 -0.19845095 (0.16802577) 159 18.4 % 0.82 [ 0.59, 1.14 ]
Coates 1988 148 171 -1.2039728 (1.118034) 0.6 % 0.30 [ 0.03, 2.68 ]
Total (95% CI) 100.0 % 0.81 [ 0.68, 0.97 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 10.32, df = 8 (P = 0.24); I2 =23%
Test for overall effect: Z = 2.34 (P = 0.019)
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Analysis 1.13. Comparison 1 Highest versus lowest selenium exposure, Outcome 13 Stomach cancer risk.
Review: Selenium for preventing cancer
Comparison: 1 Highest versus lowest selenium exposure
Outcome: 13 Stomach cancer risk
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 stomach
Nomura 1987 0.10536052 (0.60607205) 9.3 % 1.11 [ 0.34, 3.64 ]
Kabuto 1994 0 (0.3405615) 18.2 % 1.00 [ 0.51, 1.95 ]
vd Brandt 1993 -0.4462871 (0.3437958) 18.1 % 0.64 [ 0.33, 1.26 ]
Knekt 1990 -2.4079456 (1.0652725) 3.7 % 0.09 [ 0.01, 0.73 ]
Knekt 1990 -1.3093333 (0.88197684) 5.1 % 0.27 [ 0.05, 1.52 ]
Subtotal (95% CI) 54.4 % 0.65 [ 0.35, 1.19 ]
Heterogeneity: Tau2 = 0.18; Chi2 = 6.61, df = 4 (P = 0.16); I2 =39%
Test for overall effect: Z = 1.40 (P = 0.16)
2 stomach: cardia cancer
Wei 2004 -0.75502258 (0.1729285) 27.3 % 0.47 [ 0.33, 0.66 ]
Subtotal (95% CI) 27.3 % 0.47 [ 0.33, 0.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.37 (P = 0.000013)
3 stomach: non-cardia cancer
Wei 2004 0.06765865 (0.33933798) 18.3 % 1.07 [ 0.55, 2.08 ]
Subtotal (95% CI) 18.3 % 1.07 [ 0.55, 2.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Total (95% CI) 100.0 % 0.66 [ 0.43, 1.01 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 12.20, df = 6 (P = 0.06); I2 =51%
Test for overall effect: Z = 1.93 (P = 0.053)
Test for subgroup differences: Chi2 = 4.86, df = 2 (P = 0.09), I2 =59%
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Analysis 1.14. Comparison 1 Highest versus lowest selenium exposure, Outcome 14 Stomach cancer risk
(by gender).
Review: Selenium for preventing cancer
Comparison: 1 Highest versus lowest selenium exposure
Outcome: 14 Stomach cancer risk (by gender)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 all (female + male)
Wei 2004 0.06765865 (0.33933798) 17.4 % 1.07 [ 0.55, 2.08 ]
Kabuto 1994 0 (0.3405615) 17.4 % 1.00 [ 0.51, 1.95 ]
Wei 2004 -0.75502258 (0.1729285) 24.0 % 0.47 [ 0.33, 0.66 ]
Subtotal (95% CI) 58.9 % 0.75 [ 0.41, 1.36 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 7.12, df = 2 (P = 0.03); I2 =72%
Test for overall effect: Z = 0.94 (P = 0.35)
2 female
Knekt 1990 -1.3093333 (0.88197684) 5.6 % 0.27 [ 0.05, 1.52 ]
vd Brandt 1993 0.51879379 (0.69436409) 8.0 % 1.68 [ 0.43, 6.55 ]
Subtotal (95% CI) 13.6 % 0.73 [ 0.12, 4.35 ]
Heterogeneity: Tau2 = 1.04; Chi2 = 2.65, df = 1 (P = 0.10); I2 =62%
Test for overall effect: Z = 0.35 (P = 0.73)
3 male
vd Brandt 1993 -0.91629073 (0.44161603) 13.9 % 0.40 [ 0.17, 0.95 ]
Nomura 1987 0.10536052 (0.60607205) 9.6 % 1.11 [ 0.34, 3.64 ]
Knekt 1990 -2.4079456 (1.0652725) 4.1 % 0.09 [ 0.01, 0.73 ]
Subtotal (95% CI) 27.6 % 0.43 [ 0.14, 1.32 ]
Heterogeneity: Tau2 = 0.53; Chi2 = 4.56, df = 2 (P = 0.10); I2 =56%
Test for overall effect: Z = 1.47 (P = 0.14)
Total (95% CI) 100.0 % 0.66 [ 0.42, 1.04 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 15.22, df = 7 (P = 0.03); I2 =54%
Test for overall effect: Z = 1.79 (P = 0.074)
Test for subgroup differences: Chi2 = 0.74, df = 2 (P = 0.69), I2 =0.0%
0.01 0.1 1 10 100
114Selenium for preventing cancer (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.15. Comparison 1 Highest versus lowest selenium exposure, Outcome 15 Colorectal cancer risk.
Review: Selenium for preventing cancer
Comparison: 1 Highest versus lowest selenium exposure
Outcome: 15 Colorectal cancer risk
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 colon and rectal cancer
Knekt 1990 -0.22314354 (0.52904067) 9.1 % 0.80 [ 0.28, 2.26 ]
Knekt 1990 -0.63487833 (0.7845604) 4.2 % 0.53 [ 0.11, 2.47 ]
Garland 1995 0.71294979 (0.43009643) 13.6 % 2.04 [ 0.88, 4.74 ]
Subtotal (95% CI) 26.8 % 1.11 [ 0.50, 2.46 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 3.19, df = 2 (P = 0.20); I2 =37%
Test for overall effect: Z = 0.26 (P = 0.79)
2 colon cancer
vd Brandt 1993 -0.26136479 (0.32223513) 23.5 % 0.77 [ 0.41, 1.45 ]
Nomura 1987 -0.58778664 (0.42140211) 14.1 % 0.56 [ 0.24, 1.27 ]
vd Brandt 1993 -0.19845095 (0.3319885) 22.2 % 0.82 [ 0.43, 1.57 ]
Menkes 1986 0.19845095 (0.43422125) 13.3 % 1.22 [ 0.52, 2.86 ]
Subtotal (95% CI) 73.2 % 0.80 [ 0.56, 1.15 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.71, df = 3 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.21 (P = 0.23)
Total (95% CI) 100.0 % 0.89 [ 0.65, 1.23 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 6.24, df = 6 (P = 0.40); I2 =4%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Chi2 = 0.54, df = 1 (P = 0.46), I2 =0.0%
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Analysis 1.16. Comparison 1 Highest versus lowest selenium exposure, Outcome 16 Colorectal cancer risk
(by gender).
Review: Selenium for preventing cancer
Comparison: 1 Highest versus lowest selenium exposure
Outcome: 16 Colorectal cancer risk (by gender)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 all (female + male)
Menkes 1986 0.19845095 (0.43422125) 13.3 % 1.22 [ 0.52, 2.86 ]
Subtotal (95% CI) 13.3 % 1.22 [ 0.52, 2.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
2 female
vd Brandt 1993 -0.26136479 (0.32223513) 23.5 % 0.77 [ 0.41, 1.45 ]
Garland 1995 0.71294979 (0.43009643) 13.6 % 2.04 [ 0.88, 4.74 ]
Knekt 1990 -0.22314354 (0.52904067) 9.1 % 0.80 [ 0.28, 2.26 ]
Subtotal (95% CI) 46.2 % 1.06 [ 0.57, 2.00 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 3.57, df = 2 (P = 0.17); I2 =44%
Test for overall effect: Z = 0.19 (P = 0.85)
3 male
Knekt 1990 -0.63487833 (0.7845604) 4.2 % 0.53 [ 0.11, 2.47 ]
Nomura 1987 -0.58778664 (0.42140211) 14.1 % 0.56 [ 0.24, 1.27 ]
vd Brandt 1993 -0.19845095 (0.3319885) 22.2 % 0.82 [ 0.43, 1.57 ]
Subtotal (95% CI) 40.5 % 0.69 [ 0.42, 1.12 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.65, df = 2 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.52 (P = 0.13)
Total (95% CI) 100.0 % 0.89 [ 0.65, 1.23 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 6.24, df = 6 (P = 0.40); I2 =4%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Chi2 = 1.91, df = 2 (P = 0.39), I2 =0.0%
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Analysis 1.17. Comparison 1 Highest versus lowest selenium exposure, Outcome 17 Total cancer incidence
and mortality.
Review: Selenium for preventing cancer
Comparison: 1 Highest versus lowest selenium exposure
Outcome: 17 Total cancer incidence and mortality
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 incidence
Willett 1983 -0.64185387 (0.28025823) 12.2 % 0.53 [ 0.30, 0.91 ]
Knekt 1990 -0.15082287 (0.17949557) 17.4 % 0.86 [ 0.60, 1.22 ]
Ringstad 1988 -0.33647222 (0.44989504) 6.8 % 0.71 [ 0.30, 1.73 ]
Virtamo 1987 -0.13102825 (0.28025823) 12.2 % 0.88 [ 0.51, 1.52 ]
Peleg 1985 0 (0.32691842) 10.3 % 1.00 [ 0.53, 1.90 ]
Coates 1988 0 (0.32676883) 10.3 % 1.00 [ 0.53, 1.90 ]
Knekt 1990 -0.89159813 (0.19836824) 16.4 % 0.41 [ 0.28, 0.60 ]
Nomura 1987 -0.26236423 (0.29924162) 11.4 % 0.77 [ 0.43, 1.38 ]
Persson 2000 -1.6486586 (0.75775878) 2.9 % 0.19 [ 0.04, 0.85 ]
Subtotal (95% CI) 100.0 % 0.69 [ 0.53, 0.91 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 15.61, df = 8 (P = 0.05); I2 =49%
Test for overall effect: Z = 2.67 (P = 0.0076)
2 mortality
Bleys 2008 -0.37106368 (0.13508107) 29.2 % 0.69 [ 0.53, 0.90 ]
Kornitzer 2004 -0.78845738 (0.26682873) 21.7 % 0.45 [ 0.27, 0.77 ]
Kok 1987 -0.64185387 (0.33397056) 18.1 % 0.53 [ 0.27, 1.01 ]
Akbaraly 2005 -1.401183 (0.5047159) 11.4 % 0.25 [ 0.09, 0.66 ]
Kornitzer 2004 0.35667496 (0.4270348) 14.0 % 1.43 [ 0.62, 3.30 ]
Salonen 1985 -1.757858 (0.81249343) 5.6 % 0.17 [ 0.04, 0.85 ]
Subtotal (95% CI) 100.0 % 0.55 [ 0.36, 0.83 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 11.86, df = 5 (P = 0.04); I2 =58%
Test for overall effect: Z = 2.86 (P = 0.0042)
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Analysis 1.18. Comparison 1 Highest versus lowest selenium exposure, Outcome 18 Total cancer incidence
and mortality (ascending order of selenium levels).
Review: Selenium for preventing cancer
Comparison: 1 Highest versus lowest selenium exposure
Outcome: 18 Total cancer incidence and mortality (ascending order of selenium levels)
Study or subgroup Upper border/lowest level Lower border/highest leve log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 incidence
Virtamo 1987 46 -0.13102825 (0.28025823) 60 14.0 % 0.88 [ 0.51, 1.52 ]
Knekt 1990 49 -0.89159813 (0.19836824) 78 19.3 % 0.41 [ 0.28, 0.60 ]
Knekt 1990 49 -0.15082287 (0.17949557) 78 20.8 % 0.86 [ 0.60, 1.22 ]
Ringstad 1988 114 -0.33647222 (0.44989504) 115 7.4 % 0.71 [ 0.30, 1.73 ]
Peleg 1985 103 127 0 (0.32691842) 11.6 % 1.00 [ 0.53, 1.90 ]
Willett 1983 114 -0.64185387 (0.28025823) 128 14.0 % 0.53 [ 0.30, 0.91 ]
Nomura 1987 103 -0.26236423 (0.29924162) 133 12.9 % 0.77 [ 0.43, 1.38 ]
Subtotal (95% CI) 100.0 % 0.69 [ 0.52, 0.91 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 11.45, df = 6 (P = 0.08); I2 =48%
Test for overall effect: Z = 2.64 (P = 0.0083)
2 mortality
Salonen 1985 47 47 -1.757858 (0.81249343) 5.6 % 0.17 [ 0.04, 0.85 ]
Kornitzer 2004 72 85 0.35667496 (0.4270348) 14.0 % 1.43 [ 0.62, 3.30 ]
Kornitzer 2004 72 -0.78845738 (0.26682873) 85 21.7 % 0.45 [ 0.27, 0.77 ]
Akbaraly 2005 75 96 -1.401183 (0.5047159) 11.4 % 0.25 [ 0.09, 0.66 ]
Kok 1987 103 -0.64185387 (0.33397056) 103 18.1 % 0.53 [ 0.27, 1.01 ]
Bleys 2008 117 -0.37106368 (0.13508107) 130 29.2 % 0.69 [ 0.53, 0.90 ]
Subtotal (95% CI) 100.0 % 0.55 [ 0.36, 0.83 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 11.86, df = 5 (P = 0.04); I2 =58%
Test for overall effect: Z = 2.86 (P = 0.0042)
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Analysis 1.19. Comparison 1 Highest versus lowest selenium exposure, Outcome 19 Total cancer incidence
and mortality (women).
Review: Selenium for preventing cancer
Comparison: 1 Highest versus lowest selenium exposure
Outcome: 19 Total cancer incidence and mortality (women)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 incidence
Knekt 1990 -0.15082287 (0.17949557) 68.7 % 0.86 [ 0.60, 1.22 ]
Peleg 1985 0.51082558 (0.6016002) 23.9 % 1.67 [ 0.51, 5.42 ]
Peleg 1985 -1.757858 (1.2286268) 7.3 % 0.17 [ 0.02, 1.92 ]
Subtotal (95% CI) 100.0 % 0.90 [ 0.45, 1.77 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 2.90, df = 2 (P = 0.23); I2 =31%
Test for overall effect: Z = 0.32 (P = 0.75)
2 mortality
Bleys 2008 -0.07257069 (0.08211736) 90.6 % 0.93 [ 0.79, 1.09 ]
Bleys 2008 -0.4942963 (0.39748588) 3.9 % 0.61 [ 0.28, 1.33 ]
Kok 1987 -0.40546511 (0.52696443) 2.2 % 0.67 [ 0.24, 1.87 ]
Kornitzer 2004 0.35667496 (0.4270348) 3.3 % 1.43 [ 0.62, 3.30 ]
Subtotal (95% CI) 100.0 % 0.92 [ 0.79, 1.07 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.52, df = 3 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.30)
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Analysis 1.20. Comparison 1 Highest versus lowest selenium exposure, Outcome 20 Total cancer incidence
and mortality (men).
Review: Selenium for preventing cancer
Comparison: 1 Highest versus lowest selenium exposure
Outcome: 20 Total cancer incidence and mortality (men)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 incidence
Peleg 1985 0.51082558 (0.85634884) 6.2 % 1.67 [ 0.31, 8.93 ]
Nomura 1987 -0.26236423 (0.29924162) 22.1 % 0.77 [ 0.43, 1.38 ]
Knekt 1990 -0.89159813 (0.19836824) 27.5 % 0.41 [ 0.28, 0.60 ]
Peleg 1985 0.10536054 (0.49602147) 13.6 % 1.11 [ 0.42, 2.94 ]
Virtamo 1987 -0.13102825 (0.28025823) 23.1 % 0.88 [ 0.51, 1.52 ]
Persson 2000 -1.6486586 (0.75775878) 7.5 % 0.19 [ 0.04, 0.85 ]
Subtotal (95% CI) 100.0 % 0.66 [ 0.42, 1.05 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 11.43, df = 5 (P = 0.04); I2 =56%
Test for overall effect: Z = 1.75 (P = 0.081)
2 mortality
Bleys 2008 -0.35667496 (0.12845059) 54.1 % 0.70 [ 0.54, 0.90 ]
Kornitzer 2004 -0.78845738 (0.26682873) 30.3 % 0.45 [ 0.27, 0.77 ]
Kok 1987 -0.99325179 (0.43360709) 15.6 % 0.37 [ 0.16, 0.87 ]
Subtotal (95% CI) 100.0 % 0.56 [ 0.38, 0.81 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 3.66, df = 2 (P = 0.16); I2 =45%
Test for overall effect: Z = 3.02 (P = 0.0025)
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A P P E N D I C E S
Appendix 1. Electronic search strategies
Database Date of most recent literature
search
Search strategy Comment
www.cancer.gov 4 Feb 2011 medication: selenium
indication: prevention
Cancerlit Oct 2004 1 selen* OR organoselen*
OR natriumselen*
2 random* OR placebo* OR
clinical trial* OR controlled
trial* OR controlled clinical
trial* OR double blind* OR
single blind*
3 epidemiologic stud*ORco-
hort OR case-control stud* OR
nested case-control* OR case-
control design*ORprospectiv*
4 2 OR 3
5 1 AND 4
now included in Medline
database
Clinical Contents in Medicine
(CCMed)
4 Feb 2011 selen*ORorganoselen*ORna-
triumselen*
CENTRAL Issue 1 2011 selen*
Cochrane Library Issue 1 2011 selen*
metaRegister of Controlled Tri-
als (mRCT, www.controlled-
trials.com)
4 Feb 2011 selen AND cancer
EMBASE 2010 week 50 1 selenium/ or selen$.mp.
2 exp Clinical Study/
3 exp NEOPLASM/
4 1 and 2 and 3
5 Selenium 75/
6 4 not 5
7 limit 6 to human (707)
8 exp Selenium Derivative/
(765)
9 methylseleninic acid/ or
methylselenium.mp.
10 exp Organoselenium
Derivative/
11 1 or 8 or 9 or 10
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(Continued)
12 11 and 2 and 3
13 12 not 5
15 limit 13 to human
GermanCancer StudyRegister:
www.studien.de
4 Feb 2011 selen
Medline (via Pubmed) 4 Feb 2011 #1 Search selen* OR seleno*
OR selenium[mesh] OR sele-
nium com-
pounds[mesh] OR organosele-
nium compounds[mesh]
#2 Search randomized-con-
trolled-trial[pt] Or controlled-
clinical-trial[pt] OR clinical-
trial[pt]
#3
Search randomized-controlled-
trials OR random-allocation
OR double-blind-method OR
single-blind-method OR place-
bos OR research-design OR
follow-up-studies OR prospec-
tive-studies
#4 Search epidemiologic study
characteristics[mesh]
#5 Search clinic*[tiab] NEAR
trial*[tiab]
#6 Search placebo*[tiab] OR
random*[tiab]
#7 Search clinical trial[tiab]
#8 Search (singl*[tiab] OR
doubl*[tiab] OR trebl*[tiab]
OR tripl*[tiab]) NEAR
(blind*[tiab] OR mask*[tiab])
#9 Search control*[tiab]
OR prospect*[tiab] OR volun-
teer*[tiab]
#10 Search #2 OR #3 OR #4
OR #5 OR #6 OR #7 OR #8
OR #9
#11 Search neoplasms[mesh]
#12 Search cancer* OR can-
cers* OR cancero* OR carcino*
OR carcinom* OR carcinog*
OR malignan* OR neoplasm*
OR tumor* OR tumori* Or tu-
mors OR tumour*
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(Continued)
#13 Search melanoma* OR
sarcoma* OR adenoma* OR
adenosarcoma* OR adenocar-
cinoma* OR carcinosarcoma*
OR
chondrosarcoma* OR fibrosar-
coma* OR dermatofibrosar-
coma* OR neurofibrosarcoma*
OR hemangiosarcoma* OR
leiomyosarcoma* OR liposar-
coma* OR myosarcoma* OR
rhabdomyosarcoma* OR myx-
osarcoma* OR osteosarcoma*
OR lymphoma*
#14 Search #11 OR #12 OR #
13
#15 Search animals[mh] NOT
human[mh]
#16 Search #1 AND #10 AND
#14
#17 Search #16 NOT #15
SIGLE Oct 2004 ?selen? database discontinued in 2005
Appendix 2. Newcastle-Ottawa-Scale for Cohort Studies
((*) means that a ’star’ was assigned to the study for the corresponding item)
1) SELECTION
1.1) representativeness of the exposed cohort
a) truly representative of the average ˙˙˙˙˙˙˙˙˙˙˙˙˙ (target population) in the community (*)
b) somewhat representative of the average ˙˙˙˙˙˙˙˙˙˙˙˙˙ (target population) in the community (*)
c) selected group of users, e.g. volunteers / nurses
d) no description of the derivation of the cohort
1.2) selection of the non-exposed cohort
a) drawn from the same community as the exposed cohort (*)
b) drawn from a different source
c) no description
1.3) ascertainment of selenium exposure
a) secure record (biochemical records) (*)
b) structured interview (*)
c) written self report or medical record only
d) no description
1.4) demonstration that outcome of interest was not present at start of study
a) no history of disease or exclusion of cases that occurred in the first 12 months (*)
b) not stated
2) COMPARABILITY
2.1.) comparability of cohorts on the basis of the design or analysis
a) study controls for AGE (*)
b) study controls for SMOKING (*)
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3) OUTCOME
3.1) assessment of outcome
a) independent blind validation (> 1 person/record/time/process to extract information or reference to primary source such as X-rays/
hospital records) (*)
b) record linkage (e.g. ICD codes in databases) (*)
c) self report
d) no description
3.2) Was follow-up long enough for outcomes to occur?
a) yes (> 3 years)
b) no
3.3) adequacy of follow up of cohorts
a) complete follow-up of all subjects (*)
OR
b) subjects lost to follow-up unlikely to introduce bias (< 5% lost to follow-up or description provided of lost people) (*)
c) follow-up-rate < 95% and no description of those lost
d) no statement
Appendix 3. Additional Newcastle-Ottawa-Scale for Nested Case-Control Studies
((*) means that a ’star’ was assigned to the study for the corresponding item)
1) SELECTION
1.1) case definition
a) independent validation (> 1 person/record/time/process to extract information or reference to primary source such as X-rays/hospital
records) (*)
b) record linkage (e.g. ICD codes in databases) or self-report with no reference to primary record
c) no description
1.2) representativeness of cases:
a) all eligible cases with outcome of interest over a defined period, cases in a defined catchment area/hospital etc. or an appropriate/
random sample of those cases (*)
b) not satisfying requirements in part (a) or not stated
1.3) selection of controls:
a) community controls (same community and would be cases if had outcome) (*)
b) hospital controls (within the same population e.g. city as cases)
c) no description
1.4) definition of controls
a) cases had no history of outcome controls had no history of outcome OR case had new (not necessarily first) occurrence of outcome
controls with previous occurrence of outcome should not be excluded (*)
b) no mention of history of outcome
2) COMPARABILITY
(validated in cohort assessment in question 2 - number of stars was copied)
3) EXPOSURE
3.1) ascertainment of selenium exposure:
(validated in cohort assessment in question 1.3 - number of stars was copied)
3.2) Same method of ascertainment for cases and controls
a) yes (*)
b) no
3.3) non-response rate
a) same rate for both groups (*)
b) non-respondents described
c) rate different and no designation
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H I S T O R Y
Protocol first published: Issue 2, 2005
Review first published: Issue 5, 2011
C O N T R I B U T I O N S O F A U T H O R S
GD is the primary author and co-ordinator of the authors’ group and was involved in all steps of realising the protocol and the review.
MZw commented on the protocol, extracted data from papers, conducted the data analyses in STATA and commented on the review
and provided a methodological perspective.
MB commented on the protocol, assisted by checking the original literature search and inclusion criteria, providing a brief and early
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